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Background: Balance, mobility impairments and falls are common problems for people with multiple
sclerosis (MS). Our ongoing research has led to the development of Balance Right in MS (BRiMS), a
13-week home- and group-based exercise and education programme intended to improve balance and
encourage safer mobility.
Objective: This feasibility trial aimed to obtain the necessary data and operational experience to finalise
the planning of a future definitive multicentre randomised controlled trial.
Design: Randomised controlled feasibility trial. Participants were block randomised 1 : 1. Researcher-blinded
assessments were scheduled at baseline and at 15 and 27 weeks post randomisation. As is appropriate in
a feasibility trial, statistical analyses were descriptive rather than involving formal/inferential comparisons.
The qualitative elements utilised template analysis as the chosen analytical framework.
Setting: Four sites across the UK.
Participants: Eligibility criteria included having a diagnosis of secondary progressive MS, an Expanded
Disability Status Scale (EDSS) score of between ≥ 4.0 and ≤ 7.0 points and a self-report of two or more
falls in the preceding 6 months.
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Interventions: Intervention – manualised 13-week education and exercise programme (BRiMS) plus usual
care. Comparator – usual care alone.
Main outcome measures: Trial feasibility, proposed outcomes for the definitive trial (including impact
of MS, mobility, quality of life and falls), feasibility of the BRiMS programme (via process evaluation) and
economic data.
Results: A total of 56 participants (mean age 59.7 years, standard deviation 9.7 years; 66% female; median
EDSS score of 6.0 points, interquartile range 6.0–6.5 points) were recruited in 5 months; 30 were block
randomised to the intervention group. The demographic and clinical data were broadly comparable at
baseline; however, the intervention group scored worse on the majority of baseline outcome measures.
Eleven participants (19.6%) withdrew or were lost to follow-up. Worsening of MS-related symptoms
unrelated to the trial was the most common reason (n = 5) for withdrawal. Potential primary and secondary
outcomes and economic data had completion rates of > 98% for all those assessed. However, the overall
return rate for the patient-reported falls diary was 62%. After adjusting for baseline score, the differences
between the groups (intervention compared with usual care) at week 27 for the potential primary outcomes
were MS Walking Scale (12-item) version 2 –7.7 [95% confidence interval (CI) –17.2 to 1.8], MS Impact
Scale (29-item) version 2 (MSIS-29vs2) physical 0.6 (95% CI –7.8 to 9) and MSIS-29vs2 psychological –0.4
(95% CI –9.9 to 9) (negative score indicates improvement). After the removal of one outlier, a total of
715 falls were self-reported over the 27-week trial period, with substantial variation between individuals
(range 0–93 falls). Of these 715 falls, 101 (14%) were reported as injurious. Qualitative feedback indicated
that trial processes and participant burden were acceptable, and participants highlighted physical and
behavioural changes that they perceived to result from undertaking BRiMS. Engagement varied, influenced
by a range of condition- and context-related factors. Suggestions to improve the utility and accessibility of
BRiMS were highlighted.
Conclusions: The results suggest that the trial procedures are feasible and acceptable, and retention,
programme engagement and outcome completion rates were sufficient to satisfy the a priori progression
criteria. Challenges were experienced in some areas of data collection, such as completion of daily diaries.
Future work: Further development of BRiMS is required to address logistical issues and enhance
user-satisfaction and adherence. Following this, a definitive trial to assess the clinical effectiveness and
cost-effectiveness of the BRiMS intervention is warranted.
Trial registration: Current Controlled Trials ISRCTN13587999.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 27.
See the NIHR Journals Library website for further project information.
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Plain English summary
People with secondary progressive multiple sclerosis (SPMS) often have problems with walking andbalance, which lead them to fall. Undertaking exercise and learning about falls prevention could help
reduce injury risk and improve mobility.
We developed a mobility, balance and falls programme called Balance Right in MS (BRiMS). Before testing
its effectiveness in a large-scale trial, we needed to conduct a small-scale version of the trial.
We asked people with SPMS who had balance and mobility problems to be assigned by chance to
undertake the BRiMS programme plus their usual care, or to continue with usual care only.
Questionnaires were used to ask people about their mobility, falls and quality of life, and we measured
their balance and activity levels. We interviewed participants about BRiMS and being in the trial, and
collected information about costs.
Fifty-six people entered the trial from three areas of the south-west and from Ayrshire. At completion of
the study we were able to review 44 people. The key measures were completed by 98% of those we
assessed, but only around half (62%) of the diaries detailing falls were returned. As this was a feasibility
trial, the numbers were too small for us to look at differences between the groups.
Participants liked the BRiMS programme; some did a lot of exercise and learning activities, but most did
not manage the amount we asked them to do. People reported feeling a little overwhelmed by the
educational content of BRiMS, and that this should be reduced in future. They told us that they felt that
their balance had improved and that they fell less frequently after the BRiMS programme.
Our assessment of the trial methods we used showed that it would be possible to conduct a full-scale trial
using this design, but that we need to adapt the BRiMS programme further to make it more user-friendly.
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Scientific summary
Background
Multiple sclerosis (MS) is an incurable, unpredictable but typically progressive, life-long neurological
condition, affecting approximately 100,000 people in the UK (Royal College of Physicians. The National
Audit of Services for People with Multiple Sclerosis 2011. London: Royal College of Physicians; 2011).
Although most people start with a relapsing–remitting disease course, approximately two-thirds move to a
progressive phase, with a steady rise in the total percentage of progressive cases as the disease advances.
Within approximately 15 years of a MS diagnosis, an estimated 50% of people are unable to walk
unaided, and eventually 25% are dependent on a wheelchair. An important contributor to difficulties in
mobility is impaired balance, which is reported by roughly 75% of people and has been shown to be
more compromised in those with secondary progressive multiple sclerosis (SPMS) than in those with
relapsing–remitting multiple sclerosis (RRMS). Rehabilitation interventions that improve balance and
physical activity and decrease the risk of falls may slow this deterioration, providing a persuasive argument
for ensuring that optimal physical management is a clinical priority. With only limited medical interventions
available for this patient group, such rehabilitation programmes are considered key to the treatment of
SPMS but currently lack a robust evidence base.
In partnership with service users, providers, other key stakeholders (including commissioners) and
international collaborators, our ongoing research programme systematically developed Balance Right in MS
(BRiMS), an innovative evidence-based, user-focused self-management programme designed to improve
safe mobility and reduce falls for people with MS. BRiMS is a novel 13-week, therapy-led personalised
education and exercise programme structured to maximise the development of self-efficacy and support
participant engagement. It addresses modifiable risk factors, enabling self-management through the use of
individualised mobility, safety and falls risk management strategies.
The National Institute for Health Research commissioning brief (Health Technology Assessment commissioning
call reference number 15/47) requested applications for studies undertaking primary research in rehabilitation
therapies to improve quality of life (QoL) in patients with SPMS. Having previously developed BRiMS, it
was critical, and timely, to assess the feasibility of the delivery of this programme and proposed evaluation
methods before undertaking a definitive trial to assess the clinical effectiveness and cost-effectiveness of the
programme.
Research questions
l Is it feasible and acceptable to conduct a multicentre randomised controlled trial of the BRiMS
intervention?
l Is it feasible and acceptable to deliver the BRiMS programme for ambulant people with SPMS who live
in the community?
Aim
This feasibility trial aimed to obtain the necessary data and operational experience to finalise the planning
of an intended future definitive multicentre randomised controlled trial to compare a manualised 13-week
education and exercise programme (BRiMS) plus usual care with usual care alone in improving mobility and
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QoL and reducing falls in people with SPMS. The intention was to learn lessons to enable a definitive trial
to be successfully delivered with confidence. The objectives were grouped into four clusters:
l trial feasibility
l trial outcomes
l process evaluation
l health economics analysis.
Methods
The trial recruited from four UK sites: Cornwall, Plymouth, East Devon and Ayrshire. The sample size was
set at 60 to ensure that the feasibility objectives could be achieved with a sufficient degree of certainty.
Participants were identified through several sources: local and national advertising through MS centres,
MS Society (www.mssociety.org.uk) branches and support groups, websites and newsletters; adoption
onto the local Clinical Research Network portfolio and via the caseload of local MS neurologists, MS nurse
specialists and NHS therapists.
Potentially eligible participants were screened by telephone interview undertaken by a research therapist
linked to the recruiting site. As each delivery of BRiMS was pre-scheduled to ensure the availability of
staffing and facilities, potential participants were assigned to a specific BRiMS delivery at this point (if they
were randomised to the BRiMS intervention plus usual-care group). Final eligibility checking, informed
consent and baseline measures were undertaken at a single face-to-face meeting at a health-care venue
local to the participant, at a time point no more than 2 weeks before the pre-scheduled randomisation
date for each BRiMS delivery.
Randomisation was undertaken by the Peninsula Clinical Trials Unit after the baseline assessments were
completed for all participants in a block (block size 8–12 participants). Participants were individually
randomised on a 1 : 1 basis, blocked within each site.
Participants were followed up on two occasions: 13 weeks (± 1 week) and 27 weeks (± 1 week) following
randomisation. This reflected an assessment at the end of the intervention period and a further follow-up
3 months later.
Participants
The target population was English-speaking men and women, aged ≥ 18 years, with a confirmed diagnosis
of SPMS, who reported having walking difficulties and experiencing falls.
Inclusion criteria
The patient:
l had a confirmed diagnosis of MS as determined by a neurologist; and, in the secondary progressive
phase, as confirmed by a MS specialist clinician
l was aged ≥ 18 years
l was willing and able to understand/comply with all trial activities
l had an Expanded Disability Status Scale (EDSS) score of between ≥ 4.0 and ≤ 7.0 points
l had self-reported two or more falls in the past 6 months
l was willing and able to travel to and participate in BRiMS group sessions at local sites and to commit to
undertaking their individualised home-based programme
l had access to a computer or tablet and to the internet.
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Exclusion criteria
The patient:
l Had reported relapse or receiving steroid treatment within the past month {patient-reported relapse was
defined as ‘the appearance of new symptoms, or the return of old symptoms, for a period of 24 hours
or more – in the absence of a change in core body temperature or infection’ [MS Society. Relapsing
Remitting MS (RRMS). 2016. URL: www.mssociety.org.uk/what-is-ms/types-of-ms/relapsing-remitting-rrms
(accessed 21 December 2016)]}.
l Had any recent changes in disease-modifying therapies. More specifically, patients were excluded
if they:
¢ had ever had previous treatment with alemtuzumab (Lemtrada®, Sanofi Genzyme, Cambridge,
MA, USA); or
¢ had ceased nataluzimab (Tysabri®, Biogen, Cambridge, MA, USA) in the past 6 months; or
¢ were within 3 months of ceasing any other MS disease-modifying drug.
l Had participated in a falls management programme (e.g. for older people) within the past 6 months.
l Had comorbidities that may have influenced their ability to participate safely in the programme or that
were likely to have an impact on the trial (e.g. uncontrolled epilepsy).
l Had been recruited to a concurrent interventional trial.
Interventions
Participants were randomised to one of two groups: BRiMS plus usual care or usual care alone. Those
allocated to undertake the BRiMS programme were invited to attend two one-to-one sessions (an initial
assessment and a home visit), to undertake a home exercise programme and falls prevention education
programme supported by online resources and a paper manual, and to attend three group sessions for
peer support, group exercise and interactive learning activities. Participation in the attended sessions was
recorded by the treating therapists, and engagement in the online activities was captured by website
log-in and usage. Participants were asked to record their adherence to the home exercise programme,
and details of the progression of exercises undertaken, in a weekly diary that was integrated into the
online exercise platform.
Outcomes
Trial feasibility
The outcomes were participant recruitment, retention and completion rates, trial acceptability and
feasibility (via participant interviews), measures of trial safety and adverse events.
Trial outcomes
In addition to those on participant demographics, clinical characteristics and medication use, data were
collected to inform the potential primary and secondary outcomes for a future definitive trial.
Potential primary outcomes
l MS Walking Scale (12-item) version 2 (MSWS-12vs2).
l EuroQoL-5 Dimensions, five-level version.
l MS Impact Scale (29-item) version 2 (MSIS-29vs2).
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Potential secondary outcomes
l Falls frequency and injury rates (from participant self-report daily paper diaries).
l Physical activity [measured for 1 week after each trial assessment using an activPAL™
(Paltechnologies Ltd, Glasgow, UK) activity monitor].
l Two-Minute Walk Test.
l Mini-Balance Evaluation Systems Test.
l Functional Reach and Lateral Reach Tests.
l Falls Efficacy Scale – International.
l Community Participation Indicators.
BRiMS programme feasibility (process evaluation)
This included an assessment of programme acceptability and utilisation (from participant and therapist
interviews), records of attendance at face-to-face sessions, online exercise diary completion and web-based
programme log-in data.
Health economics
Evaluation of the feasibility of the proposed methods for assessing health, social care and other resource
use in a future definitive trial was undertaken, plus evaluation of the intervention delivery costs for the
BRiMS programme.
Results
A total of 56 participants (mean age 59.7 years, standard deviation 9.7 years; 66% female; median EDSS
score of 6.0 points, interquartile range 6.0–6.5 points) were recruited in 5 months; 30 were block
randomised to the intervention group.
Trial feasibility objectives
A total of 11 participants (19.6%) withdrew or were lost to follow-up, seven of whom were in the
intervention group. Worsening of MS-related symptoms unconnected to the trial was the most common
reason (n = 5) for withdrawal.
There were nine reports of serious adverse events during the trial, none of which was assessed to be
related to the BRiMS intervention. The adverse events reported were not unexpected for this sample of
people with progressive MS, and are in line with other MS rehabilitation and exercise trials.
Qualitative feedback indicated that trial processes and participant burden were acceptable, although some
areas for improvement were highlighted. For example, participants recommended that written pre-trial
information be reviewed to ensure that the content and format are straightforward while remaining
comprehensive.
Trial outcome objectives
The groups were broadly comparable at baseline, although the intervention group scored worse on the
majority of the baseline outcome measures. Potential primary and secondary outcomes had excellent
completion rates of > 98% for all those assessed at each time point. There were a number of issues with
diary data, which meant that the overall return rate was 62%, with a rate of 58.6% of the expected total
for falls, and 40.6% of the expected total for injurious falls.
After adjusting for baseline score, the differences between the groups (intervention compared with usual
care) at week 27 were –7.7 on the MSWS-12vs2 [95% confidence interval (CI) –17.2 to 1.8], 0.6 on the
MSIS-29vs2 physical (95% CI –7.8 to 9.0), –0.4 on the MSIS-29vs2 psychological (95% CI –9.9 to 9.0) and
0.0 on the EuroQol-5 Dimensions, three-level version (crosswalk) (95% CI –0.1 to 0.1).
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After one outlier was removed, a total of 715 falls were reported over the 27-week trial period, with
substantial variation between individuals (range 0–93 falls). Of these 715 falls, 101 (14%) were reported as
injurious. The falls rate at week 27 was 25.9 falls per person per year in the usual-care group and 21.9
falls per person per year in the intervention group. The injurious falls rates at 27 weeks were 4.7 falls per
person per year (usual care) and 2.2 falls per person per year (intervention).
Based on this feasibility study and other relevant data, with MSWS-12vs2 as the primary outcome and
27 weeks post randomisation as the primary end point, the estimated sample size for a definitive trial
would be within a range of 575 to around 990.
Process evaluation objectives
Therapists and participants were generally positive when describing their engagement with the BRiMS
programme. Therapists particularly valued the ethos of the programme, and the resources provided to
them, which they felt enabled them to deliver a structured and comprehensive approach to support
self-management, incorporating both educational and exercise activities.
Levels of participant engagement with the programme varied both over time and between participants,
influenced by a range of condition- and context-related factors. A number of suggestions were made by
therapists and participants to improve the utility and accessibility of the programme model and delivery
methods.
Patterns of participant recorded exercise varied, with only six (21%) of the 28 participants who
commenced the programme logging at least 100 of the advised 120 minutes of weekly exercise activity
over the 12 weeks. Participants and treating therapists reported a number of technical and logistical issues
with the recording of exercise activities.
Participants highlighted both physical and behavioural changes that they perceived had resulted directly
from undertaking the BRiMS programme. These included changes in balance confidence and competence,
an increased awareness of falls risk and the introduction of falls prevention strategies.
Health economics analysis objectives
As with the potential primary and secondary outcome measures, the health economics resource-use
questionnaires and therapist contact sheets had excellent completion rates, at > 98% for all those
assessed.
The estimated mean cost for the delivery of BRiMS was £400 per person, although qualitative feedback
from treating therapists suggests that the time allocation should be increased in future deliveries by
approximately 15%.
Participants reported relatively modest levels of resource use, predominantly focused on primary and
secondary care. Provision of informal unpaid care was consistent between the groups at 24–25 hours per
week. When applying a unit cost to hours of informal care, the estimated weekly cost of this care is
approximately £445 per participant.
Conclusions and recommendations
This trial aimed to assess the feasibility of undertaking a definitive trial to compare BRiMS plus usual care
with usual care alone in a sample of people with SPMS. The results suggest that the trial procedures are
feasible and acceptable, and the retention, programme engagement and outcome completion rates were
sufficient to satisfy the a priori trial progression criteria. Challenges were experienced in some areas of data
collection, such as the recording of adherence to exercise activity and the completion of daily diaries; the
lessons learnt in this feasibility trial will enable these processes to be refined for a future trial. Further
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development of the BRiMS programme is required to address logistical issues and enhance user satisfaction
and adherence. Following this, a definitive trial to assess the effectiveness and cost-effectiveness of
the BRiMS intervention is warranted. Estimated sample sizes for this trial range from 575 to around
990 participants.
Trial registration
This trial is registered as ISRCTN13587999.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Multiple sclerosis (MS) is an incurable, unpredictable but typically progressive, life-long neurological condition,
affecting approximately 100,000 people in the UK.1 It is the most common cause of neurological disability
in young adults, with an estimated cost of £1.4B per annum to the NHS and society.2 More recently, new
insights into the burden and costs of MS in Europe have demonstrated that, on average, costs are €22,800 in
mild, €37,100 in moderate and €57,500 in severe disease (adjusted for purchasing power parity).3 Although
most people start with a relapsing–remitting (RR) disease course, approximately two-thirds move to a
progressive phase, with a gradual rise in the total percentage of progressive cases as the disease advances.4
At this point, medical interventions are limited and further disease progression is usually inevitable.5 People in
this phase, the majority of whom have limited mobility, are often excluded from clinical trials, which tend to
focus on the RR stage.6
Balance and falls in multiple sclerosis
Eighty-five per cent of people with MS report gait disturbance as their main problem.7 Within approximately
15 years of diagnosis, 50% of people are unable to walk unaided, and over time an estimated 25% are
dependent on a wheelchair.8 It is, therefore, unsurprising that mobility is a major concern for people with
MS and the health professionals involved in their care, and an area that is consistently highlighted by
research, policy and service user fora. Surveys of people with MS consistently rank mobility as their highest
priority9 and the most important, yet most challenging, daily function.10 Furthermore, mobility has been
correlated with employment status, earnings and quality of life (QoL).11,12 An important contributor to
difficulties in mobility is impaired balance, which is reported by approximately 75% of people with MS13 and
has been shown to be more compromised in people with secondary progressive multiple sclerosis (SPMS)
than in those with relapsing–remitting multiple sclerosis (RRMS).14 Our own work suggests that falls may be
an early marker of mobility deterioration associated with disease progression.15 Rehabilitation interventions
that improve balance and physical activity and decrease the risk of falls may slow this deterioration,
providing a persuasive argument for ensuring that optimal physical management is a clinical priority. With
only limited medical interventions available for this patient group, such rehabilitation programmes are
considered key to the treatment of SPMS but currently lack a robust evidence base.5
Our research,16 in line with that of others, demonstrates that, alongside impaired mobility and balance,
falls are a common issue for people with SPMS, who are twice as likely to fall as those with RRMS.17
The evidence shows that approximately 70% of people with MS fall regularly,15 at a rate of > 26 falls per
person per year with SPMS.16 More than 10% of these falls lead to injuries18 and people with MS are three
times more likely to sustain a fracture than the general population.19 Falling and fear of falling have a
profound impact on individuals, leading to activity curtailment, social isolation and a downwards spiral of
immobility, deconditioning and disability accumulation.20 This has significant implications for an individual’s
health, well-being and QoL. Unsurprisingly, 4 out of the 10 research priorities identified by the James Lind
MS Priority Setting Partnership relate directly to this area.21 This trial has provided an opportunity for
people with SPMS, whose limited mobility often excludes them from clinical trials, to participate in a trial
targeting what they themselves consider to be a key concern.
Implications of impaired mobility and falls for society and for health practice
There are substantial economic and social costs related to increasing immobility, impaired balance and falls
in people with MS. Costs of health and social care have been shown to increase steeply with increasing
disease severity/immobility.2 By this stage of the disease, rehabilitation interventions form the mainstay of
treatment and drug therapy options are limited. The mean cost per wheelchair-dependent patient is four
to five times higher than that for an ambulatory patient.22 This, together with the associated costs of falls
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for those who continue to ambulate, underlines the importance of optimising safe mobility for as long as
possible: a key aim of our work. This is particularly relevant given recent evidence that people with MS are
living longer, leading to a rising population living with the disease.23 This has important implications for
resource provision in the UK and for the NHS, as highlighted in a national audit of neurological services,24
which demonstrated a significant increase in emergency hospital admissions in people with progressive
neurological disability, including MS. The importance of mobility and falls is emphasised by their consistent
prominence in recent policy documents for long-term neurological conditions.25
An overwhelming proportion of a physiotherapist’s MS caseload comprises people who have balance and
mobility impairments, many of whom are falling. Improving balance and mobility in people with SPMS and
reducing falls is likely to have a significant impact on QoL and independence. Our recent literature reviews,
however, demonstrate that there is a lack of available evidence to support this assertion, although data from
mixed samples of patients with RRMS or SPMS are suggestive.5,26 Furthermore, professionals and patients
have identified serious problems with the feasibility and sustainability of a traditional weekly outpatient
model of programme delivery.27 The emphasis on evidence-based practice heavily influences whether or not
interventions are provided, as does local policy. These decisions rely on the availability of robust evidence of
clinical effectiveness and cost-effectiveness. Currently, there is minimal evidence-based guidance to inform
optimal mobility management and none to inform falls management in people with MS. This paucity of
evidence is highlighted in the National Institute for Health and Care Excellence (NICE) clinical guideline 186,25
which nominates the rehabilitation of mobility as one of its five key research recommendations. Although
evidence is available for older people and for other neurological conditions, research suggests that
translating existing interventions to people with MS is likely to be ineffective.28,29 Small, limited-duration
studies have evaluated single elements of MS balance and falls interventions, individually demonstrating
short-term improvements in mobility, balance or falls awareness,13,30,31 but these elements have not yet been
implemented or evaluated collectively. Moreover, no studies have focused on people with SPMS.
The BRiMS programme
Development of the BRiMS programme
Health-care policy prioritises the need to empower patients to self-manage through partnership working
and self-management programmes,32 with emphasis placed on a future NHS that implements interventions
that promote self-care and lifestyle behavioural change and are community based.33
In partnership with service users, providers, other key stakeholders (including commissioners) and
international collaborators, our ongoing research programme systematically developed Balance Right in MS
(BRiMS), an innovative, evidence-based, user-focused self-management programme, designed to improve
safe mobility and reduce falls for people with MS. The development of BRiMS has been based on the
Medical Research Council framework34 for the development and evaluation of complex interventions and
supplementary guidance identifying specific tasks to be undertaken in the development process.35 It was
informed by input from a number of internationally recognised experts,36 which is explicitly acknowledged
in the programme documentation. The programme’s underlying philosophy is based on the premise that
interventions must promote lifestyle behavioural change, be community based and focus on prevention
and self-care, an approach in line with the future direction of the NHS.33
Overview of the BRiMS programme
BRiMS is a novel 13-week, therapy-led personalised education and exercise programme structured to maximise
the development of self-efficacy and support participant engagement (Figure 1). It addresses modifiable risk
factors, enabling self-management by individualised mobility, safety and falls risk management strategies.
The programme includes two individual and three group sessions addressing physical, behavioural and
environmental aspects of mobility and falls management. These are supplemented by a home-based
package delivered via an established web-based interactive resource to ensure integration into daily life
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from the outset. As emphasised in the NICE guideline,25 this combined approach (which was developed
in collaboration with people with MS, physical therapists, sports scientists, occupational therapists and
psychologists) aims to equip the person with MS with the knowledge, skills and motivation to sustain
long-term behaviour change. Developing and supporting motivation is addressed throughout using new
functional imagery techniques37,38 to supplement established motivational techniques.
The BRiMS education component aims to improve exercise self-efficacy and develop individualised falls
prevention and management practices through the acquisition and application of relevant knowledge and
skills.39 This component is delivered through a mix of home and group activities embedded throughout
the programme. It utilises a number of evidence-based self-management practices, specifically group
brainstorming, problem-solving and action-planning.40 It also applies the principles of cognitive–behavioural
therapy to facilitate self-efficacy enhancement. In group sessions, BRiMS utilises peer modelling, vicarious
learning, social persuasion and guided mastery to boost self-efficacy41 and encourages the setting and
imagery of short-term exercise goals to boost the desire to achieve them.42
The BRiMS exercise component is designed to achieve a minimum of 120 minutes of individualised,
progressive, gait, balance and functional training per week. The content is guided by a comprehensive
literature review of MS balance exercise interventions,43 while the structure and format are informed by
comprehensive stakeholder input.27
The BRiMS exercise component is designed to be predominantly home-based, with exercise planning and
progression undertaken in partnership between the participant and the programme leader. The group
sessions include exercise activities to encourage peer support and problem-solving. Motivational support
is built into both elements. Additionally, BRiMS integrates an online exercise prescription resource
(https://webbasedphysio.com)44 to support and guide participants’ home-based practice. The resource
can be customised to the participant’s individual exercise prescription and remotely amended during the
programme to maintain an appropriate level of challenge.
Intervention description and standardisation
The BRiMS programme has been manualised to provide a detailed description of the intervention and to
ensure consistency of content, approach and delivery of sessions across time, region and groups. The
manual includes identification of the critical elements of each part of the programme, key objectives of each
session and detailed guidance/scripts for programme leaders along with accompanying participant resources.
Figure 2 shows the BRiMS ‘logic model’,45 which maps the programme content and delivery methods,
along with causal assumptions, the mechanisms that are theorised to drive the programme and any
expected external factors that may affect the outcomes. Table 1 provides an overview of the schedule of
content delivery.
Assessment
Week 1 2 3 4 5 6
BRiMS programme
7 8 9 10 11 12 13
Home visit
Group
session 1
Group
session 2
Home
package
1
Home
package
2
Home
package
3
Home
package
4
Group
session 3
Home exercise programme (guided by online resource)
FIGURE 1 The BRiMS programme delivery plan.
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Problem Evidence base Resources/inputs Activities Outcomes Impact
People with MS
fall frequently.
Falls are related
to injury, activity
curtailment and an
increased risk of
mobility deterioration
• Exercise
   (especially gait,
   balance and
   functional training) 
   can improve balance
   and mobility among 
   people with MS43
• Highly challenging
   gait, balance and
   functional training
   can reduce falls in
   older people46
• A falls education
   programme can
   increase confidence, 
   falls self-efficacy 
   and awareness of 
   falls prevention
   strategies30
• There are a range
   of factors that
   have an impact on 
   the design, content 
   and structure of a
   MS-specific falls
   prevention plan27
Programme resources
Specialist programme therapists
with MS-specific knowledge and
experience
BRiMS programme manual 
• Individualised
   progressive exercise
   programme
• Strategies to
   support long-term
   adherence to
   exercise and
   physical activity
• Identification of
   personal fall risk
   factors (using
   BAASE analysis)
• Development of
   individual plans to
   reduce fall risk
   factors (via falls
   action-planning)
• Increasing the
   individual’s
   confidence in
   balance and safe
   mobility
• Identification of
   barriers to, and
   facilitators of, fall
   prevention plan
   enactment (via
   problem-solving
   activities)
Completion of the
programme will lead
to:
• improved balance
• improved mobility
• improved falls 
   self-efficacy
• reduced incidence 
   of falls
• reduced falls-
   related injuries
• reduced resource 
   use for falls-related 
   care
Improvements in
mobility and
reduction in falls
will slow mobility
deterioration and
improve QoL/
community
participation
Home
package 1
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Home visit
Group
session 1
Group
session 2
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FIGURE 2 The BRiMS programme logic model. BAASE, Behaviours and Attitudes, Activities, MS Symptoms, Environment.
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Trial rationale and objectives
The National Institute for Health Research (NIHR) commissioning brief (Health Technology Assessment 15/47)
requested applications for studies undertaking primary research in rehabilitation therapies to improve QoL
in patients with SPMS. Having previously developed BRiMS, it was critical, and timely, to assess the feasibility
of delivering this programme and the proposed evaluation methods before undertaking a definitive trial to
assess the clinical effectiveness and cost-effectiveness of the programme.
There were a number of uncertainties about the optimal parameters for the definitive trial. This current
trial tested the feasibility of conducting such a trial, providing estimates of recruitment, attrition and
concordance, completion rates of measures, and baseline scores and standard deviations (SDs) of proposed
outcomes. We also assessed the acceptability of the intervention, and of participating in the trial, from
both the participants’ and the health professionals’ perspectives, and the process of delivering BRiMS.
This feasibility trial aimed to obtain the necessary data and operational experience to finalise the planning
of an intended future definitive multicentre randomised controlled trial (RCT) to compare a manualised
13-week education and exercise programme (BRiMS) plus usual care with usual care alone in improving
mobility, improving QoL and reducing falls in people with SPMS. The intention was to learn lessons to
enable a definitive trial to be successfully delivered with confidence. The objectives were divided into four
areas, as follows.
Trial feasibility objectives
To determine the:
i. feasibility, utility and acceptability of the trial procedures
ii. suitability and feasibility of eligibility criteria
iii. numbers of eligible participants from the target population
TABLE 1 Overview of BRiMS content
Week BRiMS activities
1 Session 1: individual assessment and introduction to the programme. The therapist develops a personalised
exercise programme based on assessment findings and agreed outcomes
Takes place at a local health-care establishment
Home activities: patient receives BRiMS manual and website login, and completes first home package
2 Session 2: home visit by BRiMS therapist to explain and set up the exercise programme
2–4 Home-based individual practice of exercise programme, plus education activities, with online support from the
BRiMS therapist
Therapist undertakes online review and adjustment of web-based exercise prescription every 2 weeks
4 Group session 1: group exercise and education activities
Takes place at a local health-care establishment
5–8 Home-based practice of exercise programme, plus education activities
8 Group session 2: group exercise and education activities
Takes place at a local health-care establishment
9–13 Home-based practice of exercise programme, plus education activities
13 Group session 3: group exercise and education activities
Takes place at a local health-care establishment
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iv. willingness of clinicians to recruit patients
v. willingness of patients to be randomised
vi. likely recruitment and retention rates as participants move through the trial.
Potential full trial outcome objectives
To determine the:
i. completion and performance of proposed outcome measures, including rates of outcome measure
completion, baseline scores, distributional properties and SDs of outcome measures, and
responsiveness to inform selection of primary outcome (and refine the number of secondary outcomes)
for a definitive trial
ii. baseline factors most strongly associated with outcomes, as potential stratification factors in a
definitive trial
iii. sample size required for a fully powered RCT to evaluate the effectiveness of the BRiMS intervention.
BRiMS programme feasibility (process evaluation) objectives
To determine:
i. the optimum way of delivering the BRiMS programme
ii. intervention fidelity and application between sites
iii. the acceptability of, and adherence to, the 13-week BRiMS programme.
Health economics objectives
To determine:
i. estimates of resource use and related costs associated with delivery of the BRiMS intervention
ii. a framework for assessing the cost-effectiveness of the BRiMS intervention in a future economic
evaluation alongside a full trial.
INTRODUCTION
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Chapter 2 Trial design and methods
This was a pragmatic, multicentre, feasibility RCT with blinded outcome assessment. Participants wererandomised either to a manualised 13-week education and exercise programme (BRiMS) plus usual
care (intervention group), or to usual care alone (usual-care group). The protocol for the trial has been
published previously.47
Trial participants
The target population was English-speaking men and women aged ≥ 18 years who had a confirmed
diagnosis of SPMS and reported having walking difficulties and experiencing falls. This population
constitutes an estimated 70% of all individuals with SPMS, as, by the time this phase has been reached,
balance, mobility and physical activity levels are usually compromised.
The trial was explicitly designed to have high applicability to people with SPMS, and so it used broad
inclusion criteria and relatively few exclusion criteria.
Inclusion criteria
The patient:
l Had a confirmed diagnosis of MS as determined by a neurologist; and, in the secondary progressive
phase, as confirmed by a MS specialist clinician.
l Was aged ≥ 18 years.
l Was willing and able to understand/comply with all trial activities.
l Had an Expanded Disability Status Scale (EDSS) score of between ≥ 4.0 and ≤ 7.0 points.
l Had self-reported two or more falls in the past 6 months.
l Was willing and able to travel to and participate in BRiMS group sessions at local sites and to commit to
undertaking their individualised home-based programme.
l Had access to a computer or tablet and to the internet.
Exclusion criteria
The patient:
l Had reported relapse or receiving steroid treatment within the past month (patient-reported relapse is
defined as ‘the appearance of new symptoms, or the return of old symptoms, for a period of 24 hours
or more – in the absence of a change in core body temperature or infection’).48
l Had any recent changes in disease-modifying therapies. More specifically, patients were excluded if they:
¢ had ever had previous treatment with alemtuzumab (Lemtrada®, Sanofi Genzyme, Cambridge,
MA, USA) because it was felt to be a major disease modifier that had long-term effects after the
usual courses given 12 months apart; or
¢ had ceased nataluzimab (Tysabri®, Biogen, Cambridge, MA, USA) in the previous 6 months; or
¢ were within 3 months of ceasing any other MS disease-modifying drug.
l Had participated in a falls management programme (e.g. for older people) within the previous 6 months.
l Had comorbidities that may have influenced their ability to participate safely in the programme or that
were likely to have an impact on the trial (e.g. uncontrolled epilepsy).
l Had been recruited to a concurrent interventional trial.
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Trial settings
The sites involved were based in two geographical regions of the UK: south-west England (Devon/Cornwall)
and Ayrshire.
Research activity took place at four sites:
1. Plymouth
2. Exeter
3. Cornwall
4. Ayrshire and Arran.
All sites implemented the trial protocol in the same manner. Physiotherapists (treating therapists) from
each of these sites performed the interventions (as part of their NHS role) and two BRiMS research
therapists (employed specifically for the trial) undertook the blinded assessments.
Sample size
In accordance with relevant best-practice,49 we wanted to test processes within and across the three sites
to ensure that this feasibility trial gave a realistic indication of the practicalities for conducting the intended
full trial. This included gaining robust information on likely recruitment and retention rates and full testing
of the procedures involved in all trial processes. Therefore, the more common sample size calculation,
based on considerations of power for detecting a between-group clinically meaningful difference in a
primary clinical outcome, was not appropriate.18
From other studies in similar settings, it was estimated that retention rates would be in the region of
80%.19,20 A target sample size of 60 participants in total would allow estimation of the overall retention
rate with precision of at least ± 13%; for example, if the 6-month follow-up rate was around 80%, the
estimate would have precision of ± 10%. Assuming a non-differential follow-up rate at 6 months of 80%,
it was estimated that recruiting 60 participants would provide outcome data on a minimum of 24 participants
in each of the two allocated groups, enabling reasonable estimates to be made of the variability (i.e. SD) in
each of the proposed outcomes.
Recruitment and screening
A summary of the recruitment and screening process is shown in Figure 3.
Recruitment
To our knowledge, there are no data that report recruitment rates to MS clinical trials from national sources
and so it was difficult to estimate what these would be. This feasibility trial aimed to elucidate this, as we
recorded the sources of recruitment for all participants. However, for this feasibility trial, we could be more
confident of recruitment rates from the local sites involved. For example, our previous work15,50 in ambulant
individuals with MS, using similar local recruitment methods, demonstrated high recruitment rates, with
60–65% of those who were eligible participating. However, given that BRiMS involved attendance at three
group sessions and the commitment to undertake a home-based exercise programme and work package,
we believed that a 50% local recruitment rate was more realistic. Based on this, and on a conservative
estimate of approximately 600 eligible local participants (Devon/Cornwall, n = 284; Ayrshire, n = 330),
our data demonstrated that sufficient numbers of eligible people would be available within our two recruiting
regions from whom to recruit our target sample.
TRIAL DESIGN AND METHODS
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For this feasibility trial, the aim was to recruit 60 participants across the four sites (40 in the south-west
and 20 in Ayrshire) over 6 months. This meant running six intervention groups, each with approximately
five participants. It was anticipated that, to recruit these 60 participants, around 240 people would need to
be screened, assuming that around 80% would agree to participate (n = 190), of whom approximately
35% (n = 70) would be found to be ineligible after screening, leaving around 120 eligible people.
Following this screening, it was anticipated that approximately 50% of eligible people would consent to
participate, leaving around 60 participants to be randomised.
Our recruitment period was relatively short, at 6 months. Our rationale for this was efficiency: to minimise
the overall length and, therefore, the cost of this feasibility trial. Trial awareness-raising activities
commenced during the 4-month set-up period. In line with recommendations from Treweek et al.’s51
systematic review, a multifaceted recruitment approach was undertaken using both national and local
routes. In doing this, we anticipated that we would have a list of potential participants to screen as soon
Potential participants are identified or self-refer;
provided with BRiMS study information pack 
by CRN staff or research therapist
Interested: return reply
form to PenCTU
Research therapist telephones patient to discuss study,
screens for eligibility and confirms planned BRiMS
programme dates
Interested and
potentially eligible
Baseline assessment visit
• Final eligibility check
• Written consent
• Baseline data collection
• Provided with falls diary (and completion and return instructions)
PenCTU notify CRN and
participant’s GP of successful
recruitment
Randomisation
Allocated to intervention group
(BRiMS + usual care)
Allocated to control
group (usual care only)
CTU e-mails NHS treating therapist to notify them 
of group allocation and e-mails participants about 
their individual allocation, and asks that they start 
their falls diaries
Not interested
and/or not eligible
Not interested
FIGURE 3 Recruitment pathway. CRN, Clinical Research Network; GP, general practitioner; PenCTU, Peninsula
Clinical Trials Unit.
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as sites confirmed research capacity and capability. As necessary, during the recruitment period we
complemented this approach by utilising direct recruitment strategies. Our first priority was to send out
consultant invitation letters, as this has been demonstrated to be a cost-effective strategy for recruitment
in other MS rehabilitation trials.52–54
Nationally, recruitment was promoted via a number of sources:
l the UK MS Register via their quarterly newsletter and social networking sites
l promotion through the MS charitable bodies’ regular open access newsletters (i.e. MS Society
‘Research Matters’)
l promotion through the MS Society online resources that alert people with MS to studies they may be
interested in participating in
l promotion and support from the NIHR Clinical Research Network (CRN) and national specialty lead
for neurology
l the trial’s website (www.brims.org.uk), which included generic e-mail contact details.
All promotional materials included information inviting people to make contact via the trial’s generic
e-mail address. These e-mails were monitored by the Peninsula Clinical Trials Unit (PenCTU), which triaged
enquiries and redirected them to the appropriate research therapist.
Local recruitment was also promoted via a number of routes, which included:
l adoption onto the UK CRN Portfolio; the local Clinical Research specialty lead also promoted the trial
through existing clinical networks
l through the caseloads of neurologists, MS specialist nurses and NHS therapists who discussed the trial
with interested patients, or wrote a letter of invitation to potential participants
l leaflets and posters placed in relevant outpatient clinics of the participating health establishments
l promotion through local initiatives where they existed, for example the South West Impact of MS
(SWIMS) project55
l local MS centres and MS Society branches, via posters, newsletters, personal contact with the regional
and branch leaders, and informal presentations at local MS branch meetings.
All people with MS who expressed an interest in participating were sent a BRiMS trial information pack by
the CRN staff or research therapists at the appropriate site. The pack consisted of a letter of invitation, the
participant information sheet, a list of local pre-scheduled BRiMS programme dates and venues, a reply
form and a reply-paid envelope. Where packs were distributed through direct contact (either face to face
or by telephone), potential participants were given the option to be contacted by the local research
therapist to verbally discuss the project and ask any questions. If the potential participant opted in to this
option, the member of staff passed the person’s name and contact details (e-mail address or telephone
number) to the local research therapist.
All patients were asked to read the participant information sheet and return the reply form to indicate
their interest, to confirm that they felt they were eligible, and to give consent for the staff undertaking
screening to contact their treating team to confirm their diagnosis of SPMS. This also gave the CRN staff or
research therapists permission to contact the potential participant to establish fully whether or not the
individual met the trial’s eligibility criteria.
Screening
On receipt of the completed reply form, the research therapist telephoned the person with MS to answer
any further questions and to screen them for eligibility using a pre-formatted screening checklist based on
the eligibility criteria. This included determining the person’s disability level using a telephone version of
the EDSS.56 During this screening telephone call, the participant’s preferred contact details were confirmed
and the planned dates of the BRiMS programme were discussed to ensure that they were able to attend if
TRIAL DESIGN AND METHODS
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they were allocated to the BRiMS group. Screen failures (i.e. patients who did not meet the eligibility
criteria at time of screening) were informed if they were eligible for re-screening at a later date and, in this
case, the research therapist arranged a follow-up screening call for a suitable date.
Clinical Research Network staff and research therapists maintained a screening log of potential participants
who made contact with the research team to be considered for entry to the trial. Anonymised data from the
screening log were transferred to PenCTU as required for the purpose of monitoring recruitment. These data
included the reason individuals were not eligible for trial participation, if they were eligible but declined, and
their reason(s) for declining if they were happy to divulge this. Furthermore, a record was kept of all people
who were sent invitation letters to determine the proportion of those who expressed an interest in the trial.
Once initial eligibility checks were completed, the individual’s details were forwarded on to the research
therapist (if screening had been undertaken by CRN staff). The research therapist telephoned the
participant to confirm eligibility and send an appointment e-mail for the baseline assessment. It was the
intention that the final face-to-face screening and the baseline assessment would be undertaken up to
2 weeks before the participant commenced the pre-scheduled BRiMS programme, should they subsequently
be allocated to the intervention group. To minimise travel costs and burden on the participants, this
baseline assessment was undertaken at a local health-care establishment. Reasonable travel expenses were
reimbursed for all visits additional to normal care, namely for the three research assessments at the local
health-care establishments at day 0, 15 weeks (± 1 week) after randomisation and 27 weeks (± 1 week)
after randomisation. All participants were reminded that the allocation to either group of the trial was by
chance and would occur after baseline assessment (see the next section).
Randomisation, concealment and blinding
The group-based element of the BRiMS intervention necessitated the confirmed recruitment and
participation of a sufficient number of patients within a recruiting site before randomisation was
undertaken. Each of the four sites aimed to recruit 10 participants per block/BRiMS delivery, but there was
flexibility to recruit 8–12 participants. After the completion of the block of participants, each participant
within the block was randomised (i.e. all participants within a block were simultaneously randomised).
A participant was deemed recruited once they had provided written informed consent, confirmed their
ability to attend a BRiMS group and completed the baseline assessment.
Once the decision was taken to declare a block of participants complete, randomisation was undertaken a
minimum of 3 and a maximum of 7 working days before the BRiMS programme commenced. Individuals
in the block were randomised approximately 1 : 1 to the intervention or usual-care arm following a strict
and auditable protocol. When the block size was 9 or 11, allocation was forced to have one more
participant in the intervention group than the usual-care group to maximise learning opportunities in this
feasibility trial. Randomisation was conducted via a secure web-based system. The randomised allocations
were computer-generated by PenCTU in conjunction with a statistician independent to the trial team,
in accordance with PenCTU’s relevant standard operating procedure. An automatic e-mail was sent by
PenCTU to the NHS treating therapist leading the BRiMS programme to notify them of those participants
allocated to the BRiMS programme plus usual care (intervention).
Access to the randomisation process was confined to the PenCTU data programmer only. This ensured
effective allocation concealment from every other member of the trial team. Following randomisation,
only appropriate members of the trial team were made aware of the allocations to the intervention or
usual-care arm [e.g. clinical trials unit (CTU) trial manager, chief investigator and site principal investigators].
Clearly, the participants and the NHS treating therapists leading the BRiMS programme could not be blinded
to which treatment the participants were receiving. However, the research therapist (outcome assessor)
remained blinded to the allocated treatment arm at all stages. In addition, the trial statisticians remained
blinded until the database was locked for analyses.
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Treatment
The two trial groups are shown in Figure 4, which includes a summary of the participant pathway.
Usual care (usual-care group)
All participants allocated to this group continued to receive their usual clinical care; thus, with the exception
of the trial assessments, they were not asked to attend any additional visits or sessions. Although usual care
varies across the country,57 it rarely involves regular ongoing physiotherapy intervention in the community or as
an outpatient on either an individual or a group basis. As a general rule, for those with SPMS, physiotherapy
input is provided when an event has caused a significant deterioration in the person’s ability to function
BRiMS study
visit: baseline
Randomisation
Allocated to intervention group
(BRiMS + usual care)
BRiMS week 1
Clinic visit
BRiMS week 2
Home visit
BRiMS week 4
Group session
BRiMS week 8
Group session
BRiMS week 13
Group session
BRiMS study visit
15 weeks (± 1 week) after
randomisation
BRiMS study visit
27 weeks (± 1 week) after
randomisation
Qualitative telephone interviews
Allocated to control
group (usual care)
U
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↓
FIGURE 4 Participant pathway. activPAL™ (Paltechnologies Ltd, Glasgow, UK). a, All participants wear the activity
monitor for 1 week from visit and then return it to the research therapist.
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(e.g. a respiratory infection or an injurious fall). The standard physiotherapy care pathway usually comprises
short, intermittent episodes of face-to-face intervention, which are generally limited to a few sessions.
The typical approach and content of these sessions is one wherein presenting problems are managed
(e.g. providing mobility aids, a written home exercise programme and advice) rather than focusing on the
promotion of long-term self-management strategies.
For people with mobility impairment who are at risk of falling, physiotherapy regimes typically consist of
gait re-education and the provision of a written home exercise programme, which is aimed at strengthening
muscles and/or optimising balance. In line with NICE guidelines,7 for individuals with mild to moderate
disability, advice may also be given to enhance cardiovascular fitness, as this has been demonstrated to
optimise general physical and emotional well-being and minimise deconditioning. For individuals whose
mobility is more severely impaired, advice and information to support their carer in terms of facilitating
movement (e.g. manual handling advice to enhance the safety of assisted transfers) may be given.
Usual care may also involve appointments with a variety of other health professionals (e.g. an occupational
therapist, a general practitioner, a MS nurse specialist, a neurologist or a rehabilitation consultant). As with
physiotherapy, multidisciplinary interventions are usually short term as resource restrictions limit the
provision of long-term maintenance therapy.
Falls programmes for older people exist in most locations across the UK;58 however, anecdotal evidence
highlights that people with MS are seldom referred to these services.27 Some programmes specifically
exclude those with neurological conditions from attending, and have lower minimum age restrictions,
which present further barriers.
This trial recorded the content of usual care on the participant resource-use questionnaire at each trial
assessment. Details of actual use for both groups are in see Table 41.
Usual care plus BRiMS (intervention group)
During the trial, six deliveries of the BRiMS programme were undertaken. The dates were planned in
advance to secure the services of the NHS treating therapists at each site and to facilitate participants’
advance diary planning. The intervention groups were conducted by band 7 NHS physiotherapists who
were experienced clinical specialist neurological therapists (see Table 25). The therapist training took
the form of a 1-day workshop delivered by two members of the research team (HG and JA), which all
treating therapists attended. The workshop included an overview of the key elements of the programme,
interactive sessions to introduce therapists to less familiar activities and an opportunity to practise setting
up and amending the online exercise activities. Ongoing support was provided in the form of an online
forum, promoting peer support and with additional input from a member of the research team (JA).
As participants were recruited in blocks that were related to each programme delivery, they were already
aware of the expected programme dates. Therefore, when participants received confirmation that they had
been allocated to the intervention group, they were simply contacted by the relevant treating therapist to
arrange the one-to-one sessions and to confirm their ongoing availability for the group sessions. All BRiMS
programmes were delivered in accordance with the programme manual and plan (see Chapter 1, The
BRiMS programme). In addition to participating in the BRiMS programme, all of those allocated to this
group were encouraged to continue utilising their usual clinical care and services.
Data collection and outcome measures
The BRiMS trial had four main analytical strands:
1. evaluation of trial feasibility
2. clinical outcomes
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3. health economics evaluation
4. BRiMS programme process evaluation.
All of the required data, assessment tools, collection time points and processes are summarised in Table 2.
TABLE 2 Outcome measures and data collection schedule
Outcome group/measure Objective
Evaluation time point(s)
Baseline
13 weeks ±
1 weeka
27 weeks ±
1 weeka
Post
trial
Trial feasibility
l Recruitment, retention and completion rates i–vi ✗ ✗ ✗
l Trial acceptability and feasibility
(participant interviews)
✗
l Trial safety and adverse events —————————————————▶
Potential full trial outcomes
Participant characteristics
l Demographic and clinical characteristics ✗
l Medication use ✗ ✗ ✗
Primary outcomes
l MSWS-12vs2 vii–ix ✗ ✗ ✗
l EQ-5D-5L ✗ ✗ ✗
l MSIS-29vs2 ✗ ✗ ✗
Secondary outcomes
l Falls frequency and injury rates vii–ix —————————————————▶
l Physical activity (activPAL™, Paltechnologies Ltd,
Glasgow, UK)
✗ ✗ ✗
l 2MWT ✗ ✗ ✗
l Mini-BEST ✗ ✗ ✗
l Functional Reach and Lateral Reach Tests ✗ ✗ ✗
l FES-I ✗ ✗ ✗
l CPI ✗ ✗ ✗
BRiMS programme feasibility (process evaluation)
Programme acceptability and feasibility (participant and
therapist interviews)
x, xii ✗
l Attendance at face-to-face sessions x–xii —————————————————▶
l Online exercise diary completion
l Web-based programme log-in sessions
Health economics
l Intervention costs xiii–xv ✗ ✗ ✗
l Health, social care and other resource use ✗ ✗ ✗
2MWT, Two-Minute Walk Test; CPI, Community Participation Indicators; EQ-5D-5L, EuroQol-5 Dimensions, five-level
version; FES-I, Falls Efficacy Scale – International; Mini-BEST, Mini-Balance Evaluation Systems Test; MSIS-29vs2, MS Impact
Scale (29-item) version 2; MSWS-12vs2, MS Walking Scale (12-item) version 2.
a After randomisation.
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Evaluation of trial feasibility (objectives i–vi)
Feasibility outcomes
l Recruitment, retention and attrition rates [Consolidated Standards of Reporting Trials (CONSORT) data]:
number of patients assessed for eligibility, reasons for exclusion, numbers lost to follow-up, numbers
discontinuing (with reasons) and numbers analysed and excluded from the analysis. Research staff
invited participants who withdrew from the intervention or research procedures to provide a reason.
l Participants’ and therapists’ views on the acceptability of the trial procedures were obtained through
qualitative methods (see Methods of evaluation for details).
Participant safety and adverse events
Adverse events
An adverse event (AE) was defined as any unfavourable and unintended sign (e.g. including an abnormal
laboratory finding), symptom or disease that developed or worsened during the trial, whether or not it
was considered to be related to the trial intervention. The risk of an AE from participating in this trial was
assessed to be low.1 AEs such as chest infections and urinary tract infections, which are common in
people with MS, were not intentionally monitored for any participants (intervention or usual-care group).
However, all participants were asked to report any new or worsening problems that they perceived to be
related to participation in activity and/or exercise, as well as any relapses and falls, in the daily pre-formatted
paper diaries. These were completed from the day of randomisation until the final assessment (27 weeks
± 1 week following randomisation), and returned in the reply-paid envelope on a fortnightly basis to
PenCTU for data entry. AEs may also have been discovered by treating therapists or research therapists
during questioning, physical examinations or during another intervention. When this was the case, the
therapist took appropriate action and also asked the participant to record the AE in their diary to ensure
it was reported as part of the trial data. To avoid double counting AEs, the therapist was requested not to
report these to the PenCTU.
On receipt of the diary returns, PenCTU recorded any AEs in the trial database, with collated reports being
(of the whole group, i.e. not according to group allocation) regularly presented at the Trial Management
Group (TMG) meeting for review.
Adverse events considered related to the trial intervention were followed until resolution or until the event
was considered stable.
Serious adverse events
A serious adverse event (SAE) was defined as an untoward occurrence that:
l resulted in death
l was life-threatening
l required hospitalisation or prolongation of existing hospitalisation
l resulted in persistent or significant disability or incapacity
l consisted of a congenital anomaly or birth defect, or
l was otherwise considered medically significant by the investigator.
It was not anticipated that there would be any SAEs related to this feasibility trial. Any SAE, whether or not
thought to be related to any trial intervention, was reported to the CTU by the local principal investigator
or another member of the research team by telephone or e-mail within 24 hours of the research team
becoming aware of it. SAEs were recorded from the time of the baseline assessment until the date the
participant completed follow-up or withdrew from the trial. SAEs could be directly reported by the
participant or another informant (e.g. by telephone) or discovered by the treating therapist or research
therapist through questioning, physical examination or another investigation. In addition, the 2-weekly
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diaries were reviewed to check for potential SAEs that had not otherwise been reported. Within 7 days of
a local research team becoming aware of such an event, it was required that a SAE form was completed,
signed by the principal investigator and returned to PenCTU. Completion of the SAE form included the
principal investigator’s assessment of causality (i.e. whether or not there was a reasonable causal relationship
between the SAE and the trial intervention). If the available information was incomplete at the time of
reporting, all appropriate information relating to the SAE was forwarded to PenCTU as soon as possible.
If the principal investigator considered that the SAE was not, or was unlikely to be, related to the trial,
PenCTU obtained a second assessment of causality either from the Scottish regional co-ordinator (for SAEs
at the Plymouth site) or from the chief investigator (for SAEs at other participating sites).
It was protocolised that, if SAEs were adjudicated as being possibly related to the trial intervention and
unexpected, then they would be reported by PenCTU to the Research Ethics Committee within 15 days of
the local research team becoming aware of the event. This situation did not arise in this feasibility trial.
All SAEs were followed until resolution. PenCTU routinely notified the chief investigator by e-mail of all
reported SAEs as they occurred and reported organ system listings of all SAEs to the Trial Steering
Committee (TSC) and sponsor on a quarterly basis. PenCTU was responsible for the preparation and
submission of an annual safety report to the Research Ethics Committee.
Trial outcome objectives (vii–ix)
Potential primary outcome for the definitive trial
A key aim of this feasibility trial was to inform the selection of a primary outcome measure and provide
potential sample size estimates for the definitive trial. In line with the remit of a feasibility trial, a variety of
outcome measures were undertaken to determine their performance and to identify those that may be
most appropriate to use in the definitive trial. The selection of potential outcomes was informed by best
practice guidance,59,60 and refined by the findings of our previous stakeholder activities (which involved
service users, providers and commissioners),27 collaboration with our trial patient and public involvement
(PPI) representatives and guidance from methodological experts. This led to the decision to propose
mobility and quality-of-life measures as potential primary outcomes rather than as falls outcomes. There
were two main reasons for this: (1) the recognition that a reduction in falls without a corresponding
improvement in mobility or QoL outcomes would be undesirable, and (2) concern about possible issues
associated with relying on self-report falls diaries as a data collection mechanism.
As this process led to the proposal of several potential primary outcomes, one of the key objectives was
to establish what would be the most sensible choice for use in a main trial. In particular, our aim was to
select a primary outcome that, as well as being meaningful to patients, ensured that the main trial would
be feasible and provide good value for money; for example, the selected outcome should demonstrate
good completion rates and lead to a realistic sample size requirement.
Outcome time points
Standardised, validated, clinician-rated and patient self-reported clinical outcomes were measured at
baseline, at 15 ± 1 weeks after randomisation (coinciding with the end of intervention period for
participants allocated to receive BRiMS) and at 27 ± 1 weeks after randomisation (coinciding with the
12-week post-intervention period). In a definitive trial, we would ideally like to follow up participants for
6 months post intervention to determine whether long-term behaviour change (such as sustained
engagement in exercise) occurs once therapy support is withdrawn.
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Procedures
All research procedures were protocolised and any deviations were documented. A research therapist
(this was always a physiotherapist) in each region undertook all of the outcome assessments, independently
of treatment, at separate research visits at local health-care establishments. Before recruitment commenced,
the research therapists from the two regions met with each other and members of the research team to
ensure a consistent approach and to standardise procedures. Every effort was made to ensure that these
assessments were blinded, and participants were asked to not discuss whether they were attending a group
session or undertaking any exercise programme. We carefully chose the battery of measures on the basis of
proven psychometric properties, our previous research in this area, recommendations from the International
Multiple Sclerosis Falls Prevention Network, and discussions held with people with MS/carers, as well as
health professionals working in this field, to ensure acceptability and relevance. Previous trials of the
assessment protocol demonstrated that the assessment would take approximately 60 minutes. This is the
typical duration for NHS physiotherapy assessments for complex neurological conditions and well within
the maximum 90 minutes that people with MS have told us is acceptable for such assessments.
Baseline measures
The following demographic clinical characteristic data were collected by participant self-report: age, sex,
educational attainment, marital status, employment status, length of time since diagnosis, disease course,
MS relapse history (within the past 3 months), number of falls/related injuries in the past 6 months,
currently prescribed drugs and comorbid medical conditions. The diagnosis was corroborated by the
research therapists or CRN staff with the participant’s medical records.
Information about changes to health and medication use was also collected at the follow-up assessments.
Potential primary outcomes
Multiple Sclerosis Walking Scale (12-item) version 2
An important outcome to evaluate in this study was walking from the patient’s perspective. We chose
the MS Walking Scale (12-item) version 2 (MSWS-12vs2)61 to achieve this because it is a widely used,
psychometrically robust, patient-reported questionnaire that assesses the impact of MS on walking ability,
which is a key goal of the BRiMS programme. This questionnaire evaluates the impact on 12 aspects of
walking function and quality (walking, running, climbing stairs, standing, balance, distance, effort, support
needed indoors, support needed outdoors, speed, smoothness, and concentration needed to walk)
identified as important by people with MS. The original Multiple Sclerosis Walking Scale (MSWS-12) has
been robustly evaluated in terms of its psychometric properties,62–65 and the revised version 250,61,66,67 has
minor modifications to response options. Of the 12 items, three are scored 1–3 and the other nine are
scored 1–5. The category descriptors range from 1 (‘not at all limited’) to 5 (‘extremely limited’). Scores on
the 12 items are summed, giving a total raw score whose range is 12–54. To ease interpretation, this raw
score is transformed to 0–100 (minimum to maximum walking disability) by subtracting the minimum score
from the sum, dividing the result by 42 and then multiplying by 100.68
Quality of life (EuroQol-5 Dimensions, five-level version)
The EuroQol-5 Dimensions, five-level version (EQ-5D-5L)69 is a standardised self-report measure of health
status, recommended for use in UK health technology appraisals and health policy decision-making.70
Taking approximately 5 minutes to complete, the EQ-5D-5L collects data across five dimensions; mobility,
self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is scored by the
participant as no problems, slight problems, moderate problems, severe problems or extreme problems.
From the initial collection of the EQ-5D-5L, data can be mapped to be reported as the EuroQol-5
Dimensions, three-level version (EQ-5D-3L), in accordance with relevant guidance (see Health economics
analyses). The EQ-5D-5L would also be used to inform the economic evaluation in a follow-on definitive
trial, wherein it is expected that it would be used in combination with a UK tariff of health state values71
to estimate quality-adjusted life-years (QALYs) for use as the primary economic end point.
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Quality of life [Multiple Sclerosis Impact Scale (29-item) version 2]
The MS Impact Scale (29-item) version 2 (MSIS-29vs2)61,72,73 is a condition-specific measure of health-related
QoL. This widely used self-report questionnaire was devised specifically for people with MS and was
founded on interviews with patients exploring how MS affects their QoL. The original Multiple Sclerosis
Impact Scale (MSIS-29) has been robustly evaluated in terms of its psychometric properties,61,74–77 and the
revised version 2 has minor modifications to response options.67,73 It consists of 29 items, all of which have
four response categories numbered 1 (‘not at all limited’) to 4 (‘extremely limited’); a higher score indicates
greater impact on the individual’s life. The MSIS-29vs2 provides domain scores for QoL and summary scales
for physical and psychological elements. There is an accumulating body of evidence to support the internal
consistency, reproducibility, validity and responsiveness of this later version.67,73 Furthermore, the MSIS-29vs2
data can be used to derive a MS-specific preference-based measure, the Multiple Sclerosis Impact Scale
(8-dimensions) (MSIS-8D),73,78,79 which may be used in assessment of cost-effectiveness.
Potential secondary outcomes
Falls frequency and injury rates
Evaluation of falls status is important, as there is a known link between falls status and activity
curtailment20 that may, in turn, have an impact on mobility and QoL. In this trial, falls were assessed by
prospective direct measurement, as it is widely acknowledged that other methods lack reliability and
validity.80,81 In line with best practice guidance,59 participants were asked to complete the pre-formatted
daily paper diaries throughout the trial to record falls and any related injuries (see Appendix 1). A fall was
defined as ‘an unexpected event in which you come to rest on the floor or ground or lower level’.60 In
addition, participants were asked to record any injuries and the related use of medical services as a result
of each fall. In line with recommendations from Coote et al.,59 participants were asked to complete the
diary daily and return a batch of 14 completed daily diaries in a reply-paid envelope every 2 weeks
throughout the trial. Participants received an automatic e-mail on six occasions throughout the trial to
thank them for their engagement and to prompt ongoing diary returns. Returned diaries were reviewed by
the trial managers and the data were entered into the trial database. Automatic e-mail reminders were
triggered when diary returns fell more than 2 weeks behind schedule. Up to two reminders were sent to
participants to remind them to complete and return their diary. Pre-formatted diaries to record falls and
related injuries have been used in a number of MS studies.16,82,83 Previous studies using this method have
indicated that high completion and return rates are consistently gained (75–99%), with our own previous
study demonstrating a 93% completed diary return rate.16
Physical activity level
It is important to measure levels of physical activity, as these reflect much more than simply walking,
and potentially provide a clearer indication of the impact of both the disease and the intervention on
the physical dimensions of an individual’s daily life. For instance, although falls may reduce if people
remain sitting (appearing to be a positive outcome from a falls perspective), this would not generally be
considered a positive outcome for the person with MS. The intention of BRiMS is to encourage increased
levels of safe mobility/physical activity, which has been demonstrated to enhance people’s QoL and
minimise secondary complications such as deconditioning.
The level of physical activity was measured objectively over 7 days using an activity monitor (activPAL™,
Paltechnologies Ltd, Glasgow, UK).84 The activPAL is a tri-axial accelerometer, worn on the thigh, which
can record data continuously for up to 21 days. It is smaller and lighter than other accelerometers and
attaches securely to the skin. The activPAL, and its accompanying manufacturer’s software, classifies
activity in terms of the time spent sitting or lying, standing and stepping, the number of steps taken, the
cadence, and the number of sit-to-stand and stand-to-sit transitions. To our knowledge, these are features
that no other comparable device offers. To ensure that the data collected are a true representation of the
individual’s physical activity, 5 consecutive days of data are required.85 Thus, to improve the likelihood of
achieving 5 full days of data, participants were asked to wear the monitor continuously (24 hours a day)
for 7 consecutive days and to undertake normal daily activity. The device was not removed during the data
TRIAL DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
collection period. The time spent in each posture and the number of steps were averaged over the 5-day
period. The activity monitor was fitted to the participant at each assessment session and participants were
instructed to remove the device after 7 days and post it back to the research team in the pre-paid
addressed envelope provided. This methodology has been successfully used in previous studies,86 including
several undertaken by some of the co-applicants.87,88
Walking capacity
To complement the self-report MSWS-12vs2, we also undertook an objective clinician-rated measure of
walking capacity: the Two-Minute Walk Test (2MWT). This determines the longest distance an individual can
walk (using walking aids if required) over 2 minutes on a hard, flat surface.89 This measure was chosen as it is
strongly correlated with community mobility levels,90 which is a potentially important outcome of the BRiMS
programme. There is evidence to support the reliability, validity and responsiveness of the 2MWT in a range
of rehabilitation studies, and reference values are available regarding clinically meaningful improvement,
according to disability level, in people with MS.50,90,91 The 2MWT has been recommended as the timed
walking measure of choice for evaluating rehabilitation interventions in people with MS who have moderate
disability.91 In this study, the 2MWT was undertaken using a 5-metre track set up in a quiet corridor.
Participants were instructed to walk as many lengths as possible in the time allowed, taking breaks if required.
Balance
Poor balance has been identified as a key modifiable risk factor for falls in MS15 and is one of the primary
targets of the BRiMS exercise component. The multidimensional nature of balance means that some
measures have been criticised for lacking responsiveness.92 In this trial, balance was evaluated using the
following two measures:
1. The Mini-Balance Evaluation Systems Test (Mini-BEST),93 a 14-item clinician rated balance assessment
tool that aims to target and identify the contributions of six different balance control systems to
functional stability: anticipatory postural adjustments, reactive postural correction and dynamic balance
during gait (including cognitive effects). Each item is scored on a three-level ordinal scale (0–2), with
higher scores indicating better performance; the maximum possible score is 28 points. The Mini-BEST
has established psychometric properties, including excellent internal consistency, reliability, validity and
responsiveness.94 It is recommended for inclusion as part of a core outcome set for measuring balance
in adult populations.95
2. The Functional Reach and Lateral Reach Tests are clinician-rated measures of standing balance that
mirror the everyday activity of reaching for objects beyond arm’s length. The person stands adjacent to
a wall with their shoulder flexed (forwards reach) or abducted (lateral reach) to 90 degrees, and leans
forward (or laterally) as far as possible without stepping, thereby testing the limits of stability.
Measurements are taken with a metre rule and an average of three repetitions is used.96 The Functional
Reach and Lateral Reach Tests are considered psychometrically robust for use in neurological clinical
practice97 and have been used in a number of studies to evaluate the effect of exercise interventions
that aim to improve the balance of people with MS.66,98
Fear of falling
Fear of falling has been highlighted as a risk factor for falls99 and is also associated with activity curtailment
in MS.20 A reduction in fear of falling is, therefore, a potentially important outcome of BRiMS, given the
recognised association between physical activity levels and QoL.100 We measured fear of falling with the
Falls Efficacy Scale – International (FES-I),101 which has been recommended by the European falls network
ProFane (www.profane.eu.org) as the preferred measure of fear of falling for clinical and research use
because of its speed and simplicity of completion.60 The FES-I has also been validated for use in ambulant
people with MS, demonstrating excellent internal reliability and construct validity.102 The FES-I produces a
single score based on the summed total of the individual responses to the 16 questions; the maximum
possible score is 64, with higher scores indicating a greater degree of anxiety.
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Community Integration
The World Health Organization’s focus on participation as a key construct in the International Classification
of Functioning, Disability and Health103 recognises that high-quality health care looks beyond mortality and
disease to focus on how people live with their conditions within their environments. As a result, participation
is increasingly a focus of measurement in rehabilitation studies.104,105 We measured participation using the
Community Participation Indicators (CPI),105 a self-report measure that evaluates participation using three
key indicators: engagement (20 items), involvement in life situations (14 items) and control over participation
(13 items). There is preliminary evidence supporting the validity of the CPI; however, its use has been
relatively small-scale to date. The CPI was recommended for use in an expert review paper published by
members of the International MS Falls Prevention Research Network;106 this feasibility trial provided an
opportunity to evaluate its performance before its potential inclusion in the definitive trial.
Programme feasibility objectives (x–xii)
Evaluation of programme feasibility: BRiMS process evaluation
There is growing recognition of the complexity of designing, implementing and evaluating rehabilitation
interventions and the challenges of moving programmes from the research setting into clinical practice.
The updated Medical Research Council guidance on the evaluation of complex interventions calls for
researchers to combine assessment of outcomes alongside evaluation of process.34 This reflects the
recognition that for evaluations to inform policy and practice, emphasis is needed not only on whether
interventions ‘work’ but also on how they are implemented, their causal mechanisms and the impact of
the ‘real world’ on programme uptake, delivery and engagement.
This trial provided an opportunity to evaluate the implementation of BRiMS as the next step in the complex
intervention development process.35 The BRiMS process evaluation was developed in accordance with best
practice guidelines45 and with reference to key theoretical and evaluation frameworks. The overarching
approach to the BRiMS PE is one of realist evaluation, as laid down by Pawson and Tilley.107 The paradigm
driving the evaluation is one of pragmatism, recognising the influence of historical, cultural and political
contexts on programme design, implementation and user experience.108
The process evaluation explored three main areas of programme delivery (Figure 5):
1. intervention implementation
2. mechanisms of impact
3. context.
The process evaluation plan
The overarching methodological approach to the BRiMS process evaluation is that of mixed methods.
A mixed-methods approach allows a number of strategies to be employed concurrently or sequentially.
Each element supports the findings of the other methods to create a coherent whole109 to inform the
development of holistic, realistic recommendations.110
Sources of data
The sources of data for the process evaluation are detailed in Figure 6.
TRIAL DESIGN AND METHODS
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BRiMS programme
logic model
Outcomes
Assumptions: participants’ engagement with BRiMS will be moderated by:
Implementation assumptions Assumptions: mechanisms of impact
• Participants’ health and MS symptoms (e.g. fatigue, relapses, disease progression)
• Participants’ level of competence in and confidence with using computers
• Participants’ relationship with the BRiMS therapist
• Logistical/lifestyle issues that may have an impact on programme engagement
• Previous experience with exercise/falls management programmes
• Support from family and friends
Exercise:
• Implementation of a challenging targeted
   programme of gait, balance and functional training
   will increase mobility and decrease falls
• The BRiMS exercise resources and group sessions will
   enable participants to progress their exercises and
   become increasingly self-directed
• Succeeding in balance training will increase the
   individual’s confidence in balance and safe mobility
   and enhance function/participation
Education:
• The BRiMS home packages and group sessions will
   support participants to identify their personal fall risk
   factors, enabling participants to modify activities to
   improve safe mobility and will improve confidence/
   self-efficacy
• Identifying barriers to, and facilitators of, fall
   prevention plan enactment will support long-term
   adoption of the plans
Imagery:
• The addition of functional imagery training to the
   programme will aid participants in goal-setting and
   maintaining motivation to exercise
Training and support:
• The BRiMS manual and materials will provide
   sufficient information to enable effective
   programme delivery
• The BRiMS training provision and resources will
   support therapists to deliver the key elements of
   the programme
Dose:
• The BRiMS resources will enable users to exercise
   safety and effectively, achieving 120 minutes of 
   exercise activity per week with appropriate 
   progression and adaptation over time
• The programme resources and support will enable
   participants to set, review and amend realistic
   programme goals
• The BRiMS home packages and group sessions will
   support participants to evaluate their personal
   falls risks and identify potential solutions
Reach:
• People with SPMS who are at risk of falling will 
   be able to access the programme information 
   and referral
FIGURE 5 The BRiMS process evaluation framework.
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Methods of evaluation
Intervention fidelity
The assessment of intervention fidelity aimed to measure the degree of concordance between the BRiMS
manual and the actual programme delivery. The BRiMS fidelity assessment was carried out by three
members of the research team who had a range of expertise relevant to the programme:
l assessor 1 – consultant neurological physiotherapist; expertise in clinical management of MS, site
principal investigator for the Ayrshire site
l assessor 2 – professor of psychology; lead for the development of functional imagery and motivational
support aspects of BRiMS
l assessor 3 – lecturer in physiotherapy; developer of BRiMS programme and BRiMS trial co-ordinator.
Fidelity assessments, customised according to the content of each session, were undertaken by scoring
audio-recordings of a sample of BRiMS sessions against the relevant checklist rating scale. The items scored
included both generic behaviours and session-specific content. The checklists were based on the Dreyfus
system for assessing skill acquisition111 and an adaptation of the Motivational Interviewing Treatment
Integrity scale.112
The fidelity checklist rating scales
The fidelity assessment for every session type included four common items that were scored according to
the criteria specific to the item (see Fidelity assessment; full manual available from the authors on request).
In addition, session-specific items were included that were scored according to the generic criteria (see
Appendix 2). Thus, the scale assessed adherence to the content of the intended intervention techniques,
the depth of coverage and the delivery approach. Each item was rated according to a four-point Likert scale;
to aid with the rating of items, an outline of the key features of each item was provided. The tool was
piloted, and scoring comparisons were made between the three reviewers, for three session recordings.
This enabled a consensus to be reached about its application before its use in the full evaluation.
BRiMS
process
evaluation
Participant
interviews
Therapist
focus group
Fidelity
assessment
Trial
outcome
measures
Trial
recordsa
Website
usage data
Participant
diary returns
Quantitative
Qualitative 
Mixed
FIGURE 6 Sources of data for the BRiMS process evaluation. a, Treating therapist contact sheets, withdrawal and
adverse event data.
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Method
With the participants’ permission, all face-to-face BRiMS sessions were audio-recorded (clinic assessment,
home visit and all group sessions). The recorded sessions were used to measure fidelity by comparing
the session audio recording against the checklist for that session. A random sample of 25% of the
audio-recordings was scored. No patient identifiable information was recorded on the fidelity checklist
and the audio-recordings were destroyed at the earliest opportunity after the checklist was completed.
The recorded sessions were used to evaluate the quality of the intervention delivery and the degree of
concordance with the BRiMS manual.
Participant engagement and adherence to the BRiMS programme
The BRiMS programme comprises five face-to-face sessions (two individual and three group based);
attendance at these face-to-face sessions was monitored and recorded. Participants were also advised to
undertake a minimum of 120 minutes of home-based exercise per week for a minimum of 12 weeks,
utilising a web-based physiotherapy programme, completing a web-based exercise diary each time. Thus,
adherence to the home-based programme was monitored based on the number of web-based log-in
sessions and the exercise diary data recorded online by the participant during the programme; adherence
to each element was calculated as a percentage. For example, with regard to adherence to the requested
time spent exercising, the optimum duration of exercise was 24 hours (2 hours per week for 12 weeks);
if a participant reported completing 18 hours, then they had 75% adherence. In addition, the weekly
adherence was monitored throughout the programme, as evidence suggests that adherence to internet-
delivered interventions reduces over time.113
Participants’ and therapists’ views on acceptability of the BRiMS intervention
The BRiMS programme has not yet been trialled for use by therapists in the clinical setting, and nor has it
been fully evaluated in a clinical trial. Therefore, a qualitative component was included in the process
evaluation to enable an exploration about the experience of participating in the trial (for both allocated
groups) and engaging in the BRiMS intervention (for the intervention group only), from the perspective of
both people with MS and the therapists delivering the intervention.
Procedures
The qualitative data from BRiMS participants were collected through one-to-one telephone interviews,
and a telephone focus group114 with treating therapists was held at the end of the programme. For the
participant interviews, a purposive sample of 13 participants was recruited, including people from different
regions and different BRiMS intervention groups, together with a sample of usual-care group participants.
At the end of the trial period, participants were contacted and a mutually convenient time was agreed to
undertake a telephone interview within 2 weeks of the completion of the BRiMS final trial visit.
All four treating therapists were invited to participate in the telephone focus group, which was convened
within 10 weeks of the completion of the final BRiMS programme delivery. All qualitative interviews were
facilitated by members of the research team (participant interviews, HG or JF; therapist focus group, HG
and JA). All interviews were digitally recorded and transcribed verbatim before being thematically analysed
(see Qualitative analyses) and synthesised into the process evaluation.
Health economics objectives (xiii–xiv)
Health economics outcomes
The main aims of the health economics analyses were to (1) provide an estimate of the resource use and
associated cost of delivering the BRiMS intervention; (2) develop a framework for collecting data on costs
and outcomes, and (3) develop methods for conducting cost-effectiveness analyses (CEA) in a future full trial.
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Methods for future conduct of economic evaluation were developed and tested, within this feasibility trial, on
the collection of resource use, cost and outcome data. The data on resource use associated with the set-up
and delivery of the BRiMS intervention were collected via within trial reporting, including participant-level
contact and non-contact time for staffing input on delivery, equipment and consumable costs, training and
supervision for delivery staff. Data on health and social care resource use were collected at participant level
using a resource-use questionnaire, developed for this trial based on resource-use forms used successfully in
previous studies in people with MS.67
The EQ-5D-5L was used to assess health outcomes from an economic viewpoint. The EQ-5D-5L is used to
derive health state values associated with the health status (states) described by trial participants. A future
economic evaluation would be expected to use the EQ-5D-5L as the primary economic end point (over a
6-month follow-up) to estimate the cost per QALY and, accordingly, EQ-5D-5L data were collected in this
trial. However, given some debate and uncertainty over the appropriateness of the EQ-5D-5L for people
with MS, the MSIS-29vs2 data collected during the trial were also used to estimate health state values
(QALYs) via the MS-specific preference-based measure developed by Goodwin and Green.79
Progression to definitive trial
We pre-defined a number of progression criteria for consideration as part of the decision about whether
we would either progress to a full trial application, or need to undertake further developmental work.
These criteria, described below, were designed to address the key aims and objectives of this feasibility
trial. The progression criteria were finalised in discussion with the TSC, with whom we were also able to
discuss whether or not there was sufficient evidence, with appropriate changes, to move forwards to a
definitive trial. The criteria were:
l A minimum of 80% recruitment of the intended 60 participants within the planned 6-month
recruitment window.
l A minimum of 80% of consented participants randomised to the intervention group fulfilling the
minimum engagement criteria of engaging with the 13-week BRiMS intervention, which was to attend
the initial face-to-face clinic appointment where the participant was assessed, their individualised home
programme was designed and explained, and the paper-based BRiMS participant manual was provided
to them.
l A minimum of 80% completion rate of at least one of the proposed primary outcome measures among
participants attending the planned primary end point of 27 weeks (± 1 week).
l The total resource estimated to conduct the definitive trial at a level that is likely to attract funding.
We considered that there would most likely be unforeseen issues raised during the trial that could affect
the decision to progress, but we anticipated that the process evaluation data and input from PPI team
members would be helpful in finding potential solutions and indicating remedial action.
Trial governance
Ethics and research governance
Application for ethics review via NHS and university ethics was submitted during the pre-trial period
(January–September 2016) in time for the commencement of the trial in September 2016. During this
period, relevant NHS trust research and development department and Clinical Commissioning Group
approvals were also obtained.
Patient and public involvement
From the outset, the programme was informed by people with SPMS. In 2010, this topic was identified by
participants in the chief investigator’s longitudinal study evaluating mobility. A survey (n = 116) asked for
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views about what future research should focus on: safe mobility and falls were priorities. Subsequently,
two discussion groups confirmed this and were used to focus research questions, determine acceptable
study designs and problem-solve implementation issues. People with SPMS have sat on advisory
committees in our subsequent studies: the BRiMS programme is a direct output. They were intimately
involved in the development of BRiMS through participation in the nominal group study [n = 36 (50%)
people with MS],27 which was innovative in how it facilitated people with MS, health professionals,
commissioners and the research team to work together. Dedicated training sessions (facilitated by the local
NIHR user involvement group) supported people with MS to engage fully and confidently in the process.
This high level of user engagement continued throughout this feasibility trial: Ben Marshall (who has MS)
was a co-applicant on the trial and had input on the development of the qualitative interview schedule/
evaluation/validation checks. John Kendrick, who also has SPMS, sat on the TSC. They provided advice on
issues such as recruitment, on participant materials such as the information sheet and plain English
summary, and on publications designed for patient/general public consumption such as MS organisation
newsletters. Participants from the nominal group phase, who helped us to design the BRiMS intervention,
gave permission for us to involve them in related discussion groups, and we contacted some of these
individuals again to use them as a ‘sounding board’ for materials during this study. In line with INVOLVE
guidance, lay members were financially reimbursed for attending discussion groups, TSC and TMG
meetings, as well as for the associated preparation time (included in the trial costs). The project team has a
well-established relationship with the MS Trust and the MS Society; both organisations were consulted
about the development of the trial protocol application and were highly supportive, playing a key role in
ensuring that it was possible to access people with SPMS through local branches.
Human and data management
As chief investigator, Jenny Freeman assumed overall responsibility for the trial, ensuring that it finished on
time and within budget. The trial was sponsored by University Hospitals Plymouth NHS Trust (formerly
Plymouth Hospitals NHS Trust). It was managed by the UKCRC-registered PenCTU, which co-ordinated the
development of the trial protocol and trial-specific documentation, managed the approvals process, liaised
with both trial sites, monitored recruitment and was responsible for the day-to-day conducting of the trial
in conjunction with the chief investigator. The CTU also provided a bespoke web-based randomisation
system, database and data management services for the trial.
Trial Management Group
A TMG, chaired by Jenny Freeman and including the co-applicants, the PenCTU trial manager, the PenCTU
data manager, patient representatives and sponsor representative, met monthly to monitor general
progress/timelines, recruitment, retention, adherence to the trial intervention and budgetary issues and to
discuss any problems as they arose.
Trial Steering Committee
Make-up
The TSC was a group of experienced triallists with majority independent representation: the chairperson
(independent), an external statistician (independent), the chief investigator (non-independent) and a lay
member (independent).
Frequency of meetings
The TSC met before the start of the trial in person and subsequently by teleconference on four occasions.
In addition, the TSC received a quarterly report of SAEs and injurious falls.
Responsibilities
The responsibility for calling and organising the TSC meetings lay with PenCTU in association with the
chairperson.
DOI: 10.3310/hta23270 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 27
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Gunn et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
Degree of independence from sponsor and investigators
Confirmation that independent members of the TSC were unconnected to either the trial sponsor or the
investigators was made through the completion of conflict of interests documents by all TSC members.
Minutes of meetings were sent to all members, the sponsor and the funder, and were retained in the trial
master file.
Data Monitoring Committee
Make-up
The group comprised an independent statistician and two experienced methodologists, one of whom was
a MS specialist consultant neurologist (the chairperson).
Frequency of meetings
The Data Monitoring Committee (DMC) first met at a telephone conference (November 2016) to agree the
terms of reference. There was no planned interim analysis for this trial, and thus there were no definitive
plans for the DMC to meet again. The TSC was charged with reviewing a quarterly report of all SAEs and
injurious falls, pooled across allocated groups (thus avoiding unblinding the TSC). It was agreed that the
TSC chairperson would trigger a DMC meeting to review the unblinded safety data in the event of more
than four fall-related injuries that required medical care in any consecutive 3-month period. This was based
on data from Peterson et al.,18 who reported rates of injurious falls requiring medical care of 0.23 falls
per person per year. This equates to a rate of 0.05 per person over 3 months, which, when rounded to
60 participants, equates to a rate of 3.45 falls per 3-month period. Therefore, a rate of four or more reports
of injurious falls requiring medical care represented a rate in excess of the known average. For the purposes
of this analysis, the number of falls that required medical care was used to calculate the rate, and not the
number of times that the person saw a medical practitioner.
A DMC teleconference was triggered on one occasion because there were five such falls reported between
May and July 2017. A DMC teleconference was held in early November 2017, during which the committee
reviewed the unblinded data and concluded that there were no concerns, recommending that the trial
continue through what remained of the follow-up period.
Responsibilities
The DMC maintained the interests of trial participants, with particular reference to safety.
Degree of independence from sponsor and investigators
This committee was independent of the trial organisers and the TSC. The TSC and the DMC met
independently of each other.
Data management
Peninsula Clinical Trials Unit was responsible for data management in this trial.
Data protection
Data were collected and stored in accordance with the Data Protection Act 1998.115 Electronic trial records
were stored in a Microsoft SQL Server (Microsoft Corporation, Redmond, VA, USA) database, stored on a
restricted-access, secure server maintained by the University of Plymouth. Data were entered into the
database via a bespoke web-based data-entry system encrypted using SSL.
Participant numbering
Each participant was allocated a unique trial number by the CRN staff/research therapists when they were
registered on the data collection website.
TRIAL DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
Data collection tools and source document identification
Case report form (CRF) entries were considered source data. These were printed and collated into
booklets. The research therapists completed the CRFs for all participants. Completeness of data was
maximised by the research therapists, who:
l checked all forms at each assessment to ensure that there were no missing items
l arranged another assessment session, wherever possible, if the pre-scheduled session was cancelled or
participants did not attend.
PenCTU prompted the participants if they failed to return their diaries (within 2 weeks of each due date).
In addition, periodic e-mail reminders were sent to all participants to maximise the completion of diary data.
Data handling and record-keeping
Completed CRFs were checked and signed by the research therapists before being scanned and
transmitted to the Plymouth-based PenCTU on a participant-by-participant basis; the original CRF was
retained at site. When PenCTU received the completed CRFs and diaries, all data were double-entered into
a password-protected database. Double-entered data were compared for discrepancies. Discrepant data
were verified using the original paper data sheets.
Treating therapists completed contact sheets following every contact they had with BRiMS programme
participants. These were sent to the PenCTU on completion of each BRiMS delivery for data entry as
above.
Qualitative data in the form of telephone interview and focus group audio-recordings were transcribed
and anonymised as soon as practicable; original recordings were held securely until completion of the
qualitative data analysis process, and then deleted.
The research teams ensured that participants’ anonymity was maintained on all documents. All paper
forms (including all original signed informed consent forms and copies of the CRF pages) were archived by
each site in a secure location and will be stored for a minimum of 5 years after trial closure, in line with
the sponsor’s archiving requirements. Records remain accessible for the purposes of monitoring and
auditing, or at the request of regulatory bodies.
Trial data were analysed by Siobhan Creanor and Kara Stevens (trial statisticians), Hilary Gunn (trial
co-ordinator), Jenny Freeman (chief investigator) and Colin Green (in charge of economic data).
Archiving
The sponsor was responsible for archiving the original trial data (in paper and electronic formats) and
essential documentation (the contents of the trial master file) in a secure location for a minimum period
of 5 years after the end of the trial. Archiving was authorised by the sponsor following submission of
the end-of-trial report. Each individual trial site was responsible for archiving copies of local trial data
(as applicable where copies exist) and essential documentation (the contents of the investigator site file) in
a secure location for the same period. No essential documents will be destroyed unless or until the sponsor
gives authorisation to do so.
Monitoring, audit and inspection
The PenCTU trial manager devised a monitoring plan specific to the trial, based on an initial pre-trial risk
assessment that was updated as required throughout the trial. The monitoring plan included both central
monitoring strategies and trial site visits as appropriate, and was reviewed and agreed by the TMG.
Monitoring included oversight of processes relating to the safety of participants and the integrity/reliability
of the trial data, including AE reporting, participant enrolment, consent, eligibility and allocation to trial
groups, adherence to trial interventions and policies to promote the accuracy, and timeliness of data
collection.
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All trial procedures were conducted in accordance with the protocol and according to the principles of
good clinical practice. Procedures specifically conducted by the CTU team (e.g. randomisation, data
management, trial management and trial monitoring) were conducted in compliance with PenCTU
standard operating procedures. Principal investigators and the participating NHS trusts were required to
permit the CTU trial manager or deputy to undertake trial-related monitoring to ensure compliance with
the approved trial protocol and applicable standard operating procedures, providing direct access to source
data and documents as requested.
Protocol amendments
No substantial amendments were made to the protocol during the lifetime of the trial, however, a number
of non-substantial amendments were made. These included minor changes to improve consistency and
clarity throughout; an update to the sponsor contact details; an update to the title of the chief investigator;
and the removal of the clause ‘and adherence to’ from a sentence in section 14.4 that relates to participants
engaging with the trial. This was removed on the advice of the TSC members, who felt that it would be
overly optimistic to expect that the research team could reliably and comprehensively measure participants’
adherence to the programme. The TSC members also emphasised the complexity in understanding the level
of engagement required in programmes of this nature to instigate behavioural change. They cautioned,
therefore, about being very specific about required levels of adherence.
Data analyses
Statistical methods
A detailed statistical analysis plan was written by the team statisticians and approved by the TSC (statistical
analysis plan version 1.0, dated 15 March 2018) prior to trial database lock.
Analytical approach
All analyses were undertaken in accordance with appropriate analytical and reporting guidelines.116 Primary
analysis (in the form of summary statistics, not formal/inferential analysis) was undertaken on an intention-
to-treat basis, whereby participants were analysed according to their allocated group, regardless of
adherence to the protocol or lack of participation or completion if allocated to the intervention group.
Statistical significance levels
As this was a feasibility trial, no inferential between-group comparisons were undertaken (i.e. there was no
between-group hypothesis testing). When presented, confidence intervals are at the 95% level, unless
otherwise stated.
Interim analysis
There was no planned interim analysis for this trial.
Time points of statistical analysis
Statistical analysis was undertaken once the final group of participants completed the final assessment at
27 (± 1) weeks post randomisation and the database was locked following final approval and sign-off of
the statistical analysis plan by the TSC.
Data sources and data quality
The data from this trial came from information entered onto CRFs completed by a blinded research
therapist at baseline, 15 (± 1) and 27 (± 1) weeks post randomisation. All participants were asked to
complete a 2-weekly self-reported pre-formatted paper diary. In addition, intervention participants were
asked to complete an online exercise diary to record their adherence to the programme. Attendance at the
BRiMS face-to-face sessions and the number of log-ins to the online exercise portal were also recorded.
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Missing data
One of the objectives of this feasibility trial was to assess the completeness of potential outcome measures
for the definitive trial, at the level of both item and outcome measure. Missing outcome data were noted
and used to inform the likely pattern of missing data in a full-scale trial.
Imputation methods
For the validated outcome measures MSWS-12vs2,61 MSIS-29vs261,72,73 and FES-I,101 the established
methods for imputing missing item-level data were implemented, when the minimum number of items
required to impute the missing data was met.
If the participants completed at least 11 of the 14 Mini-BEST test components, the final score was imputed
by replacing missing values with the mean of the non-missing test component scores.
The mean of the three Functional Reach Test values (forwards and lateral) was calculated and analysed.
If participants were missing any of the three repeated test components of the Functional Reach Tests,
the mean of the successful attempts was used.
If there were up to four missing items from the FES-I score, the total score was imputed by replacing the
missing items with the mean score.117
A validated imputation method was not available for any CPI score. Therefore, if a participant was missing
at least one item, he or she was excluded from the analysis.
Statistical software
The statistical analyses were undertaken using Stata/SETM version 14 (StataCorp LP, College Station, TX, USA),
supplemented, where required, by R (The R Foundation for Statistical Computing, Vienna, Austria).
Statistical analyses
As this was a feasibility trial, it was not powered to be able to support or justify any conclusions regarding
treatment effectiveness and efficacy realised from hypothesis testing,23 and, indeed, that was not the
purpose of the trial. As such, the analysis of the results did not involve formal/inferential statistical
comparisons between groups, but rather it was descriptive with the view to informing the design of a fully
powered BRiMS RCT.
Continuous measures were summarised as means, SDs and ranges when the distribution appeared normal,
and as medians, interquartile ranges (IQRs) and ranges when the distribution appeared otherwise. Categorical
data were summarised by frequencies and percentages. When appropriate, parameter estimates (e.g. between-
group differences) were presented with 95% confidence intervals (CIs). With the exception of the falls diary
analyses (see Analysis of patient-reported and clinician-rated outcome measures), any potential outliers were
identified and reported but not removed from the descriptive statistics of this feasibility trial unless stated.
Analyses of quantitative data were conducted to summarise feasibility outcomes (objectives i–vi), evaluate
acceptability and adherence to BRiMS (objective xii), and the completion and summary statistics of the planned
primary and secondary patient-reported and clinical outcomes measures (objective vii). In addition, appropriate
plots were used to illustrate key data and assess potential relationships.
Trial population
Data from the screening process through to the completion of the trial were recorded and presented in a
CONSORT-style flow diagram.116
Baseline characteristics and demographics
Baseline characteristics, collected before randomisation, were summarised by allocated group to informally
check for balance between groups (by visual inspection) and provide an exploratory overview of the trial
population.
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Analysis of randomised groups at baseline is not good practice118 and so this was not undertaken, but any
considerable imbalances were noted to inform the design of the full trial.
Participants who discontinued, withdrew or were lost to follow-up
It was possible that participants would withdraw consent part-way through the trial, or that their treatment
would be discontinued for medical reasons. It was unlikely that a participant would be discontinued on
medical grounds (in either allocated group), but for reasons such as injury, some participants may not have
been able to complete the trial. Participants who discontinued were categorised as follows:
l continued to consent for follow-up and data collection
l consented to use pre-collected data only
l complete withdrawal of consent to use any data.
Reasons for withdrawal or loss to follow-up were summarised, where these were reported, at each stage
of the process. These included ‘participant withdrew before randomisation’, ‘participant did not receive
their allocated treatment’, ‘participant did not complete treatment’ and ‘participant was lost to follow-up’.
Participants who withdrew from the trial, or whose treatment was discontinued on medical grounds, were
not replaced. No participant who withdrew from the trial requested that their previously collected data be
removed from the trial database. The extent of discontinuation, withdrawal and loss to follow-up will be
used to inform the design of the anticipated fully powered trial, predominantly to ensure a sufficiently
powered trial after allowing for losses to follow-up.
Trial feasibility outcome analyses
In addition to the summary statistics detailed in Statistical analyses, data pertaining to a range of feasibility
issues were summarised, including the time to recruit each block of individuals; the number of completed
assessments within the pre-defined assessment window; a detailed breakdown on attendance at each
BRiMS face-to-face session; and the recorded web-based log-ins and diary completions.
Analysis of patient-reported and clinician-rated outcome measures
Summary statistics were calculated for each of the patient-reported and clinician-rated outcome measures
at each time point, including CIs for the SDs. Between-group differences at 15 weeks (± 1 week) and
27 weeks (± 1 week) post randomisation were calculated, together with 95% CIs (no p-values are presented).
The correlation between baseline and follow-up scores was calculated across all participants with available
data, with corresponding CIs, for each of the candidate primary outcome measures for use in future sample
size calculations.
Visual displays, such as box plots and scatterplots, with point and interval estimates, were used to identify
any baseline characteristics that have a strong association with each or all of the candidate primary
outcomes.
Analysis of EuroQol-5 Dimensions, five-level version, data
The advice from NICE is to use the EQ-5D-3L rather than the EQ-5D-5L,119 so the EQ-5D-5L was mapped to
the EQ-5D-3L using the ‘crosswalk’ technique.120 Therefore, we quote the EQ-5D-3L in the results tables
throughout.
Analysis of activity monitor (activPAL) data
Data cleaning
Initial data cleaning was undertaken using visual inspection of each activity summary sheet to remove any
incomplete days of data at the start and end of the recording period (e.g. data from the assessment day or
the day of the removal of the activPAL).
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Decisions relating to the classification of incomplete days at the end of the recording were informed by
reference to the typical daily activity patterns recorded by the individual participant (through visual
inspection of the summary sheets), and lack of event recordings in the following 24-hour periods
(indicating prolonged non-use). Any uncertainties were addressed by checking appointment dates for the
individual participant to inform the scheduled removal date.
Data analysis
All complete days of activity data were included. Initial analysis reported the time spent in the three activity
classifications (sitting/lying, standing/incidental stepping, and purposeful stepping), plus step count and
sit-to-stand transitions per day averaged over the number of full days of collected data.
Analysis of falls diary data
Participants returned data reporting falls and related injuries every 2 weeks for the duration of the study.
As the diary return rate and completeness of diary returns were below what we expected, these data were
analysed and presented in three ways.
Analysis 1 (reported)
Falls/injurious falls rate was calculated using the actual number of days of data available as the denominator
(i.e. valid days only):
Number of falls or injurious falls
Actual number of days of data available
× 365 (1)
Analysis 2 (expected)
Falls/injurious falls rate was calculated according to the number of days available had all those who
submitted any diary entries (n = 48) done so fully (i.e. returned 100% of their expected diaries):
Number of falls or injurious falls
Number of days, assuming a 100% diary return rate for all participants who submitted diaries
× 365 (2)
Analysis 3 (randomised)
Intention-to-treat analysis: falls/injurious falls rate was calculated according to the number of days available
had all those randomised (n = 56) done so fully (i.e. returned 100% of their expected diaries):
Number of falls or injurious falls
Number of days, assuming a 100% return rate for all randomised participants
× 365 (3)
Safety data
Data on AEs were collected at the participant level as part of the fortnightly participant diary returns
(see Potential secondary outcomes). In preparation for the analysis, any diary entries that were not for
dates within the specified trial period (i.e. 28 weeks after randomisation) were excluded from the analysis.
Potentially duplicated entries were not removed unless the diary start date was the same on both returns
(i.e. obvious duplicates), and therefore it is possible that a small proportion of duplicated data remains.
As with the falls data, AE reports were analysed and presented in three ways.
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Analysis 1 (reported)
Analysis based on actual diaries returned (denoted as ‘reported’ in see Tables 20 and 21):
l 255 diary returns from 22 participants in the usual-care group
l 234 diary returns from 26 participants in the intervention group
l 489 diary returns in the combined group (48 participants in total).
Analysis 2 (expected)
Analysis based on expected number of diary returns (for those who completed any diary returns):
l 22 (participants) × 14 (two weekly diary returns) = 308 in the usual-care group
l 26 (participants) × 14 (two weekly diary returns) = 364 in the intervention group
l 48 (participants) × 14 (two weekly diary returns) = 672 in the combined group.
Analysis 3 (randomised)
Analysis based on number of diary returns expected for all randomised participants (intention to treat):
l 26 (participants) × 14 (two weekly diary returns) = 364 in the usual-care group
l 30 (participants) × 14 (two weekly diary returns) = 420 in the intervention group
l 56 (participants) × 14 (two weekly diary returns) = 784 in the combined group.
Subsequently, all reported AEs and SAEs were cross-tabulated by group and assessed for clinical relevance
to inform the design and conduct of a full trial. They were also categorised according to Medical Dictionary
for Regulatory Activities (MedDRA)’s System Organ Classification (Version 14).121
Process evaluation analyses
Fidelity assessment
Analysis of scoring of the fidelity checklist rating scales was undertaken by combining the scoring for each
session type and calculating the median and IQR for each. Each score was recorded individually, and,
once collated, each individual entry was allocated a record number to ensure that a clear audit trail was
maintained. Qualitative feedback, in the form of written annotations, was provided by the fidelity assessors
to support scoring judgements where those judgements had been less than straightforward, rather than to
provide a comprehensive qualitative overview of delivery fidelity.
Qualitative analyses
Approach and theoretical underpinnings
The qualitative data for analysis included transcripts from one-to-one participant telephone interviews, and
the telephone focus group of staff involved in the delivery of BRiMS. Analysis aimed to achieve an in-depth
investigation and critical analysis of the data to explore the underpinning concepts and emergent themes,
rather than using the data as a simple representation of the phenomenon.
Five members of the research team contributed to the qualitative analysis, which was co-ordinated by the
BRiMS trial co-ordinator (HG). The analysis was underpinned by a pragmatic paradigm, which recognises
the influence of historical, cultural and political contexts on programme design, implementation and user
experience.108 As this analysis formed part of an evaluation of a pre-existing programme, bracketing of
previous knowledge was neither possible nor advisable.122 In addition, the need for the analysis to achieve
the specific aims of the process evaluation meant that some alignment of the data to the broad process
evaluation framework was necessary to aid synthesis of the data. Thus, the chosen qualitative analytical
framework was template analysis.123 Template analysis is a form of thematic analysis that emphasises the
use of hierarchical coding but balances a relatively high degree of structure in the process of analysing
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textual data with the flexibility to adapt it to the needs of a particular trial. Unlike framework analysis,
template analysis allows the integration of a priori themes into an initial coding template, which is then
developed and refined through analysis.123
Procedures
The data analysis was undertaken in accordance with Brook et al.’s guidance.123 Anonymised transcribed
data of the participant interviews and therapist focus group were entered into NVivo software, version 12
(QSR International, Southport, UK), and preliminary coding was undertaken to split the data into the three
categories that make up level 1 of the coding template (see Figure 6). Subsequently, a pragmatic process
of data immersion, coding and clustering was undertaken on a subset of three interview transcripts to
develop a more detailed coding template informed by the proposed themes within each of the categories,
before the template was applied to the rest of the transcripts. Ongoing review of the developing
categories and themes was undertaken as analysis continued to aid implementation of the final coding
template, agreement of findings and generation of recommendations.
Credibility and trustworthiness
Analysis was undertaken collaboratively by two researchers (HG and AD). Initially, three interview
transcripts were coded by both researchers and the outcomes were discussed and compared to agree and
refine the basic coding template. Subsequently, further transcripts were coded separately, and similarities
and differences in themes and clusters were compared and refined to develop a more detailed template.
The researchers kept reflexive diaries, and regular discussions between them were undertaken to explore
their assumptions and the potential impact of these on the analytical process. Other members of the
research team were also involved in the process of refinement of the themes and coding template, with
the aim of maximising credibility within the process.
Owing to the variety of data included in the analysis, simple respondent validation was unlikely to be
beneficial; however, interview and focus group participants were invited to review an initial draft to
ensure that the analysis represented an accurate overview of participants’ views, experiences and
recommendations. Once this was verified, we used the data to (where necessary) recommend revisions to
the BRiMS operational manual and the trial procedures to optimise the success of the proposed future
definitive trial.
Health economics analyses
The economic analyses undertaken as part of this feasibility trial is informed by expectations that any
future economic evaluation of the BRiMS programme will be undertaken primarily from the perspective of
the third-party payer (NHS and Personal Social Care/Services). A broader perspective was also considered
by incorporating into data collection a wider participant/societal perspective.
Aligned with the main statistical analysis plan, the economic analysis considers BRiMS plus usual care
versus usual care alone, and the time horizon reported is consistent with the trial assessments over a
27-week (± 1 week) post-randomisation follow-up.
General principles of the health economics analyses
Data are presented descriptively, and no formal statistical analyses were undertaken/presented (consistent
with methods for a feasibility RCT). As analyses were over a 27-week (± 1 week) period, no discounting of
future costs was required.
Analysis of resource use and cost of intervention delivery
The additional (incremental) costs associated with delivery of the BRiMS intervention, when added to usual
care, were estimated using resource-use data collected within the trial, and unit costs for resource use
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from national published/NHS source.124,125 Resource use consisted of time input from BRiMS treating
therapists (contact time, non-contact time, travel), training (set-up) costs for therapists, and consumables.
Data on treating therapist input (time) were captured/reported at the participant level using treating
therapist contact sheets. Other resource-use data were collected by research therapists during the
feasibility trial. Each component of resource use was collated and presented in a tabular format (mean),
together with the unit cost data (national estimates, e.g. by staff grade/level, with standardised currency
year, e.g. 2015/16 Great British pounds). A mean cost per participant of BRiMS intervention delivery is
presented.
Analysis of data on health, social care and other resource use
We report the resource use and associated estimated costs for health and social care service use. We also
report estimates of the resource use and costs associated with reported use of informal care and time off
work for those providing informal care and support. Data were collected using the CRF at trial assessments
[baseline, week 15 (± 1 week) and week 27 (± 1 week)]. The primary objective of this feasibility trial was
to test the methods of data collection to ensure that participants were able to report resource use using
the form supplied in the trial, and that the methods were practical, feasible and successful. We combine
participant-reported data on resource use with estimates of unit costs associated with resource use (see
Appendix 3). Mean (SD) resource use, by item, is presented for baseline assessment, and for resource use
during the follow-up period. Unit costs are applied to items of resource use, taken from national/credible
tariffs,124–127 and mean (SD) cost data are presented, by treatment arm, for the baseline assessment and
6-month (27 weeks ± 1 week) follow-up data. Cost data for resource use are presented using appropriate
subgroupings (categories) of data (e.g. primary care, hospital care). In this feasibility trial, we present
descriptive statistics based on complete-case data to inform any future economic evaluation.
Analysis of data on health outcomes
The proposed primary economic end point is the QALY. QALY data were derived from trial data on EQ-5D-5L
using the UK algorithms/tariffs, in the first instance those derived from Dolan128 (via van Hout et al.120), which
is the current recommendation of NICE in the UK. Derived health state values were used to estimate QALYs
through the application of standard area-under-the-curve methods129 using baseline, 13-week (± 1 week)
and 27-week (± 1 week) assessments. We present descriptive data on EQ-5D-3L health state values (primary
analyses),130 as well as descriptive data on health state values derived from the MSIS-29vs2, using the tariff
for the MSIS-8D.79 The descriptive statistics presented are based on complete-case data to inform any future
economic evaluation.
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Chapter 3 Trial results
Trial feasibility objectives (i–vi)
Trial procedures and implementation
Trial set-up
The original trial timeline anticipated that the approval process would commence in June 2016, predicting
that all approvals would be in place by October 2016 (see Appendix 4). However, this was reliant on
commencing the process during the pre-funding period, which proved difficult because of limited staff
availability. As outlined in Table 3, the initial ethics application was submitted in August 2016, with final
approvals gained in February 2017.
Once the final approvals had been granted, all subsequent activities took place in line with the trial Gantt
chart (see Appendix 4).
Summary
The submission of approval documents took longer than expected, which was mainly a result of staff
capacity in the pre-funded period when these activities were scheduled to be undertaken. Nevertheless,
this did not have an impact on the trial timeline.
TABLE 3 The BRiMS trial approvals timeline
Approving organisation Type of approval Date of submission Date of approval
Time taken
(days)
NRES Exeter Research Ethics
Committee
Ethics 18 August 2016 8 November 2016 82
Health Research Authority National approval 21 October 2016 13 December 2016 53
University of Plymouth
Faculty Ethics Committee
Ethics 29 November 2016 30 November 2016 1
University of Plymouth PAHC site approval 13 December 2016 22 December 2016 9
University Hospitals Plymouth
NHS Trust
C&C PIC site 5 January 2017 11 January 2017 6
Cornwall Partnership NHS
Foundation Trust
C&C recruiting site 5 January 2017 13 February 2017 39
Royal Cornwall Hospitals
NHS Trust
C&C PIC site 6 January 2017 13 February 2017 38
Royal Devon & Exeter NHS
Foundation Trust
C&C recruiting site 5 January 2017 1 February 2018 26
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NHS treatment costs and intervention delivery
The total excess treatment costs (ETCs) for delivery of the BRiMS intervention were calculated as £236.79
per patient. ETCs for 20 patients in the South-West were provided by two Clinical Commissioning Groups
[Northern Eastern and Western Devon, and Kernow (Cornwall)]. The costs for intervention delivery for
10 patients in Ayrshire fell below the threshold for requiring application for ETCs and were agreed to be
absorbed by NHS Ayrshire and Arran.
In all centres, the ETCs provided funding for treating physiotherapist time and service support costs
(e.g.travel expenses), which allowed the BRiMS programme to be delivered according to plan.
Summary
Close communication with the local CRN was key to facilitating the ETC approval process. The availability
of funding for ETCs was essential as confirmed by feedback from clinical teams who highlighted that there
was no spare capacity to deliver the BRiMS intervention, for the purposes of a research project, in addition
to their usual workload. Close communication with managers of local therapy services was important to
ensure that the additional requirements of the project fitted in with existing service commitments.
Recruitment methods
A variety of recruitment methods were used in this feasibility trial, including personal approach from
clinicians and research staff, invitation letters and enquiries prompted through media advertisements.
Social media activities included publicity via the BRiMS website and Twitter feed and university social media
accounts, and asking local and national MS support groups to share details of the study via their social
media links (predominantly Facebook and Twitter). Data on the sources of recruitment to the trial are
detailed in Table 4. Overall, 232 people are known to have been approached about taking part in the trial;
from these, we recruited 56 participants, which represents a conversion rate of 24% (objective iii). The
conversion rates vary by recruitment approach; by far the most effective method was personal approach by
clinicians or research staff, thus providing evidence of the importance of the willingness of clinicians to
recruit patients (Figure 7) (objective iv).
Figure 8 shows the flow of participants from invitation through to recruitment. The main reasons for not
wishing to participate were the time commitment required (n = 16) and not having access to a computer
or tablet/having poor information technology (IT) literacy (n = 14). The most common reason for patients
failing the screening process was that they had previously had treatment with alemtuzumab (Lemtrada);
TABLE 4 Recruitment methods and conversion rate
Recruitment method Invitations (n) Reponses,a n (%)
Recruited,b
n (%)
Conversion
ratec (%)
Media (including support groups,
social media, trial website)
10 10 (100) Yes: 10 (100) 2 (20) 20
No: 0
Letter 139 36 (26) Yes: 23 (64) 17 (74) 12
No: 13 (36)
Personal approach 38 35 (92) Yes: 23 (66) 21 (91) 55
No: 12 (34)
Personal approach with letter
follow-up
45 39 (87) Yes: 20 (51) 16 (80) 36
No: 19 (49)
a Percentage of those who replied.
b Percentage of those who were interested.
c Proportion of those recruited from initial invitation.
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all of these patients were in the South West. There were also a number of people who were keen to
participate but were excluded because they had a diagnosis of primary progressive MS (n = 3) or because
they lived outside the Clinical Commissioning Group catchment area that had agreed the ETCs for the site
(objective ii).
There were no instances in which patients declined to participate in the trial because they were unwilling
to be randomised (objective v).
South West
(n = 166)
Invited to
participate
Methods of
invitation
Replies received
Response
breakdown
Enrolment
Source of
participants
Recruitment and
allocation
Media
(n = 10)
Letter
(n = 139)
Responded
(n = 120)
Screened by
telephone
(n = 76)
Eligible
(n = 56)
Personal contact
(n = 38)
Personal contact/letter
(n = 45)
Media
(n = 2)
Letter
(n = 17)
Baseline visits
(n = 56)
Randomised
(n = 56)
Personal contact
(n = 21)
Personal contact/letter
(n = 16)
Media
(yes = 10, no = 0)
Letter
(yes = 23, no = 13)
Personal
(yes = 23, no = 12)
Personal contact/letter
(yes = 20, no = 19)
Ayrshire
(n = 66)
Not interested
(n = 44)
Ineligible
(n = 20)
• Not interested/no reason, n = 10
• Computer, n = 14
• Commitment, n = 16
• Diagnosis, n = 4
• EDSS score of < 4.0, n = 2
• Diagnosis, n = 3
• Alemtuzemab, n = 6
• Commitment, n = 4
• Conflicting trial, n = 2
• Other, n = 3
FIGURE 7 Recruitment sources.
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Summary
The most effective method of recruitment was personal approach by clinicians or research staff. Our local
recruiting colleagues were extremely supportive, but it is acknowledged that recruitment to multicentre
RCTs can be particularly challenging.131 It will be important for a future large-scale definitive trial to include
measures to facilitate engagement and active involvement from clinicians at all sites in order to optimise
recruitment.
Current exclusion criteria include participants who had previously had treatment with alemtuzumab, were
within 3 months of switching disease-modifying therapies or were within 6 months of ceasing Tysabri.
In the south-west, previous treatment with alemtuzumab was the most common reason why a patient
failed the screening process. Given the potential for an increasing number of people to be treated with
alemtuzumab, the move towards more frequently switching disease-modifying therapies,132 and the
potential for new drugs to be licensed for people in the progressive phase of MS, this exclusion criterion
should be carefully considered when determining the recruitment rate of a future trial.
Recruitment of blocks of participants
In this trial, the recruitment window for each block of participants was fixed, as BRiMS treatment sessions
needed to be pre-scheduled to enable the group elements to go ahead. According to the original timeline,
a minimum of 2 months was allowed from the commencement of screening to the dates scheduled for
baseline visits for each block. However, delays in the ethics and Health Research Authority approval
process (see Trial set-up) reduced the recruitment window for the first block to < 4 weeks and, as a result,
this had to be rescheduled to allow sufficient time for recruitment. This change did not affect the overall
trial milestones, with all programmes taking place during the originally planned trial recruitment period
(Figure 8). This timescale enabled us to recruit 56 of the anticipated 60 participants (93% of the proposed
sample).
The time to recruit each block was calculated by subtracting the date of the first screening telephone
interview from the date of the block randomisation (Table 5). The variation in the length of times of
screening to recruitment reflected the fact that the screening of patients had begun as soon as governance
permissions had been granted at each site. As a result, the sites with fewer set-up difficulties had longer
time periods between screening and randomisation. Despite the time to recruit being high for several
blocks, participants were aware of the pre-scheduled timescales from the outset and did not express any
concerns about these, with only one participant withdrawing between screening and baseline as a result
of a relapse.
0
10
20
30
40
50
60
70
January February March April May June
Actual
Target
Recruitment
N
u
m
b
er
 o
f 
p
ar
ti
ci
p
an
ts
 r
ec
ru
it
ed
Month
FIGURE 8 BRiMS recruitment: January–June 2017.
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
Summary
The pre-scheduling of deliveries, and resultant time gaps between initial approach and actual recruitment,
did not adversely affect conversion rates, and was necessary to enable patients and treating therapists to
diarise these sessions to optimise attendance and ensure availability of clinical space.
Retention
Participant flow
The flow of participants through the trial is detailed in Figure 9.
Safety and adverse events
Participants not completing the trial
Table 6 provides details of the 12 participants who did not complete the trial. Seven were from Ayrshire
and five were from across the three south-west sites. These participants were split into three categories:
withdrawals, losses to follow-up and deaths. Withdrawals and losses to follow-up were used to calculate
the overall withdrawal rate in the trial for the purposes of the progression criteria.
Eight participants (three from the usual-care group and five from the intervention group) were withdrawn.
One participant was lost to follow-up because he or she was unable to attend their final research
appointment, and the research therapist was unable to contact another two of the participants to conduct
the final follow-up visit. One of the participants lost to follow-up was from the usual-care group and two
were from the intervention group. This represents an overall withdrawal rate of 19.6%, with a rate of
11.5% in the usual-care group and 23.3% in the intervention group.
The final participant who did not complete the trial died in week 31 as a result of events unrelated to the
BRiMS intervention.
Discussion
The overall withdrawal rate was within the 20% anticipated when designing this feasibility trial. There was
a discrepancy between retention rates in the two arms of the trial, although, as the reasons for withdrawals
are very variable, it is difficult to draw conclusions about why this might be the case. The dropout rate in
the intervention group was higher than we would have hoped for. In comparison, a review of 26 exercise
intervention studies reported combined dropout rates of 15% and 16% in intervention and usual-care
groups, respectively.133 We hypothesise that the higher than anticipated dropout rate in our intervention
group may be associated with the feasibility issues within the BRiMS programme in its current form, which
are discussed later (see Implementation of the BRiMS programme).
TABLE 5 Time taken in days to recruit participants to randomise a block
Block Time to recruit (days)
Number of participants (n)
Usual care Intervention Total
Ayrshire 1 26 5 6 11
Ayrshire 2 22 4 5 9
Cornwall 1 57 4 5 9
East Devon 1 83 5 5 10
Plymouth 1 86 4 4 8
Plymouth 2 72 4 5 9
DOI: 10.3310/hta23270 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 27
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Gunn et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
39
Telephone screen
(n = 76)
Ineligible
(n = 20)
Withdrew
(n = 2)
Withdrew
(n = 2)
• Withdrew,
   n = 3
Qualitative
interviewa
(n = 3)
• Withdrew,
   n = 1
• Lost to
   follow-up,
   n = 1
Qualitative
interviewa
(n = 10)
• Lost to
   follow-up,
   n = 2
• Died, n = 1
Baseline assessment
(n = 56)
Randomisation
(n = 56)
Intervention
(n = 30)
BRiMS week 1 clinic visit
(n = 28)
BRiMS week 2 home visit
(n = 27)
BRiMS week 4 group session
(n = 17)
BRiMS week 8 group session
(n = 10)
BRiMS week 13 group session
(n = 13)
15-week follow-up visit
(n = 25)
27-week follow-up visit
(n = 22)
15-week follow-up visit
(n = 24)
27-week follow-up visit
(n = 22)
• Study sample, n = 30
• Feasibility assessment, n = 30
• Proposed primary clinician 
   and self-reported outcomes
   assessment minimum numbers
   • Baseline,b n = 29
   • Week 15, n = 25
   • Week 27, n = 22
• Study sample, n = 26
• Feasibility assessment, n = 26
• Proposed primary clinician 
   and self-reported outcomes
   assessment minimum numbers
   • Baseline, n = 26
   • Week 15, n = 24
   • Week 27, n = 22
120 minutes of exercise 
per week for 12 weeks
(n = 3)
Usual care
(n = 26)
Enrolment
Allocation
Follow-up
Assessment
FIGURE 9 The CONSORT flow diagram. a, Only a subgroup of participants were invited to participate in the
qualitative interview; b, one participant did not have complete baseline data for the EQ-5D-5L potential primary
outcome.
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
Safety and adverse events
Serious adverse events
In total, nine SAEs were reported to PenCTU (Table 7). One was identified from the diary review and the
other eight were reported by the principal investigators. The data in the column ‘Related to trial treatment?’
were selected from the SAE form by the reporting principal investigator in response to the question ‘In the
opinion of the principal investigator, what is the relationship of the event to the BRiMS programme’, to
which the options were definite, probable, possible, unlikely and not related. In each case, the SAE was
reported to the chief investigator (JF). In all cases, the chief investigator concurred with the principal
investigator. These rates of SAEs are in line with those in other MS trials.
Adverse events
As described in Chapter 2, Participant safety and adverse events, the AEs were gathered from data self-
reported by participants in the pre-formatted paper-based diaries. Analysing these data presented a number
of challenges. First, a number of participants reported contradictory information in their diaries (e.g. ticking
‘no’ in the ‘any new problems’ box, but then adding free-text details suggesting that they had experienced
an issue). Second, despite the inclusion of a written definition in each diary, participants’ definitions of a
‘relapse’ was highly variable. For example, a number ticked to say that they had experienced a relapse, but
then described its duration as extremely short, for example suggesting that it could have lasted < 1 hour.
In addition, some participants reported ongoing problems as ‘new/worsening issues’ in sequential diaries,
suggesting that there may be a degree of double-counting within the data. Finally, free-text responses
were extremely challenging to interpret; for example, participants reported ‘pain’, but a lack of further
detail made categorising this report difficult.
TABLE 6 Reasons for participants not completing the trial
Site
Withdrawal
weeka Reason Code
4 29 SAE – resolved with sequelae – participant in rehabilitation unit unable to follow up Lost to follow-up
4 3 Family member not well, unable to commit to appointments Withdrawn
4 33 Did not attend appointment week 27 × 2 Lost to follow-up
4 19 Very stressed following medical intervention and stopped filling in diaries.
Did not want to continue
Withdrawn
4 3 Bladder frequency/urgency/incontinence post Botox, and family member
unwell, unable to commit to appointments
Withdrawn
4 27 Failed to respond to multiple requests to attend the assessment. Moving from
the area. Did not want to continue
Withdrawn
4 37 SAE – resolved with sequelae – participant in rehabilitation unable to follow up Lost to follow-up
3 3 Participant very anxious about having to write because of his MS symptoms.
No answer to calls/e-mails
Withdrawn
2 31 Participant died Died
2 15 Participant expressed lack of enthusiasm and motivation to carry on. Did not
want to continue
Withdrawn
2 5 Anxious about using computer and about having to do the imagery exercise.
Unable to continue
Withdrawn
1 9 Fractured pelvis, unable to continue Withdrawn
a Withdrawal date in number of weeks post randomisation.
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The summary of reported AEs, self-reported relapses and any self-reported use of medical care is detailed
in Table 8. These data are reported as actual number of reports (N), and percentages, which have been
calculated based on the number of diaries returned, the expected number of 2-weekly diary returns and
the number of participants randomised to each group. Details of the full method of analysis are included
in Safety data.
Participants made a 114 tick-box diary entries reporting ‘new/worsening problems’ and 42 reports of
‘relapses’. The free-text details of new/worsening problems are reported in Table 9, presented using the
organ system classification. It should be noted that, as some participants detailed more than one problem/
symptom per diary, the number of free-text entries exceeds the number of tick-box reports. Among the
42 reports of ‘relapses’, 15 participants documented accessing medical care.
Discussion
One challenge when gathering AEs from patient self-report diary data is that there can be ambiguity in
both the definition and the interpretation of a new symptom/relapse, which is a problem acknowledged
in MS clinical trials.134 A further challenge is optimising the return rate of the diaries. Overall, however,
our observation is that the AEs reported were not unexpected for a sample of people with progressive MS,
TABLE 7 Serious adverse events
Site Allocation
Date of
onset Description
SAE
definition Outcome
Related
to trial
treatment? Comment
4 Usual care 26 April
2017
Admission to hospital
following macular
injection
Hospitalisation Recovered with
sequelae
Not related
1 Intervention 30 May
2017
Admission to hospital
with broken pelvis
Hospitalisation Recovered with
sequelae
Not related Fall in shower
4 Intervention 30 July 2017 Likely MS relapse Hospitalisation Recovered with
sequelae
Not related
4 Intervention 4 September
2017
Likely MS relapse Significant
disability
Recovered with
sequelae
Unlikely
2 Intervention 8 September
2017
MS relapse Hospitalisation Recovered Not related
2 Intervention 1 October
2017
MS relapse Hospitalisation Recovered Not related Possible bladder
infection –
recovered with
antibiotics
4 Intervention 31 October
2017
Admission to hospital
following a fractured
distal fibula sustained
while transferring to
wheelchair
Significant
disability
Recovered with
sequelae
Not related Reduced
mobility
4 Usual care 8 November
2017
Fall caused by loss of
balance, resulting in
fractured neck of
femur. Subsequent
treatment surgery for
partial hip replacement
and physiotherapy
Significant
disability
Recovered with
sequelae
Not related Reduced
mobility
2 Intervention 9 November
2017
Died following serious
chest infection
Died Not related
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TABLE 8 Number and percentage of reports of new or worsening problems and relapses in the 2-week diary entries
Problem
classification
Group
Combined groupUsual care Intervention
n
Reported
(%)
Expected
(%)
Randomised
(%) n
Reported
(%)
Expected
(%)
Randomised
(%) n
Reported
(%)
Expected
(%)
Randomised
(%)
New or worsening problems
No 194 39.7 28.9 24.7 135 27.6 20.1 17.2 329 67.3 49.0 42.0
Yes 50 10.2 7.4 6.4 64 13.1 9.5 8.2 114 23.3 17.0 14.5
Missing 11 2.2 1.6 1.4 35 7.2 5.2 4.5 46 9.4 6.8 5.9
‘Relapses’
No 217 44.4 32.3 27.7 196 40.1 29.2 25.0 413 84.5 61.5 52.7
Yes 25 5.1 3.7 3.2 17 3.5 2.5 2.2 42 8.6 6.3 5.4
Missing 13 2.7 1.9 1.7 21 4.3 3.1 2.7 34 7.0 5.1 4.3
Medical care
No 23 4.7 3.4 2.9 10 2.0 1.5 1.3 33 6.7 4.9 4.2
Yes 7 1.4 1.0 0.9 8 1.6 1.2 1.0 15 3.1 2.2 1.9
Missing 225 46.0 33.5 28.7 216 44.2 32.1 27.6 441 90.2 65.6 56.3
TABLE 9 System Organ Classification of new and worsening problem reports
OSC
08 Nervous system disorders (n)
17 MSK (n) 07 Psych (n) 13 Resp (n) 14 Gastro (n) 18 Renal (n) 10 Ear (n) 09 Eye (n) 24 Injury (n)Fatigue
Pain/
sensation Balance
Weakness/
mobility Other
ST 42 13 3 8 0 12 3 0 0 0 1 1 2
LT 32 5 7 18 2 2 4 1 1 2 0 1 2
Gastro, gastrointestinal; LT (long term), ≥ 8 days (including ‘ongoing’ in 2-weekly diaries); MSK, musculoskeletal; OSC, Organ System Classification (with 08 split into more detailed
symptoms); psych, psychiatric; resp, respiratory; ST (short term), ≤ 7 days.
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and are in line with those reported in other MS trials. Exercise-based interventional studies suggest that
between 0% and 12% of trial participants are likely to report AEs, with minimal difference between the
intervention and usual-care groups,133 which was also broadly the case in this feasibility trial.
Feasibility of trial procedures
Elapsed time between key trial time points
As participants were randomised in blocks, for each randomised batch of participants, the randomisation
date was defined as the same date. Within the protocol, the time from randomisation to each follow-up
was given a ± 1 week window, meaning that the week 15 follow-up should have taken place on day 105
(range 98–112 days) and the week 27 follow-up should have taken place on day 189 (range 182–196 days).
As seen in Table 10, the median and IQRs at each assessment point fell within the allowed window. Overall,
30.6% of week 15 assessments and 29.5% of week 27 assessments took place outside the allowed time.
This can be partly attributed to the logistical challenges of the block randomisation, wherein assessments
for the whole block were due on the same date. This was a particular challenge for Ayrshire, where the
research assessor was employed for only 1 day per week. Further analyses demonstrated that, despite these
challenges, 96.8% of assessments were undertaken within a ± 2-week window.
Summary
All assessments were undertaken within a ± 2-week window of the intended assessment date, rather than
the intended ± 1-week window.
Blinding
Methods to maintain blinding were largely successful, with minimal reported instances of unblinding at
week 15 (n = 3, 6.1%) and no reported unblinding at week 27 (± 1 week). All three instances were due to
participants telling research therapists about their group allocation during assessment sessions. However,
the assessors correctly identified the allocation group for between 75% and 77% of participants at these
time points. It is now acknowledged that the information that this approach provides is uncertain, and
hence CONSORT guidelines135 no longer advocate this type of testing for blinding.
Participant experiences
Thirteen participants were interviewed by telephone between 2 and 6 weeks after their final assessment to
explore their experience of participating in the trial/BRiMS programme. The participant characteristics are
detailed in Table 11.
TABLE 10 Summary statistics on elapsed times between key trial time points
Time point n Median (IQR) Minimum–maximum
Screening telephone to baseline 56 21 (10–39) 0–72
Baseline to randomisation 56 12 (7.5–14) 5–37
Randomisation to intervention start 56 5 (5–5) 5–5
Randomisation to week 15 49 104 (98–107) 96–119
Randomisation to week 27 44 183 (181.5–189) 174–205
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Motivation for joining the trial
Participants interviewed as part of the process evaluation expressed that the topic of the trial resonated
with them, with many reporting that they had been looking for extra support to address their difficulties.
One participant described feeling ‘alone’, and hoped that, if she was allocated to the BRiMS programme,
it would help her to find motivation. Other participants explained that they had previous experience of
being involved in research and wanted to help contribute for wider benefit:
Well, it was to help me to help myself actually control my walking, control where I walked, how
I walked.
P1
I was always, I am always interested in exercise for MS, I just really believe it works.
P4
Expectations of taking part
Participants’ expectations of taking part were mostly associated with a desire to improve their mobility and
balance, and to exercise more:
Anything that can help mobility really, yes, that was the main reason, yeah.
P10
Well, I was hoping that they would come out with a suitable programme that we might actually get a
chance of being able to try once all the study has gone through and got there sort of thing.
P2
TABLE 11 Participant characteristics of the qualitative interview sample
Participant code EDSS score (points) Age (years) Sex Site
Usual-care group participants
P1 6 52 Male 1
P2 7 52 Female 1
P3 4.5 59 Female 3
Intervention group participants
P4 6.5 65 Female 1
P5 6 62 Female 1
P6 6.5 64 Female 2
P7 6 58 Female 2
P8 6 53 Female 2
P9 6 49 Male 3
P10 6.5 67 Female 3
P11 6 69 Female 3
P12 6 46 Male 4
P13 6 49 Female 4
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Trial activities
Recruitment and trial information
The amount of information given to participants during the recruitment process was overwhelming for
some:
I would shorten the information, the information we got initially. For me I’m cognitively impaired
because of the MS and I can’t really focus a lot of the time. I then kind of lose focus and drift off.
More to the point, for me personally more to the point. Less information would be better actually.
P12
However, one participant reported that the amount of information was fine for her:
I think the information was OK. I didn’t have any particular problems with it. No, it was quite
explanatory, it was fine.
P13
Allocation to the intervention or usual-care group
Participants were randomised to either the intervention or the usual-care group. Not surprisingly, those
randomised into the intervention group reported satisfaction and those in the usual-care group expressed
disappointment. However, the vast majority remained committed to the trial:
Yes, I was really pleased because then I thought ‘oh great I will have some exercises to do’.
P4
Disappointed, because I would have liked to have had the exercises to do. So yeah, disappointed, but,
you know, I carried on because in the long run hopefully it is going to help everyone. So it made
sense, you know, to carry on and do it, but I was disappointed because I would have liked to have
had the exercises.
P2
Despite being allocated to the usual-care group, two participants highlighted changes that they perceived
to be related to taking part in the trial. It is possible that these changes resulted from these participants
completing the assessments and diaries, which provided an opportunity for them to reflect on their
situation and behaviour:
P1: Yes, it definitely changed my behaviour and what I was doing and how I was doing it.
Interviewer: OK, in what way?
P1: I’d say that after about the third or fourth week I’d started thinking ‘Oh yeah, that happened to
me last week so let’s change it now and not do this again in the next week’ and there was a couple
of weeks when I didn’t trip at all.
Trial assessments
All participants attended three research assessments at local community health facilities. Scheduling an
assessment with the research therapist was reported as straightforward:
It was e-mail. When I went for one she would provisionally give me the date of the next one. So I had
plenty of warning on when, well, you knew roughly what window it was going to be in anyway.
P2
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The rurality of the trial sites, and the nature of MS fatigue, meant that travel time and the effort of
attending sessions away from home was notable for some:
I think personally yes because the going out and the doing something like that is as far as I’m
concerned is exhausting anyway. If you have got a long journey to start with you are just adding to it.
You are compounding the issues, aren’t you?
P2
Participants expressed mixed feelings about the length of assessments. For some the length was not an
issue, whereas others reported feeling fatigued. A number of participants recognised that the design of
the assessment process enabled activities to be broken up, and felt that the opportunities for regular rests
were helpful:
That was all fine. I mean she did break it up a bit . . . It was nice you weren’t all doing the physical
stuff all in one go and you weren’t doing all the mental stuff all in one go. So, yeah, it was nicely
paced and it was spread out that you didn’t feel too fatigued from either of them, if that makes sense.
P2
Some reported that the assessment, and in particular the cognitive demands of the questionnaires, led to
significant fatigue. However, they did not necessarily feel that the assessment battery needed to be
changed:
Gosh, I was really tired afterwards. It was, I mean it’s easy to, you keep going, but actually it really
did sort of take it out of me . . . I think if you say that it can take up to 2 hours and there’ll be a
combination of things, you sort of think as you are doing it, ‘OK I knew this’ . . . and also you were
very clear any time I’d had enough just to say. And that’s all you need really. I don’t think you need
to change.
P5
Summary
Overall, the qualitative feedback relating to the trial processes was positive. The interviewed participants
reported that the procedures were suitable and that they were well supported during assessment sessions.
The feedback suggests that the initial patient information packs need to be reviewed to ensure that the
content and format are straightforward while remaining comprehensive.136 The feedback on trial assessments
supports our PPI work, which highlights the importance of interspersing cognitive and physical tasks, and
incorporating rest breaks. Given that the findings from this feasibility trial have highlighted the importance
of encouraging people to self-complete any questionnaires (see Table 45), it will be important to review the
format of the session to ensure that people are able to do this without significant extra participant burden.
An important consideration is the feedback from our usual-care participants that they felt that simply
taking part in the trial had changed their attitude to falls and falls prevention. In other areas of behaviour
change research, there is recognition of the potential for research processes to affect whether or not the
‘usual-care’ group has truly received ‘usual care’.137 Although it was not feasible in this feasibility trial,
falls prevention trials of other groups have included collection of falls data prior to randomisation.138
The publication of these data will be an important consideration in the design of future RCTs.
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Trial outcome objectives (vii–ix)
Data completion and accuracy
Completion of questionnaires
Potential primary outcome measures were all self-report questionnaires. Participants could request that
the questionnaires be read to them by the research assessor, who would tick the answer provided by
the participant. Typically participants requested this method of completion because of issues relating to
mental fatigue or manual dexterity, which are common in people with progressive MS. From an operational
perspective, the research assessor was instructed not to interpret the questionnaire on behalf of the
participant under any circumstances, but to simply read the question and range of potential answers and
then record the participant’s response accordingly. This was the method most commonly used at each
time point (baseline, 62.5%; week 15, 77.6%; week 27, 84.1%).
Completeness of the potential primary outcomes
In Tables 12 and 13 we have calculated the proportions using:
(a) participants who attended the baseline (n = 56), week 15 (n = 49) and week 27 (n = 44) visits
(b) participants who were randomly allocated (n = 56).
Table 12 shows the number and percentage of participants who completed all items of the questionnaire
at the baseline and follow-up visits, and the number and percentage of questionnaires for which the total
score was available (imputed if necessary). Only one participant was excluded from the baseline data for
one measure (EQ-5D-5L), as he or she declined to complete any items.
TABLE 12 Completeness of the potential primary outcomes
Outcome Time point
Completeness
Participants completed all items Questionnaire complete
n
Follow-up
(%)
Randomised
(%) n
Follow-up
(%)
Randomised
(%)
MSWS-12vs2 Baseline 55a 98.2 98.2 56 100 100
Week 15 49 100 87.5 49 100 87.5
Week 27 44 100 78.6 44 100 78.6
EQ-5D-3L (crosswalk) Baseline 55 98.2 98.2 55 98.2 100
Week 15 49 100 87.5 49 100 87.5
Week 27 44 100 78.6 44 100 78.6
EQ-5D-5L (VAS)b Baseline 55c 98.2 98.2 55 98.2 100
Week 15 49 100 87.5 49 100 87.5
Week 27 44 100 78.6 44 100 78.6
MSIS-29vs2 (physical) Baseline 56 100 100 56 100 100
Week 15 49 100 87.5 49 100 87.5
Week 27 44 100 78.6 44 100 78.6
MSIS-29vs2 (psychological) Baseline 56 100 100 56 100 100
Week 15 49 100 87.5 49 100 87.5
Week 27 44 100 78.6 44 100 78.6
a Participant number 3005 had one spoiled item response in the MSWS-12vs2 questionnaire at baseline.
b Consists of one item.
c Participant number 3008 did not complete the EQ-5D-5L questionnaire at baseline.
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Summary
In summary, completion of the potential primary outcomes was excellent and clearly met the criteria set for
progressing to a definitive trial. Most participants requested for the self-report questionnaires to be read to
them by the research assessor, who ticked the answers provided by the participant.
Completeness of the potential secondary outcomes
Table 13 describes the completeness of the potential secondary outcomes for the number of participants
who completed all components of the test; and, if the participant attempted the test, as a percentage
of the number of participants followed up and a percentage of the number of participants randomised.
TABLE 13 Completeness of the potential clinician-rated secondary outcomes
Outcome Time point
Completeness
Participants completed all test
components Assessment
n
Follow-up
(%)
Randomised
(%) n
Follow-up
(%)
Randomised
(%)
Clinician-rated outcomes
2MWT Baseline 56 100 100 56 100 100
Week 15 48 98.0 85.7 49 100 87.5
Week 27 40 90.9 71.4 43 97.7 76.8
Mini-BEST Baseline 53 94.6 94.6 55 98.2 98.2
Week 15 48 98.0 85.7 48 98.0 85.7
Week 27 41 93.2 73.2 41 93.2 73.2
Forward FRT Baseline 55 98.2 98.2 56 100 100
Week 15 48 98.0 85.7 48 98.0 85.7
Week 27 41 93.2 73.2 41 93.2 73.2
Lateral FRT Baseline 55 98.2 98.2 56 100 100
Week 15 48 98.0 85.7 48 98.0 85.7
Week 27 41 93.2 73.2 41 93.2 73.2
Self-reported questionnaires
FES-I Baseline 55 98.2 98.2 56 100 100
Week 15 49 100 87.5 49 100 87.5
Week 27 44 100 78.6 44 100 78.6
CPI score 1 Baseline 52 92.9 92.9 52 92.9 92.9
Week 15 48 98.0 85.7 48 98.0 85.7
Week 27 44 100 78.6 44 100 78.6
CPI score 2 Baseline 53 94.6 94.6 53 94.6 94.6
Week 15 48 98.0 85.7 48 98.0 85.7
Week 27 44 100 78.6 44 100 78.6
CPI score 3 Baseline 52 92.9 92.9 52 92.9 92.9
Week 15 48 98.0 85.7 48 98.0 85.7
Week 27 44 100 78.6 44 100 78.6
FRT, Functional Reach Test.
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The completeness of the secondary outcomes was high among the proportion followed up, at > 93% for
all measures. As a proportion of those randomised, it was > 73% for all measures.
Clinician-rated potential secondary outcome measures
There were some difficulties recording the time component of the 2MWT data in the CRF. The CRF
requires that the assessor records the time walked only if this is < 2 minutes. In some cases participants
reported the time even when the full 2 minutes had been walked, while in others no time was entered.
Information on assistive walking devices (free text) was also occasionally missing, which could have been
used for further analyses. The completion rates for the CPI were slightly lower than those for the other
self-report questionnaires used in this trial. Feedback from participants during the assessments highlighted
that the length and complexity of the CPI questionnaire, particularly the section that informed CPI score 1,
was a challenge.
Summary
In summary, completion of the clinician-rated and self-reported secondary outcomes was excellent, and
clearly met the criteria set for progressing to a definitive trial. There were some minor problems with
recording the 2MWT in the CRF.
Daily diary returns
To examine the diary data, entries were converted from 2-weekly records into daily entries to identify the
date that participants should have started to record diary data (i.e. the randomisation date). The BRiMS
intervention always started 5 days after the randomisation date. Participants were asked to return 28 weeks
of diary entries; had all 56 participants completed every diary, 784 2-week diaries would have been returned.
Throughout the trial, 489 2-week diaries were returned from 48 participants (usual-care group, n =22;
intervention group, n = 26), equating to a 62.3% response rate. Eight participants (four from each allocated
group) failed to return any diaries. Of the diary returns, 255 were from those allocated to the usual-care
group (mean of nine returns per participant) and 234 were from those allocated to the intervention group
(mean of nine returns per participant).
Evaluation of the quality and completeness of the daily recording of falls in the diaries highlighted a
number of issues, including duplication of data (e.g. when participants sent back two diaries with the
same dates, or when there was an overlap in the dates recorded in two sequential diaries). To maximise
the validity of the analyses, the decision was taken to identify and remove duplicate days; this resulted in
the removal of 374 days of duplicate data from the original 7546 days of data returned, which is 5%
of the available data. A further 218 (3%) entries were removed as they did not report days within the
specified trial period. Allowing for non-returns and data duplications, the final data available for analysis
represent 58.6% of the expected number of days’ data for falls, and 40.6% of the expected number of
days’ data for injurious falls, had all diaries been completed and returned according to protocol.
Qualitative feedback indicated that diaries were quick to fill in, but were described as a little complicated:
P2: It wasn’t very long even if I’d had a fall, it was sort of 5 minutes tops . . . That was OK but I didn’t
find the forms were that easy to follow . . .
Interviewer: Could you explain a bit more about that?. . .
P2: They just didn’t seem to be all that well set out . . .
Interviewer: OK, in terms of too much on a page, too little on a page or . . .?
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P2: Well, I mean where you fill in any falls you’d had that was fine because I mean I just literally when
I had to do for the next fortnight I put it in front and then if I had fallen I just put a little one because
I’d remember what the fall was sort of thing but when you turn over the pages it was a bit higgledy
piggledy the way it was set out.
Participants also suggested different formats for the diaries:
It could be an online thing but then if you struggle, some aren’t technically, and they don’t do it do
they, but online would have been. On an online basis you could then do it daily . . . I mean even
something like a little app that would prompt you and you go and you do it, you know.
P2
Summary
The diary return rates were lower than those seen in other studies,15 and there were issues with the clarity
and completeness of the data returned.
Discussion
Feedback relating to diaries suggests that the diary format, completion and mechanisms for checking
returns and following up non-returns may have had an impact on user engagement and data quality. Our
previous study used a similar format to record daily falls and injuries, but for this trial we added further
detail about the consequences of any falls, the use of medical resources and any AEs. We also used an
automated e-mail reminder system rather than personal contact details when diary returns were delayed.
Despite the fact that the format of our diaries was informed by best-practice guidance,59 the findings from
this trial suggest that this is an area that needs to be reviewed prior to any future definitive trial.
Accelerometry (activPAL monitors)
At each research assessment visit, participants had an accelerometer (activPAL monitor) attached to their
thigh. They were provided with instructions for removing the device and a reply-paid envelope to return it
to the research therapist after 1 week.
The monitors were returned according to plan by all participants who remained actively engaged in the
trial (Table 14). Despite reminders, one monitor was not returned by one participant who withdrew after
the baseline assessment. Participants reported that the monitors were comfortable to wear and there were
no recorded issues of problems other than short-lived skin redness after removal for two participants.
Data checking and cleaning according to the agreed plan was undertaken for all accelerometry data sets.
The cleaning and review process highlighted three data sets with unreliable data, all from the same
participant. This was likely to have been due to this participant’s low level of daily activity and slow
walking speed, which are known to cause issues with activity monitors of this type.139
TABLE 14 Activity monitor return data
Time point
Number of assessments
undertaken (n)
Number of monitors
returned, n (%)
Number of data sets
suitable for analysis, n (%)
Baseline 56 55 (98) 54 (96)
Week 15 (± 1 week) 49 49 (100) 48 (98)
Week 27 (± 1 week) 44 43 (97) 42 (95)
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Summary
The use and return rate of accelerometers was high, suggesting that this is a feasible method of collecting
activity data in a future trial. The data cleaning process was time-consuming.
Baseline data
Demographics and clinical characteristics
Tables 15 and 16 detail summary statistics of the participants’ demographic and clinical characteristics by
allocated group and for the whole sample.
TABLE 15 Summary statistics of participants’ demographic data at baseline
Characteristic
Group
Total (N= 56)Usual care (N= 26) Intervention (N= 30)
Age (years)
Mean (SD) 60.0 (8.5) 58.7 (10.8) 59.3 (9.7)
Minimum–maximum 46.0–81.0 34.0–80.0 34.0–81.0
Median (IQR) 58.5 (54.0–65.0) 59.5 (49.0–67.0) 59.0 (53.0–67.0)
Sex, n (%)
Male 9 (34.6) 10 (33.3) 19 (33.9)
Female 17 (65.4) 20 (66.7) 37 (66.1)
Ethnicity, n (%)
White 26 (100) 30 (100) 56 (100)
Living arrangements,a n (%)
Alone 9 (34.6) 7 (23.3) 16 (28.6)
With spouse/partner 15 (57.7) 19 (63.3) 34 (60.7)
With parent(s) 1 (3.8) 2 (6.7) 3 (5.4)
With child/children 4 (15.4) 4 (13.3) 8 (14.3)
Other 1 (3.3) 1 (1.8)
Place of residence, n (%)
Flat/apartment 4 (15.4) 5 (16.7) 9 (16.1)
House/bungalow 21 (80.8) 25 (83.3) 46 (82.1)
Other 1 (3.8) 0 (0) 1 (1.8)
Occupation status, n (%)
Unemployed 1 (3.8) 2 (6.7) 3 (5.4)
Part-time work 4 (15.4) 2 (6.7) 6 (10.7)
Full-time work 2 (7.7) 1 (3.3) 3 (5.4)
Age retired 5 (19.2) 5 (16.7) 10 (17.9)
Medically retired 14 (53.8) 19 (63.3) 33 (58.9)
a Participants could enter in multiple options, so percentages do not necessarily add up to 100.
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TABLE 16 Summary statistics of participants’ clinical characteristics at baseline
Characteristic
Group
Total (N= 56)Usual care (N= 26) Intervention (N= 30)
Age at diagnosis (years)
Mean (SD) 41.7 (13.5) 42.3 (13.2) 42 (13.2)
Minimum–maximum 18.0–65.0 21.0–68.0 18.0–68.0
Median (IQR) 42.0 (30.0–51.0) 43.0 (31.0–48.0) 43.0 (30.0–49.5)
Time since relapse, n (%)
At least 1 year 18 (69.2) 24 (80.0) 42 (75.0)
3–12 months 5 (19.2) 6 (20.0) 11 (19.6)
Within 3 months 2 (7.7) 2 (3.6)
EDSS (points)
Mean (SD) 6.1 (0.7) 6.3 (0.3) 6.2 (0.5)
Minimum–maximum 4.0–7.0 6.0–7.0 4.0–7.0
Median (IQR) 6.0 (6.0–6.5) 6.5 (6.0–6.5) 6.3 (6.0–6.5)
Cognition: SDMT
Mean (SD) 44.5 (15.1) 39.1 (10.9) 41.6 (13.2)
Minimum–maximum 7.0–77.0 20.0–60.0 7.0–77.0
Median (IQR) 47.0 (33.0–54.0) 41.5 (31.0–47.0) 44.5 (32.0–50.0)
Previous 4-week continence, n (%)
Not at all 14 (53.8) 13 (43.3) 27 (48.2)
Once 1 (3.8) 3 (10.0) 4 (7.1)
2–4 times 3 (11.5) 7 (23.3) 10 (17.9)
>More than weekly 5 (19.2) 3 (10.0) 8 (14.3)
Daily 3 (11.5) 4 (13.3) 7 (12.5)
Continence device, n (%)
No 21 (80.8) 27 (90.0) 48 (85.7)
Yes 5 (19.2) 3 (10.0) 8 (14.3)
Mood: depressed, n (%)
No 15 (57.7) 15 (50.0) 30 (53.6)
Yes 11 (42.3) 15 (50.0) 26 (46.4)
Mood: lack of pleasure, n (%)
No 19 (73.1) 20 (66.7) 39 (69.6)
Yes 7 (26.9) 10 (33.3) 17 (30.4)
continued
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TABLE 16 Summary statistics of participants’ clinical characteristics at baseline (continued )
Characteristic
Group
Total (N= 56)Usual care (N= 26) Intervention (N= 30)
Fear of falling, n (%)
Not at all 7 (26.9) 2 (6.7) 9 (16.1)
Somewhat 8 (30.8) 11 (36.7) 19 (33.9)
Fairly 4 (15.4) 8 (26.7) 12 (21.4)
Very 7 (26.9) 8 (26.7) 15 (26.8)
Do not know 1 (3.3) 1 (1.8)
3-month fall history, n (%)
Not fallena 1 (3.3) 1 (1.8)
Twice 7 (26.9) 5 (16.7) 12 (21.4)
3–5 times 11 (42.3) 13 (43.3) 24 (42.9)
More often 8 (30.8) 11 (36.7) 19 (33.9)
Indoor walking aids,b n (%)
One stick/crutch 9 (34.6) 13 (43.3) 22 (39.3)
Two sticks/crutches 5 (19.2) 4 (13.3) 9 (16.1)
Walker/frame 8 (30.8) 12 (40.0) 20 (35.7)
Wheelchair 4 (15.4) 4 (13.3) 8 (14.3)
Outdoor walking aids,b n (%)
One stick/crutch 17 (65.4) 18 (60.0) 35 (62.5)
Two sticks/crutches 10 (38.5) 7 (23.3) 17 (30.4)
Walker/frame 9 (34.6) 14 (46.7) 23 (41.1)
Wheelchair 12 (46.2) 15 (50.0) 27 (48.2)
Assistive devices,b n (%)
AFO 10 (38.5) 7 (23.3) 17 (30.4)
Functional electrical stimulation 8 (30.8) 7 (23.3) 15 (26.8)
Other 2 (7.7) 2 (6.7) 4 (7.1)
Number taking medication, n (%) 24 (92.3) 27 (90.0) 51 (91.1)
Number of medications
Median (IQR) 4 (2–7) 5 (2–7) 4 (2–7)
Minimum–maximum 0–10 0–17 0–17
Medication type,b n (%)
Disease modifying 2 (7.7) 1 (3.3) 3 (5.4)
Anti-spasticity 6 (23.1) 11 (36.7) 17 (30.4)
Tremor/ataxia 2 (6.7) 2 (3.6)
Pain 11 (42.3) 13 (43.3) 24 (42.9)
Fatigue 3 (11.5) 8 (26.7) 11 (19.6)
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TABLE 16 Summary statistics of participants’ clinical characteristics at baseline (continued )
Characteristic
Group
Total (N= 56)Usual care (N= 26) Intervention (N= 30)
Fampridine 3 (11.5) 1 (3.3) 4 (7.1)
Other 17 (65.4) 25 (83.3) 42 (75)
Missing 3 (11.5) 2 (6.7) 5 (8.9)
Participants with historical medical conditions, n (%)
Number of participants 21 (80.8) 26 (86.7) 47 (83.9)
Number of historical medical conditions
Median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Minimum–maximum 0.0–8.0 0.0–6.0 0.0–8.0
Historical medical conditions,b n (%)
COPD/asthma 4 (15.4) 3 (10.0) 7 (12.5)
Coronary heart disease/hypertension 6 (23.1) 3 (10.0) 9 (16.1)
Depression/anxiety 7 (26.9) 14 (46.7) 21 (37.5)
Diabetes 2 (7.7) 1 (3.3) 3 (5.4)
Migraine 5 (19.2) 9 (30.0) 14 (25.0)
Osteoarthritis 5 (19.2) 9 (30.0) 14 (25.0)
Osteoporosis 6 (23.1) 2 (6.7) 8 (14.3)
Other 16 (61.5) 20 (66.7) 36 (64.3)
Other neurological condition 2 (7.7) 4 (13.3) 6 (10.7)
Participants with an ongoing medical condition, n (%)
Number of participants 16.0 (61.5) 19 (63.3) 35 (62.5)
Number of ongoing medical conditions
Median (IQR) 1.0 (0.0–2.0) 1.0 (0.0–2.0) 1.0 (0.0–2.0)
Minimum–maximum 0.0–6.0 0.0–5.0 0.0–6.0
Ongoing medical conditions,b n (%)
COPD/asthma 1 (3.8) 2 (6.7) 3 (5.4)
Coronary heart disease/hypertension 1 (3.8) 1 (3.3) 2 (3.6)
Depression/anxiety 4 (15.4) 7 (23.3) 11 (19.6)
Diabetes 1 (3.8) 1 (3.3) 2 (3.6)
Migraine 3 (11.5) 1 (3.3) 4 (7.1)
Osteoarthritis 3 (11.5) 6 (20.0) 9 (16.1)
Osteoporosis 5 (19.2) 2 (6.7) 7 (12.5)
Other 10 (38.5) 11 (36.7) 21 (37.5)
Other neurological condition 1 (3.8) 1 (3.3) 2 (3.6)
AFO, ankle–foot orthosis; COPD, chronic obstructive pulmonary disease; SDMT, Symbol Digit Modalities Test.
a There was no option on the CRF for participants to report falling once.
b Participants could enter in multiple options, so percentages do not necessarily add up to 100.
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Overall, the sample demographic and diagnostic characteristics are similar to those of other groups of
MS fallers.15,17 However, as shown in Table 15, there are some differences in key characteristics between
the two groups, notably for measures of disease severity (EDSS), cognition (Symbol Digit Modalities Test)
and mood, with the intervention group scoring worse, on average, than the usual-care group. A higher
proportion of participants with historical and/or ongoing depression in their medical history were in the
intervention group. In addition, a higher proportion of participants in this group were taking medications,
more specifically for spasticity, tremor and fatigue, as well as for ‘other’ unspecified reasons.
The usual-care group tended to use two walking aids, and had a greater use of assistive devices (e.g.
ankle–foot orthoses or functional electrical stimulation). A slightly higher proportion of participants in the
intervention group had fallen more than five times in the previous 3 months, and there was a slight
imbalance between the groups in the proportions who reported being ‘fairly’ afraid of falling.
Summary
The sample is similar in baseline characteristics to other groups of fallers. There was an imbalance between
the two allocated groups in some baseline characteristics. There was no option in the CRF for a participant
to declare that they had fallen once.
Discussion
In recognition of the prevalence of comorbidity in MS,140 our recruitment criteria were specifically set to
be as inclusive as possible, and the prevalence was broadly in line with published data in this field.140
Although the distribution between groups was similar for most characteristics, the differing incidence of
some (e.g. EDSS score, anxiety/depression and cognition) could potentially affect intervention outcomes,
indicating that a future definitive trial may require stratification according to these variables.
Performance of potential trial outcome measures
Potential primary outcome measures
Table 17 shows the potential primary outcome measures at all trial time points. Although the sample
means are similar to those of other groups of MS fallers (including for MSWS-12vs2 and MSIS-29vs2),144,145
those allocated to the intervention appear to be worse across many measures at baseline. To account for
this, differences between the groups have been reported, both in their ‘raw’ format and adjusted for
baseline score.
Summary
All three of the potential primary outcome measures produced data that were comparable with those from
other similar samples. There was an imbalance in the scoring between the groups at baseline, which was
counteracted by reporting the raw and adjusted differences between the groups. The scores at 15 and
27 weeks (± 1 week) in the MSWS-12vs2 are in favour of the intervention group and exceed the available
data for the minimal clinically important difference.
Potential secondary outcome measures
Table 18 shows the data for the potential secondary outcome measures for all time points.
All of the potential secondary outcome measures had excellent rates of completion at all time points and
produced outcomes that were broadly comparable with those of other similar samples.
With regard to the potential secondary outcomes, there are two noteworthy areas of discussion. The first
relates to the measure used to evaluate participation, the CPI. When selecting this measure, we were
cognisant of the fact that there is a lack of evidence on its clinical utility and measurement properties, and
no normative data are available in the MS population. Nevertheless, we chose this measure based on the
recommendation of the International Multiple Sclerosis Falls Prevention Network (an expert panel of MS
specialists undertaking trials in the area of falls106), and a recognition that participation is a key outcome
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TABLE 17 Summary statistics, mean, SD and range of the potential primary outcomes
Variable Time point
Group
Difference between allocated groups
(intervention – usual care), mean (95% CI)
Minimal clinically important
difference, when available
Usual care Intervention
n
Mean (SD)
[minimum–maximum] n
Mean (SD)
[minimum–maximum] Unadjustedc Adjustedd
MSWS-12vs2a Baseline 26 79.6 (14.4) [52.0–100.0] 30 84.2 (16.2) [45.0–100.0] 4/6141
Week 15 24 79.8 (13.9) [48.0–100.0] 25 75.6 (19.4) [33.0–100.0] –4.2 (–14 to 5.5) –10.6 (–18.9 to 2.2)
Week 27 22 79.5 (21.9) [21.0–100.0] 22 75.4 (16.8) [40.0–100.0] –4 (–15.9 to 7.8) –7.7 (–17.2 to 1.8)
EQ-5D-3Lb
(crosswalk)
Baseline 26 0.6 (0.2) [0.0–0.8] 29 0.5 (0.2) [0.0–0.9] 0.05–0.08142
Week 15 24 0.6 (0.2) [0.2–0.9] 25 0.6 (0.2) [0.0–0.9] 0.0 (–0.1 to 0.1) 0.0 (–0.1 to 0.1)
Week 27 22 0.6 (0.3) [–0.1–0.9] 22 0.6 (0.1) [0.3–0.8] 0.0 (–0.1 to 0.1) 0.0 (–0.1 to 0.1)
EQ-5D-5L
(VAS)b
Baseline 26 64.6 (19.1) [20.0–95.0] 29 54.6 (18.6) [15.0–95.0] N/A
Week 15 24 61.3 (20.3) [20.0–90.0] 25 54.6 (16.5) [25–97] –6.7 (–17.4 to 3.9) 4.7 (–4.3 to 13.6)
Week 27 22 63.3 (17.8) [25.0–95.0] 22 49.9 (21.1) [15.0–95.0] –13.4 (–25.3 to –1.5) –2.1 (–13 to 8.8)
MSIS-29vs2a
(physical)
Baseline 26 64.2 (21.7) [25.0–97.0] 30 64.8 (16.4) [32.0–93.0] 8143
Week 15 24 59.4 (23) [13.0–98] 25 54.8 (19.5) [13–92] –4.6 (–16.8 to 7.7) –4.9 (–13.2 to 3.5)
Week 27 22 59 (24.9) [0.0–92] 22 57.9 (15.2) [27–88] –1.2 (–13.7 to 11.4) 0.6 (–7.8 to 9)
MSIS-29vs2a
(psychological)
Baseline 26 45.1 (29.7) [0.0–85] 30 50.4 (22.8) [4.0–96] N/A
Week 15 24 43.3 (26.8) [0–89] 25 43.7 (19) [0.0–70.0] 0.5 (–12.8 to 13.8) –5 (–15.5 to 5.5)
Week 27 22 40 (26.8) [0.0–93] 22 43.3 (22.6) [7.0–81] 3.3 (–11.8 to 18.4) –0.4 (–9.9 to 9)
N/A, not available.
a Decrease in score indicates improvement.
b Increase in score indicates improvement.
c The mean difference between the allocated groups (BRiMS – usual care) with 95% CI for potential primary outcomes.
d Each participants’ baseline score was subtracted from their follow-up score and we report the mean difference between the allocated groups (BRiMS – usual care) with 95% CI for
potential primary outcomes.
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TABLE 18 Summary statistics, mean, SD and range of the potential secondary outcomes
Variable Time point
Group
Difference between allocated groups
(intervention – usual care), mean (95% CI)
Minimal clinically important
difference, when available
Usual care Intervention
n
Mean (SD)
[minimum–maximum] n
Mean (SD)
[minimum–maximum] Unadjustede Adjustedf
Clinician-rated measures
2MWTa,b Baseline 26 52.7 (27.2) [7–138.5] 30 53 (32) [9–133] 12.2 to 14.7146 or 19.21 metres147
Week 15 24 51.9 (29.5) [8.5–120] 24 53.3 (27) [13–101] 1.4 (–15 to 17.9) 0.3 (–9.4 to 10)
Week 27 21 56.3 (31.1) [12–126.8] 20 55 (27.4) [16–103] –1.3 (–19.9 to 17.2) –2.2 (–14.6 to 10.2)
Mini-BESTb Baseline 26 12.2 (3.8) [6–21] 29 10.7 (5.2) [2–20] 3.594
Week 15 24 12.5 (6.2) [1–25] 24 14.2 (6.2) [4–27] 1.7 (–1.9 to 5.3) 2.6 (–0.1 to 5.4)
Week 27 21 13.6 (6) [3–27] 20 14.1 (5.7) [3–22] 0.5 (–3.2 to 4.2) 1.2 (–1.2 to 3.6)
Forward FRTa Baseline 26 16.6 (6.4) [1–28.7] 30 18.1 (7.9) [0–32.3] 6.35–6.79 (vestibular disorders)148
Week 15 24 16.1 (6.4) [0–29.3] 24 20.8 (7.6) [7.7–38.7] 4.7 (0.6 to 8.8) 2.7 (–0.3 to 5.7)
Week 27 21 17 (7.8) [0–32] 20 19.5 (5.9) [6.3–33.7] 2.5 (–1.9 to 6.9) 1 (–2.7 to 4.6)
Lateral FRTb Baseline 26 13.3 (6.2) [0–30] 30 13.4 (6.9) [0–27.3] N/A
Week 15 24 12.3 (5.2) [0–20.7] 24 16.7 (7.6) [5–33.3] 4.4 (0.6 to 8.2) 4.2 (0.9 to 7.5)
Week 27 21 11.9 (5.4) [0–21.3] 20 16.1 (4.9) [6–24.3] 4.2 (0.9 to 7.5) 4 (1.1 to 6.9)
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Variable Time point
Group
Difference between allocated groups
(intervention – usual care), mean (95% CI)
Minimal clinically important
difference, when available
Usual care Intervention
n
Mean (SD)
[minimum–maximum] n
Mean (SD)
[minimum–maximum] Unadjustede Adjustedf
Self-reported outcomes
FES-Ic Baseline 26 43.7 (9.8) [24.0–61.0] 30 44.1 (9) [27.0–60.0] 8.2 (vestibular disorders)149
Week 15 24 44.3 (10) [27.0–58.0] 25 40.1 (8.1) [28.0–55.0] –4.2 (–9.4 to 1) –5.1 (–9.8 to –0.4)
Week 27 22 44.5 (12) [22.0–62.0] 22 41.6 (8.4) [24.0–55.0] –2.9 (–9.2 to 3.4) –3.7 (–8.8 to 1.4)
CPI 1d Baseline 25 97.4 (39.2) [11.1–212.5] 27 101 (55.5) [38.9–266.7] N/A
Week 15 24 107.5 (59.1) [33.3–271.4] 24 100.2 (38.7) [38.9–187.5] –7.3 (–36.3 to 21.7) 0.3 (–29.3 to 29.8)
Week 27 22 108.3 (47.6) [17.6–200] 22 92.6 (34.6) [41.2–146.2] –15.8 (–41.1 to 9.5) –12.2 (–39 to 14.6)
CPI 2b Baseline 26 42.9 (8.3) [26.3–64.4] 27 40.8 (7.9) [26.3–53.1] N/A
Week 15 24 40.8 (9.3) [21.5–63.3] 24 42.3 (9.9) [11.4–57.3] 1.5 (–4.1 to 7.1) 2 (–2 to 6.1)
Week 27 22 41.7 (11.3) [11.4–57.3] 22 42.2 (9.4) [17.8–54.7] 0.5 (–5.8 to 6.8) 1.8 (–2.6 to 6.1)
CPI 3b Baseline 26 57.5 (10.4) [38.1–81.4] 26 53.7 (9.3) [39–81.4] N/A
Week 15 24 58.4 (14) [39–100] 24 54.1 (11.1) [37.1–88.2] –4.2 (–11.6 to 3.1) –2.1 (–6.5 to 2.4)
Week 27 22 59.4 (15.4) [23.7–88.2] 22 54.2 (10.5) [36.2–77.3] –5.2 (–13.2 to 2.8) –0.4 (–5.3 to 4.4)
FRT, Functional Reach Test; N/A, not available.
a Results of the 2MWT do not account for sub-2-minute walk times or assistive devices.
b Increase in score indicates improvement.
c Decrease in score indicates improvement.
d See Completeness of the potential secondary outcomes.
e The mean difference between the allocated groups (BRiMS – usual care) with 95% CI for clinician-rated potential secondary outcomes.
f Each participants’ baseline score was subtracted from their follow-up score and we report the mean difference between the allocated groups (BRiMS – usual care) with 95% CI for
potential secondary outcomes.
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for consideration in trials of this nature. This feasibility trial provided us with the opportunity to gain first-
hand experience of its use. Feedback from the research therapists highlighted that some participants found
the measure complicated to interpret and complete. Our analysis of item CPI 1 (satisfaction with life
activities) also highlighted ambiguity in the scoring instructions for this part of the measure.
The second area of discussion is the shorter distances walked by our participants in the 2MWT than in a
number of other studies with similar sample characteristics.89,150 For example, Gijbels et al.147 reported a
mean walking distances of 104 metres (SD 41 metres, range 40–172 metres) in a sample of 21 participants
with an EDSS score of between 4.5 and 6.5 points. In line with this, our sample reported higher levels of
concern (as measured with the FES-I) than other MS populations, although this is perhaps not surprising
given their falls history and that they have progressive MS.102
Summary
The inclusion of a measure of participation is important; however, there is a paucity of measures that have
been evaluated for use in MS. In this feasibility study, the CPI proved burdensome to complete (particularly
of part 1 of the measure), and our analysis has highlighted ambiguities in its scoring that would need to be
addressed should it be used in a definitive study.
Accelerometry (activPAL) data
The activPAL results are based on the mean estimate per day for the number of days of data available for
each research assessment visit when participants were asked to wear the device. Although all participants
were asked to wear the device for 7 days, the number of days of data available was variable after the
cleaning process undertaken to remove any incomplete days (see Potential secondary outcomes). Table 19
shows the activPAL data, highlighting the number of days of recorded data and the number of participants
with at least 1 day of data that were used to estimate the mean activity levels at each time point.
Table 20 shows the accelerometry data at each time point. Overall, among the participants randomised,
at least 1 day of activPAL data were available for 54 (96.4%) at baseline, 46 (82.1%) at week 15 and 42
(75.0%) at week 27. Although the two groups of participants were similar on the majority of measures at
baseline, in line with the other outcome measure results, data for the step count were fewer in the
intervention group.
TABLE 19 Number of participants with activPAL data
Total
number
of days
Time point
Baseline Week 15 (± 1 week) Week 27 (± 1 week)
n
Follow-up
(%)
Randomised
(%) n
Follow-up
(%)
Randomised
(%) n
Follow-up
(%)
Randomised
(%)
1 – – – – – – – – –
2 – – – 1 2.0 1.8 – – –
3 3 5.4 5.4 1 2.0 1.8 – – –
4 2 3.6 3.6 3 6.1 5.4 2 4.5 3.6
5 24 42.9 42.9 22 44.9 39.3 14 31.8 25.0
6 24 42.9 42.9 18 36.7 32.1 21 47.7 37.5
7 1 1.8 1.8 1 2.0 1.8 5 11.4 8.9
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TABLE 20 Summary statistics, mean, SD and range of activPAL accelerometer data at baseline, week 15 and week 27, by allocated group
Variable Time point
Group
Difference between allocated groupsUsual care Intervention
n
Mean (SD)
[minimum–maximum] n
Mean (SD)
[minimum–maximum] Unadjusteda Adjustedb
Step count Baseline 26 3286.4 (2760.7) [256.3–11,756.4] 28 2654.9 (1861.1) [11.7–7543.2]
Week 15 23 3443.6 (3721.8) [283.2–13,034.5] 23 2841.4 (1841) [5.2–7671.2] –602.2 (–2347.1 to 1142.7) –165.7 (1047.6 to 716.2)
Week 27 22 2982.6 (3248) [166.7–14,739.6] 20 3633.1 (2268.3) [118.3–9027.2] 650.5 (–1113.7 to 2414.7) 699.8 (–495.3 to 1894.8)
Sitting/lying time (hours) Baseline 26 19.7 (1.7) [16.8–22.9] 28 19.9 (2.1) [15.3–23.2]
Week 15 23 19.8 (2.3) [13.5–23.4] 23 19.7 (1.9) [16.5–22.9] 0 (–1.3 to 1.2) 0.3 (–0.8 to 1.4)
Week 27 22 19.7 (2.2) [13.5–23.1] 20 19 (1.9) [16.1–22.7] –0.6 (–1.9 to 0.7) –0.2 (–1.1 to 0.8)
Standing time (hours) Baseline 26 3.4 (1.4) [1–6.1] 28 3.4 (1.9) [0.6–8]
Week 15 23 3.3 (1.8) [0.4–7.5] 23 3.5 (1.7) [1–6.7] 0.2 (–0.8 to 1.2) –0.3 (–1.2 to 0.7)
Week 27 22 3.5 (1.7) [0.6–7.6] 20 4 (1.7) [1.2–7.2] 0.5 (–0.6 to 1.5) 0 (–0.8 to 0.8)
Stepping time (hours) Baseline 26 0.9 (0.6) [0.1–2.9] 28 0.8 (0.5) [0–2]
Week 15 23 0.9 (0.9) [0.1–3] 23 0.8 (0.5) [0–1.9] 0.5 (–0.6 to 1.5) 0 (–0.2 to 0.2)
Week 27 22 0.8 (0.7) [0.1–3] 20 1 (0.5) [0.1–2.2] 0.2 (–0.2 to 0.5) 0.2 (–0.1 to 0.4)
Sit to stand (transitions) Baseline 26 48.2 (16.9) [15.8–84.8] 28 48.1 (19.8) [17–95.2]
Week 15 23 47 (20.8) [18.8–101.5] 23 51.6 (21.6) [17.2–101] 4.6 (–8 to 17.2) 2 (–4.6 to 8.6)
Week 27 22 45 (19.8) [17.3–84.8] 20 56.2 (20.2) [15–101.5] 11.1 (–1.4 to 23.6) 4.7 (–4.1 to 13.6)
a The mean difference between the allocated groups (BRiMS – usual care) with 95% CIs for self-reported potential secondary outcomes.
b Each participant’s baseline score was subtracted from their follow-up score and we report the mean difference between the allocated groups (BRiMS – usual care) with 95% CIs for
self-reported potential secondary outcomes.
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Summary
The recommended minimum of 5 days of accelerometry data were available for the majority of participants
and time points.85
Falls diary data
Once the data had been cleaned (see Analysis of patient-reported and clinician-rated outcome measures),
one participant was identified as accounting for over half of the reported falls in the usual-care allocation
group; therefore, this participant’s data were classified as an outlier and removed from all falls diary
analyses.
Figures 10 and 11 represent the proportion of participants falling and sustaining injurious falls on a weekly
basis. There is a significant variation over the weeks, and between the groups, although those in the
BRiMS group tended to report injurious falls less frequently.
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FIGURE 11 The proportion of participants with at least one injurious fall per week by diary week number and
allocation group. The green area of the plot represents the 13-week BRiMS intervention period.
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FIGURE 10 The proportion of participants who fell at least once per week by diary week number and allocation
group. The green area of the plot represents the 13-week BRiMS intervention period.
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A total of 715 falls were reported across the whole sample. Of these, 362 were in the usual-care group
and 353 were in the intervention group. A total of 101 injurious falls were reported: 66 in the usual-care
group and 35 in the intervention group.
As described in Completeness of the potential primary outcomes, a range of issues was identified with the
completion and return rate of the daily diaries. Table 21 gives the details of rates of falls and injurious falls
calculated per person per year.
Consequences of falls
Data on the injuries sustained during falls, the use of medical services and the need for help to get up
after a fall are reported in Table 22. Participants were requested to report the number of each type of
injury (e.g. bruises, cuts/scrapes, fractures) that they experienced. This was not reported consistently; for
example, some participants provided specific details (e.g. bruise = bottom). Therefore, these variables were
converted into a binary variable representing the presence or absence of at least one of these injuries.
These data are from participant self-report pre-formatted diaries and therefore the injuries have not been
corroborated by medical assessments. Both the rates of falls and the rates of injurious falls reported by our
participants are high relative to published observational data.17 This may be explained, at least in part,
because all participants reported recent falls on entry to the study, and all have SPMS. Although it is
known that people with progressive MS and those with an EDSS score of around 6–6.5 points have an
increased risk of falls, changes in rate of falls with changing mobility status and/or disease classification has
not yet been established.
TABLE 21 Falls and injurious falls rate per person per year
Falls analyses
Group
TotalUsual care Intervention
Total number of falls (n) 362 353 715
Total number of injurious falls (n) 66 35 101
Falls rate (per person per year)a
Analysis 1 (reported)
Number of days with falls data (n) 3204 3180 6384
Falls rate 41.3 40.5 40.9
Analysis 1 (returned)
Number of days with injurious fall data (n) 2478 1983 4461
Injurious falls rate 9.7 6.4 8.3
Analysis 2 (expected)
Number of potential days of data (n) 4116 5096 9212
Falls rate 32.1 25.3 28.3
Injurious falls rate 5.9 2.5 4.0
Analysis 3 (randomised)
Number of potential days of data (n) 5096 5880 10,976
Falls rate 25.9 21.9 23.8
Injurious falls rate 4.7 2.2 3.4
a Please see Analysis of patient-reported and clinician-rated outcome measures for an explanation of the analyses.
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TABLE 22 Number and percentage of participants who reported injuries in the diary entries
Falls and injurious falls
Group
TotalUsual care Intervention
n
Reported
(%)
Expected
(%)
Randomised
(%) n
Reported
(%)
Expected
(%)
Randomised
(%) N
Reported
(%)
Expected
(%)
Randomised
(%)
Any injuries during the 2-week period
No 52 10.6 7.7 6.6 31 6.3 4.6 4.0 83 17.0 12.4 10.6
Yes 87 17.8 12.9 11.1 65 13.3 9.7 8.3 152 31.1 22.6 19.4
Not applicable (no fall) 101 20.7 15.0 12.9 117 23.9 17.4 14.9 218 44.6 32.4 27.8
Spoiled 1 0.2 0.1 0.1 1 0.2 0.1 0.1 2 0.4 0.3 0.3
Missing 14 2.9 2.1 1.8 20 4.1 3.0 2.6 34 7.0 5.1 4.3
Reported injuries
Bruises 45 9.2 6.7 5.7 28 5.7 4.2 3.6 73 15.7 10.9 9.3
Cut(s)/scrape(s) 25 5.1 3.7 3.2 8 1.6 1.2 1.0 33 0.6 4.9 4.2
Strain(s)/sprain(s) 9 1.8 1.3 1.1 5 1.0 0.7 0.6 14 14.0 2.1 1.8
Dislocation 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0 0.0 0.0 0.0
Broken bone(s) 3 0.6 0.4 0.4 1 0.2 0.1 0.1 4 2.2 0.6 0.5
Did you use any medical services?
No 123 25.2 18.3 15.7 79 16.2 11.8 10.1 202 41.3 30.1 25.8
Yes 5 1.0 0.7 0.6 2 0.4 0.3 0.3 7 1.4 1.0 0.9
Not applicable (no fall) 110 22.5 16.4 14.0 135 27.6 20.1 17.2 245 50.1 36.5 31.3
Spoiled 0 0.0 0.0 0.0 1 0.2 0.1 0.1 1 0.2 0.1 0.1
Missing 17 3.5 2.5 2.2 17 3.5 2.5 2.2 34 7.0 5.1 4.3
Did you have help to get up after a fall?
No 76 15.5 11.3 9.7 54 11.0 8.0 6.9 130 26.6 19.3 16.6
Yes 52 10.6 7.7 6.6 32 6.5 4.8 4.1 84 17.2 12.5 10.7
Not applicable (no fall) 110 22.5 16.4 14.0 131 26.8 19.5 16.7 241 49.3 35.9 30.7
Missing 17 3.5 2.5 2.2 17 3.5 2.5 2.2 34 7.0 5.1 4.3
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Summary
Falls data, with respect to both frequency and whether or not these resulted in injury, were recorded by
participants daily in a pre-formatted paper diary, which was requested to be returned on a 2-weekly basis.
Issues with the quality and completeness of the recorded data, and the lower than expected diary return
rate, cast some uncertainty over the confidence with which the results can be interpreted.
Associations between baseline factors most strongly associated with potential outcomes,
as potential stratification factors in a definitive trial
The associations between the potential primary outcomes and the baseline demographic and clinical
characteristics were evaluated as indicators of the possible need for stratification and/or whether or not the
final analyses of a full definitive trial may require adjustments for associations. Estimates have not been
split by allocated group and include all available data at week 27 (± 1 week) as the likely primary end
point of such a trial. Data are presented in Appendix 5.
From these analyses, it appears that associations may be significant between the potential primary outcomes
and disease severity (EDSS), depression and the use of mobility aid. There is evidence to suggest that those
who report being depressed or lacking pleasure tend to have higher mean scores, particularly MSIS-29vs2
psychological scores, for which the 95% CIs for depression do not overlap between categories. Those with
an EDSS score of ≥ 6.0 points appear to score significantly higher on all measures; however, the small
numbers of participants classified at the lower end of the EDSS scale precludes definitive recommendations.
Discussion
Analysis of possible associations between baseline characteristics and potential primary outcome measures
suggests that a future trial should consider stratification for mood and/or disease severity.151–154 Small
numbers in the lower EDSS groupings in our analyses limit the inferences we are able to draw; however,
other studies have also highlighted this association with regard to both disease severity63 and mood.155
Although stratification for disease severity according to the EDSS is quite common in MS physical
rehabilitation trials,151–154 a literature search confirmed that this is not the case for mood.
Calculation of sample size required for a fully powered randomised controlled trial to
evaluate the effectiveness of the BRiMS intervention
One of the key purposes of a feasibility trial is to obtain data to inform the sample size calculation for a
full-scale trial. Pearson’s correlation coefficients were calculated between the potential primary outcome
measures at baseline and at 27 weeks (± 1 week) to inform the sample size calculation for a future
definitive trial; data are detailed in Appendix 5. Correlation coefficients were generally moderate, with a
conservative point estimate of 0.59 for the recommended primary outcome measure for a definitive trial,
the MSWS-12vs2.
The data collected as part of this feasibility trial have been used, together with previously identified
relevant data, to provide potential target sample sizes under a range of assumptions in order to detect a
between-group difference for the primary outcome of MSWS-12vs2 of 5.2 units156 at the primary end
point of 6 months post randomisation.
It is assumed that the primary statistical analysis of such a definitive trial would be based on a multilevel
modelling approach, including adjustment for the baseline MSWS-12vs2 score, to allow for the partially
nested data: participants allocated to the intervention arm of the trial will be clustered within small groups
(≈5 participants), whereas participants allocated to the usual-care arm will not be clustered. Sample size
calculations therefore need to incorporate the estimated intracluster correlation (ICC) (‘group’ effect).157,158
It is anticipated that BRiMS intervention groups will be small (≈5 per group; in the BRiMS feasibility trial,
the intervention groups ranged from four to six participants) and, as there are only three group sessions
during the intervention period, at each site there is likely to be only one treating therapist. Furthermore,
the intervention is standardised/manualised, leading to the assumption that the ICC is likely to be small.
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The base case for the sample size calculation below assumes an ICC of 0.05, with additional calculations
shown for ICCs of 0.075, 0.100 and 0.125.
Pooling the SD of MSWS-12vs2 from previous relevant studies159,160 gives a SD of 23 units. In the BRiMS
feasibility trial, the point estimate of the SD of MSWS-12vs2 at 27 weeks (± 1 week) follow-up was
19.4 units (i.e. lower than the pooled estimate from the previous four studies), with a one-sided 80%
upper bound of 21.5 units. The base case for the sample size calculation below conservatively assumes
a SD of 23 units, with calculations also shown for SDs ranging from 19 to 25 units.
As the planned analyses would include adjustment for baseline MSWS-12vs2 scores, the effect of allowing
for the correlation between baseline and 6-month MSWS-12vs2 scores has also been considered.161 There
are few relevant published estimates of the correlation between baseline and 12 month MSWS-12vs2
scores: data from the SWIMS project,55 which collects these data annually, suggested that the correlations
between measures taken approximately 1 year apart are high and relatively stable (0.85 to 0.89). However,
in the BRiMS feasibility trial, the point estimate of the correlation between baseline and 27 weeks (± 1 week)
was 0.59, with a one-sided 80% lower bound of 0.50. The base case for the sample size calculation below
assumes a correlation of 0.6, with calculations also shown for correlations of 0.5 and 0.7.
Finally, an allowance is made for the estimated follow-up rate at 6 months. Previous studies suggested
follow-up of approximately 80%; however, the follow-up rate in the BRiMS feasibility trial was 78.6%
(95% CI 65.6% to 88.4%) and so the target recruitment rates below assume a follow-up rate of 70%.
In summary, the base case assumes detecting a between-group difference of 5.2 units, a SD of 23 units, a
cluster size (intervention group only) of five participants and an ICC of 0.05; correlation between baseline
and 6-month scores of 0.6; follow-up rate of 70%; and with two-sided 5% alpha and 90% power. The
sample size calculations were undertaken in Stata using the clsampsi package (based on Roberts and
Roberts157) before adjustments were made for the baseline/6-month correlation and the loss to follow-up rate.
Based on Table 23, the number of participants required to be followed up at the 6-month primary end
point ranges from just over 600 to nearly 1100, before allowing for the correlation between baseline and
follow-up, which reduces the equivalent numbers to a range of 400 to around 700. Table 23 illustrates
that the main drivers of the total sample size required are the SD and the correlation between baseline and
follow-up; varying the ICC or cluster size has a smaller impact.
Programme feasibility: BRiMS process evaluation (objectives x–xii)
Application of process evaluation plan
Fidelity assessment
The fidelity assessment plan was devised to ensure coverage of all four sites and session types (Table 24).
A greater number of assessments of sessions undertaken in site 4 were carried out as two of these were
used for moderation between the three assessors (assessor 3 needed to remain blinded to the group
allocation of the south-west participants). The assessors confirmed that they felt that sufficient sessions
had been evaluated to enable recommendations to be made. Undertaking the assessments using audio-
recordings was time-consuming, and at times challenging, because of difficulties hearing details during
group interactions, and not being able to pick up on the non-verbal elements of communication that could
be significant when assessing one-to-one interactions.
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TABLE 23 Sample size calculation for a definitive trial
Calculation
Between-group
difference at
6 months SD
Cluster
size
ICC of
intervention
group
Unadjusted
total sample
size required to
be followed up
Total sample
size required to
be recruited –
adjusted for
30% LTF
Correlation
between
baseline and
6-month
MSWS-12vs2
Total sample size
required to be
followed up –
adjusted for
correlation
Total sample size
required to be
recruited – adjusted
for correlation and
30% LTF
Base case 5.2 23 5 0.05 912 1303 0.6 584 836
Vary ICC 5.2 23 5 0.075 954 1363 0.6 611 876
5.2 23 5 0.100 995 1421 0.6 637 914
5.2 23 5 0.125 1040 1486 0.6 666 951
Vary SD 5.2 19 5 0.05 625 893 0.6 400 576
5.2 21 5 0.05 761 1087 0.6 487 697
5.2 25 5 0.05 1080 1543 0.6 691 987
Vary correlation 5.2 23 5 0.05 912 1303 0.5 684 979
5.2 23 5 0.05 912 1303 0.7 465 666
Vary cluster size 5.2 23 6 0.05 936 1337 0.6 599 856
5.2 23 7 0.05 956 1366 0.6 612 878
LTF, loss to follow-up.
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TABLE 24 Mapping of fidelity assessments
Session type
Sessions
undertaken, n
Assessed for
fidelity, n (%)
Mapping by site, n (%)
Site 1 Site 2 Site 3 Site 4
Undertaken Assessed Undertaken Assessed Undertaken Assessed Undertaken Assessed
Initial assessment 28 8 (29) 5 1 9 2 4 2 10 3a
Home visit 28 7 (25) 5 1 9 2 4 1 10 3
Group sessions 17 5 (29) 3 1 5 1b 3 1 6 2
Total face-to-face contacts 73 20 (27) 13 3 (23) 23 5 (22) 11 4 (36) 26 8 (31)
a Includes two sessions moderated by all three assessors.
b One fewer group assessment than planned was undertaken as the group did not run.
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Participant interviews
A total of 13 participants were interviewed within the process evaluation; the relevant data are detailed in
Participant experiences.
Therapist focus group
All four treating therapists contributed to the telephone focus group (Table 25), which was undertaken
3 weeks after the final programme delivery had been completed.
Summary
The fidelity assessment and qualitative aspects of the process evaluation were undertaken according to
plan, and the stated aims were achieved. Listening to audio-recordings was time-consuming, but the
recordings were of sufficient quality to allow an effective assessment to be undertaken, and the recorders
were only minimally intrusive for both participant and therapist.
Findings
The findings are presented below using the process evaluation framework that informed the coding
template used in the analysis. Issues were systematically explored regarding overall experiences,
programme implementation, mechanisms of impact and context.
Overall experiences
All four therapists and most participants reported that they enjoyed being part of the programme and, although
they highlighted improvements that could be made, could see value in its aims, approach and content:
. . . very positive and I have to say a very good feel-good factor about the study as well.
P8
I thought it was a wonderful concept that was really, well, it was incredibly thorough and the
resources at last have gone beyond physio tool handouts and it enabled [a group of] people with MS
. . . who lived in really as far apart as you could from each other, it enabled me to deliver a really
high-quality content.
T1
The positive perceptions among both therapists and participants were tempered by some who expressed
frustration at specific design elements of the programme, and feelings of being overwhelmed by the
volume and type of content to be delivered, particularly at the beginning. For others, however, this was
expressed as an issue more of pacing and presentation than of overall quantity:
There was a bit too much information.
P10
I think at the moment it lacks coherence in terms of the two web-based elements being not integrated
as a whole would be one comment, that it feels a bit like bits rather than a real seamless thread.
T2
TABLE 25 Therapist focus group participants
Therapist
code Profession Sex
Years of
experience Clinical specialty
Number of BRiMS
deliveries
T1 Physiotherapist Female 18 Neurorespiratory and community
rehabilitation
1
T2 Physiotherapist Female 35 Neurorehabilitation 2
T3 Physiotherapist Female 21 Community/neurorehabilitation 1
T4 Physiotherapist Female 15 Neurorehabilitation 2
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Implementation of the BRiMS programme
Here we explore the feedback from participants and treating therapists about their experiences of
delivering and attending the BRiMS programme, and of using the resources available within BRiMS.
Feedback about specific BRiMS sessions is also included in this section.
Attendance rates
As part of the BRiMS intervention, each participant had two individual sessions (clinic and home visit) and
three group sessions, giving a total of five face-to-face sessions with a treating therapist. Therefore, there
were a potential 150 face-to face sessions (five sessions × 30 participants). Summing all of the completed
face-to-face session attendances gives a total of 95 (63.3%) successfully completed. Attendance rates for
the one-to-one sessions were considerably higher than those for the group sessions (Table 26).
Discussion
As with other programmes with occasional group sessions, attendance was variable over time and
between participants.30 The majority of the interviewees who attended the group sessions reported finding
them beneficial and that the sessions supported their engagement with the more independent parts of the
programme. Some feedback suggested that reduced or non-attendance did not necessarily equate to a
lack of engagement; some participants who did not attend all of the group sessions still reported positive
experiences with the programme. This may be because educational material was available in the paper
manual provided to all participants at the first session, or because the information most critical to their
personal falls management was obtained in the sessions attended. Further exploration of ‘how much is
enough’ for these types of programmes is required.
The decision to run the group sessions with small cohorts was based on the need to ensure safety during
the exercise components of these sessions, and to maximise opportunities for participants to interact
effectively. However, the findings of this feasibility trial suggest that the current format may not be
optimal, either for effective use of the therapist‘s time or to maximise the benefits reported from peer
interaction. Consideration of alternative formats (e.g. a single longer workshop, rather than several
sessions) is warranted.
TABLE 26 Session attendance rates
Session Attendees (n) Randomised (%)
BRiMS visit
Clinic 28 93.3
Home 27 90.0
Group session
Week 4 23 76.7
Week 8 10 33.3
Week 13 13 43.3
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Programme delivery
Experiences of delivering the programme
The therapists reported positive experiences of delivering the programme, including their use of the
programme resources and their interactions with participants. However, they did express frustration and
disappointment when they perceived that participants were not engaging fully with the programme:
T1: I enjoyed reviewing their exercises online and the follow-up e-mails and so on, that was a really
constructive way of delivering that information, so for me there was some design aspects of the actual
site, but overall I really enjoyed working with them as tools.
T3: One of the things I really enjoyed was the home visits, and to be able to set up the exercises and
use what people had in their own homes.
T1: I felt really frustrated when people, when some people weren’t giving it [online exercise
programme] a chance, but it wasn’t the package per se it was the individuals not giving the internet
a chance.
Fidelity to the spirit of BRiMS
Four key attributes and behaviours were defined as core to the delivery of BRiMS, and these were
evaluated in every fidelity assessment. The majority of scores indicate that the items were addressed well
by therapists, although there was scope for additional depth and detail.
The collated results of the assessments for these four items are detailed below. In addition to the fidelity
scoring, assessors provided written qualitative feedback to support judgments where those judgements
had been less than straightforward, and where they thought this was necessary.
Facilitation style
Facilitation style scores are given in Table 27.
Qualitative feedback Therapists were described as encouraging, respectful, positive and warm in their
interactions (e.g. records 21, 61 and 161), with evidence of a positive rapport being built between
therapist and participants in both individual (record 121) and group (record 181) sessions. There were
examples of specific techniques being used to encourage participants to engage actively with the session
(e.g. records 51 and 81) and also of therapists needing to utilise high-level skills to support and facilitate
participant interaction (e.g. record 141). Lack of time in sessions was felt to result in missed opportunities.
TABLE 27 Fidelity assessment of facilitation style
Score
Assessment
Initial (n= 8)
Home visit
(n= 7)
Group 1
(n= 1)
Group 2
(n= 2)
Group 3
(n= 2) All (n= 20)
Median (IQR) 2 (2–2.25) 2 (1.5–3) 3 (0) 2.5 (2.25–2.75) 2 (1.5–2.5) 2 (2–3)
Scoring
0. Absence or minimal use of active participant involvement techniques. An overly ‘directing’, practitioner-led or
‘lecturing’ style of interaction, which may increase or sustain client’s resistance.
1. Occasional use of participant involvement techniques. The practitioner sometimes dominates the discussion.
2. Some use of participant involvement techniques. Some collaborative working evident.
3. Appropriate use of participant involvement techniques, facilitating shared understanding and decision-making.
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Utilisation of multiple sclerosis-specific knowledge and expertise
Utilisation of multiple sclerosis-specific knowledge and expertise scores are given in Table 28.
Qualitative feedback Feedback suggested that MS-specific issues were recognised and discussed where
required, with evidence of tailoring of exercise to address issues such as heat sensitivity and fatigue
(records 132 and 172).
Developing and maintaining challenge and motivation
Developing and maintaining challenge and motivation scores are given in Table 29.
Qualitative feedback Written comments identified that therapists utilised an encouraging and supportive
approach (records 123, 173 and 192). However, four out of the six records that had comments relating to
this topic also identified additional opportunities to support motivation and engagement.
Supporting self-management skills and autonomy
Supporting self-management skills and autonomy scores are given in Table 30.
TABLE 28 Fidelity assessment: utilisation of MS-specific knowledge and expertise
Score
Assessment
Initial (n= 8)
Home visit
(n= 7)
Group 1
(n= 1)
Group 2
(n= 2)
Group 3
(n= 2) All (n= 20)
Median (IQR) 3 (2.5–3) 2 (2–2.75) 2 (0) 2.5 (2.25–2.75) 3 (0) 2.5 (2–3)
Scoring
0. Absence of discussion to identify MS-specific issues and formulate an appropriate plan. Session structure is likely to
inhibit people with fatigue/cognitive issues from participating effectively.
1. Minimal discussion to identify MS-specific issues and formulate an appropriate plan. Session structure is not tailored to
enable people with fatigue/cognitive issues to participate effectively.
2. Some discussion to identify MS-specific issues and formulate an appropriate plan, but not in sufficient depth or detail.
Some tailoring of session structure to enable people with fatigue/cognitive issues to participate effectively is evident,
but this is inconsistent.
3. Appropriate discussion to identify MS-specific issues and formulate an appropriate plan. Session structure is highly likely
to support people with fatigue/cognitive issues to participate effectively.
TABLE 29 Fidelity assessment: developing and maintaining challenge and motivation
Score
Assessment
Initial (n= 8)
Home visit
(n= 7)
Group 1
(n= 1)
Group 2
(n= 2)
Group 3
(n= 2) All (n= 20)
Median (IQR) 2 (2–2.5) 2 (1.5–2.5) 3 (0) 2 (0) 2 (1.5–2.5) 2 (2–3)
Scoring
0. Sessions do not (or minimally) challenge participants and support motivation.
1. Minimal support for motivation and consideration that ensuring participants are suitably challenged. Participants are
not supported to exercise effectively or set inspiring goals.
2. Some support for motivation and consideration of ensuring that participants are suitably challenged. The importance
of exercising effectively and setting inspiring goals is highlighted, but not considered in sufficient depth or detail
(e.g. missed opportunities to practise imagery, insufficient use of aids to support motivation and challenge).
3. Appropriate support for motivation and consideration of ensuring participants are suitably challenged is seen regularly
in the session. There is evidence of individual participants being supported to exercise effectively and set inspiring goals,
with appropriate use of aids to support motivation and challenge. Imagery is encouraged and practised during the
session to strengthen motivation.
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Qualitative feedback Assessors noted that peer support was used proactively to encourage participants
to problem-solve during group sessions (records 154 and 164), although more time and space in sessions
to enable participants to consider and develop their ideas may be valuable in future (records 24, 34 and 44).
Discussion
Feedback from the fidelity assessments and qualitative interviews suggests that the therapists needed to
utilise high-level skills to establish an effective relationship with participants and to deliver the key elements
of the programme. Feedback from participants was positive, but some of the evidence from the process
evaluation suggests that the aim of supporting participants to take the lead in how, when and the way in
which they engaged with the programme could be improved. For instance, it appears that many of the
participants relied on the therapists to guide the progression of their exercise programme. Despite the
reviews being scheduled regularly, the quality of information that patients provided to the therapists was
often limited, potentially resulting in missed opportunities to maximise the amount of ‘highly challenging’
exercise undertaken. There is a need to explore ways of encouraging better use of exercise resources to
ensure that the exercises remain challenging and that participants are able to progress without sustained
face-to-face supervision from therapists. It is also important to consider how the BRiMS programme could
further enhance a collaborative approach that supports self-management. Evidence from other settings
and other conditions suggests that this is an ongoing challenge in clinical practice that requires a paradigm
shift among many rehabilitation professionals.162 It is acknowledged that effective training and support is
essential to achieve this.163,164
Factors affecting delivery
The therapists acknowledged that there were elements of the programme that they were less familiar with
(e.g. the functional imagery training), which presented challenges. They found the peer support provided
through the BRiMS website a valuable resource, and those therapists who ran two deliveries of the
programme reported that familiarity did help their confidence and the ease of programme delivery. There
was a recommendation from all therapists that more initial training was required than was delivered in this
trial, particularly training that focused on less familiar areas:
I think that’s where my skills very quickly ran out because I didn’t have the, um, background to then
be able to counsel them into a more positive attitude; I think on the whole I felt I needed more help
to present the imagery.
T1
TABLE 30 Supporting self-management skills and autonomy
Score
Assessment
Initial (n= 8)
Home visit
(n= 7)
Group 1
(n= 1)
Group 2
(n= 2)
Group 3
(n= 2) All (n= 20)
Median (IQR) 2 (1–2) 2 (0) 3 (0) 2 (0) 2.5 (2.25–2.75) 2 (1.5–2)
Scoring
0. Absence of support for self-management skills and autonomy.
1. Minimal support for self-management skills and autonomy. The participant has a limited understanding of how to
monitor and progress activities, and plan for decision making is unclear, or poorly specified.
2. Some support for self-management skills and autonomy. The participant has a basic understanding of how to monitor
and progress activities, with some autonomy in decision-making.
3. Appropriate support for self-management skills and autonomy. The participant has a clear understanding of how to
monitor and progress activities, with appropriate autonomy in decision-making.
DOI: 10.3310/hta23270 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 27
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Gunn et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
. . . by the second group, actually I felt much more comfortable with it, and so I could see that how
initially in running a programme within an NHS setting you’d need the induction and the training etc.,
but actually fairly soon it will get embedded into practice fairly reasonably.
T2
The therapists highlighted that they consistently needed more time than was allocated to deliver the
programme content and provide effective feedback to participants. The therapists also recommended that
the duration of the overall programme should be reviewed to consider whether or not extending this
would enable participants to experience more meaningful changes in ability:
On the home visit I consistently took one and a half hours really for that rather than the one that was
allocated – I couldn’t get it any shorter than that and still be reasonably polite.
T3
Discussion
Therapists reported positive experiences of the programme, and perceived the novel format and delivery
style to have many advantages. Even though the therapists we recruited were all highly experienced, there
were elements for which the need for more training and support was highlighted, both in the fidelity
assessment and by the therapists themselves. The therapist training session in this trial was kept short to
minimise excess treatment costs and to enable all therapists to be trained at the same time (as one
therapist had had to fly from Ayrshire to the south-west to attend). However, our recommendation for
future trials of the programme is that a longer training session is essential. The use of a discussion board
was appreciated by the therapists, which presents an opportunity for the development of further online
support, such as peer-supervision sessions and debriefs.
Future deliveries of BRiMS should also be costed to reflect the actual time needed to deliver the
programme, as this was underestimated in this trial. In particular, the therapists required more contact time
for the one-to-one sessions than was originally allocated [see Intervention costs (objective xiii)]. A mobile
version of this website should be considered, as it has the potential to simplify the logistics of some of the
home visits.
Sessions and resources
BRiMS education resources (BRiMS website and paper manual)
This section analyses participant’s experiences of using the education resources associated with BRiMS,
including the online education programme and its accompanying paper manual.
The therapists valued the BRiMS website resources, although some felt that the logistics of the online
provision were challenging:
The BRiMS package, again it was very helpful, but the one thing that was very frustrating was not
being able to jump ahead without saying that you’ve completed where you were – because I wanted
to skim through quite a lot to make sure I knew what I was doing and I got a bit frustrated with
having to say that I’d read it and stuff, but it was really well laid out and it contains all of the
resources we needed and the fact that all the audio was uploaded on that.
T1
Participant engagement with the educational elements of BRiMS was variable, as evidenced by the website
data (Table 31).
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Participants’ feedback highlighted a number of elements that they found useful, both in the online
resources and in the group sessions. However, there were mixed feelings about some of the activities, and,
at times, about the approach used:
But I put down, ‘I did enjoy the online part’, and I mean the exercises and the online BRiMS. You’re
working through that, I did like that and I liked the fact that you could dip in and out of it.
P13
I found the [education] exercises . . . but then I’m an ex-primary school teacher, we did them with
primary school children. I did find that difficult to do exercises like that.
P5
Participants identified the exercises that encouraged self-reflection and evaluation to be particularly of
value; however, the paper manual that accompanied the online resources received mixed reviews, with a
general sense that the amount and format of the information provided needed to be simplified. It was
identified that preferences over information format varied between participants:
The part of the manual that I found which is kind of surprising, I’ve had MS for 29 years and I think to
myself ‘you are getting to know it by now’, but it’s one of those things you never know. But there
were parts of the manual I really thought were important in there so for me and those were the bits
that were throwing things back at you ‘what about this and how do you do this and do you feel
about that’ and I thought I should know that, but actually writing it down where I had oh I did this
today, kind of how was it for you.
P13
There was a big booklet the yellow pages, I think. I couldn’t begin by reading all that stuff, there were
too many words and too complicated.
P9
Discussion
As with many programmes that use online delivery methods, we saw variable patterns of engagement
among participants, and a drop-off over time.44,113 The findings of our process evaluation suggest that the
BRiMS education resources need to be reviewed, in particular to ensure that the amount of falls prevention
content is rationalised and that the delivery style is further optimised for online delivery to a UK-based
audience. As BRiMS utilised resources from an existing MS falls-prevention programme, it was not
TABLE 31 Summary statistics on the usage of the home education programme
Element n (%)
Total number of logins
Median (IQR) 5 (4–13)
Minimum–maximum 0–85
Component
Exercise advice 15 (50.0)
Home package 1 (week 1) 16 (53.3)
Home package 2 (weeks 2–4) 12 (40.0)
Home package 3 (weeks 5–8) 9 (30.0)
Home package 4 (weeks 9–13) 7 (23.3)
Percentages are of the total number allocated to the intervention group.
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considered appropriate to omit elements of this programme without first identifying what worked and
what did not in this new format. Having undertaken our feasibility trial, feedback from our participants
and therapists has identified a number of areas in which content changes could be made, and adaptations
to the format could make it more engaging. Simple changes, such as reducing repetition and ensuring that
participants can progress easily through the online resources, could reduce the frustration and disengagement
brought about by the logistical issues our participants encountered.
Exercise activities
This section looks at the exercise programme and investigates the engagement with the BRiMS online
programme. Therapists and participants generally viewed the exercise component of BRiMS positively, and
felt that the flexibility it offered was helpful. Participants appreciated feeling in control of their activities,
compared with a more prescriptive approach. The combination of one-to-one, online and group support
was seen to be helpful in maintaining engagement:
I thought the web-based exercises were wonderful, I thought they were a really brilliant resource.
T1
One of the good things is that it is very flexible, so if you wanted to do it anytime in the day you could
do it . . . You put the person in the control and that’s a very good feeling as well as opposed to ‘you
must show up on Monday morning at 9 o’clock to do this’. Whatever day you were having you chose
the time to do it.
P8
I actually found it OK. Which almost surprised me, because you know, continuing exercises is quite
difficult on your own, but I think the fact that you had something to look at or other people; it sounds
a little bit weak really, but other people to do it with but when you are watching on the program I
found it very helpful and without it I wouldn’t have continued for 12 weeks.
P10
The fact that the video exercises were filmed with people with MS helped participants to engage with the
programme:
The people that were actually doing the exercises weren’t 18-year-old stick insects. They were the likes
of you and me, they were people who you could see that it wasn’t easy necessarily for them to do it
as well. So again that’s a good psychological side for us as the recipient. To think you are not being
shown by some super-fit person, somebody else challenged like yourself is doing it . . .
P8
Although the exercise videos were available online and participants were requested to log their exercises
online, some preferred to use the paper manual for guidance:
Interestingly most of my people favoured the paper manual over the electronic version. So they, they
tended to take the paper manual with them into different rooms, and if they haven’t have had the
manual . . . they didn’t really engage so well at all with the electronic versions.
T2
Documentation of exercise use began in week 2 of the programme and ended in week 13 to obtain the
required 12 weeks of exercise. Some participants reported that they found the accumulative online diary a
useful way of logging their exercise, while others reported challenges with the logistics of using the diary
to log exercise. Quantitative data on the usage of the exercise programme were available for 27 out of the
30 participants (90.0%). The number of participants who commenced BRiMS was taken from the number
who completed a clinic visit during which the participant’s online exercise programme was individualised.
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Online login data (Tables 32 and 33) show that the pattern of logging exercise was variable, with five
participants (17% of those randomised) entering data on only 1 of the possible 12 recording weeks. By
contrast, 10 participants (32% of those randomised) entered data on ≥ 10 weeks. As with the education
programme, the number of participants logging data reduced over time, although patterns of use varied
among participants: some dipped into and out of the programme over time, some did not enter data after
the initial weeks and some logged exercise consistently.
TABLE 32 Cumulative number of weeks where participants entered exercise data in the online exercise diary
Cumulative number of weeks
of entered exercise data Participants (n) Commenced BRiMS (n= 28) (%) Randomised (n= 30) (%)
1 5 18.5 16.7
2 1 3.7 3.3
3 3 11.1 10.0
4 2 7.4 6.7
5 0 0 0
6 1 3.7 3.3
7 1 3.7 3.3
8 1 3.7 3.3
9 3 11.1 10.0
10 4 14.8 13.3
11 2 7.4 6.7
12 4 14.8 13.3
TABLE 33 Number and percentage of participants who entered exercise data in the online exercise diaries by
programme week
Programme week number Participants (n) Commenced BRiMS (n= 28) (%) Randomised (n= 30) (%)
2 23 82.1 76.7
3 20 71.4 66.7
4 21 75.0 70.0
5 18 64.3 60.0
6 16 57.1 53.3
7 14 50.0 46.7
8 11 39.3 36.7
9 13 46.4 43.3
10 12 42.9 40.0
11 11 39.3 36.7
12 13 46.4 43.3
13 10 35.7 33.3
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Therapists reported that they were confident about developing exercise prescriptions using the BRiMS
exercise menu and about uploading them to the web-based physiotherapy resource, but also that this took
more time than they had anticipated, and was challenging, as the two online systems did not fit together:
I think from the BRiMS exercise menu if it tied up more easily with the [online] site that would be
more helpful, and if maybe the exercises, where you’ve got some progression [they’re] not always on
the site – things like carrying a tray with a cup of water and things like that, so that won’t be in the
video, but I did find, mine all enjoyed using the site to record their exercises.
T3
Evaluation of the online exercise programme data indicates that the participants undertook exercises from
across the six BRiMS exercise categories, suggesting that the therapists utilised the prescription principles
appropriately (Table 34 and Figure 12). Participants also logged exercise substitutions throughout the
programme, despite these being ‘formally’ introduced only at week 8.
Logged minutes of exercise
Table 35 shows the time logged by participants during the 12 weeks of the intervention. Participants were
asked to undertake 120 minutes of exercise per week, which some considered too demanding, particularly
early in the programme:
I think a lot of my people were commenting that 120 minutes initially was a bit like wow! One person
in particular felt that that was a lot and it should have been may be titrated up initially.
T3
Perceived change and achievement were significant factors influencing motivation to continue exercising;
participants highlighted the importance of feeling that they were making progress by using a target/timer
to record this on the exercise website, or by exercises being changed as the programme progressed:
I never got back. So I think it would have been much better to start with just a few small things, build
up. My exercises were never changed so I never felt I was progressing. And that psychologically had
an effect on me because I knew I wasn’t quite good enough. I hadn’t done them well enough. So
psychologically I think it would be better to start small and say ‘you can ask for more and we can offer
you more as we go through’, and I think that would have been a real help actually.
P5
TABLE 34 Number of minutes logged by exercise category
Period
BRiMS exercise categories, median (IQR)
Height
changes Reaching Sit–stand Standing Stepping Substitution Walking
Programme (weeks 3–13)
Participants (n) 13 (11–15) 13 (11–15) 11 (9–15) 12 (11–15) 12 (11–16) 6 (4–8) 10 (10–14)
Minutes/
participant/week
10 (6–20) 12 (8–20) 12 (6–18) 16 (8–22) 18 (9–24) 27 (20–46) 10 (7–17)
Follow-up (weeks 14–27)
Participants (n) 5 (3–5) 4 (3–5) 4 (3–4) 4 (3–4) 4 (3–5) 3 (2–3) 4 (3–4)
Minutes/
participant/week
6 (4–12) 10 (5–15) 13 (7–19) 11 (6–16) 13 (8–16) 47 (25–55) 9 (6–14)
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Therapists reported that use of the online exercise resource varied among their participants. A number of
logistical issues were highlighted, including the use of the timer, free-text and ‘exercise completed’ boxes
and timer rollover dates. They also reported that some participants engaged with their exercises but did
not use the web-based resource to log their exercise activity, and that others needed paper handouts
because of logistical challenges or IT problems. Participants expressed a range of preferences for the
format of the exercise resources, with some users preferring paper handouts over video for their exercises.
For others, the combination of paper, video and audio contents worked well. This is important as it calls
into question the validity of the online diary records of these participants:
I think in part that was also, some of them found it a bit challenging, you had to tick a box to say
you had completed the exercise and if you hadn’t done that then, even though you’d filled out the
number of reps, etc., it hadn’t logged that the exercise had been done and also the time, so that they
might press the time and then they’d forget to stop the timer and so it looked as if they’d done like
2 hours, well maybe not 2 hours but an hour of sit to stand!
T2
[Paper exercise sheet] Absolutely fine, you know I was able to do it far better than I would have been
trying to watch a video. It just doesn’t work for me, I’m sure it works for most, well lots of people,
but it doesn’t, I need to have it there and be able to keep looking at it.
P4
Height changes
Reaching
Sit – stand
Standing
Stepping
Substitution
Walking
(a)
10%
18%
17%
17%
12%
15%
11%
Activity
(b)
11%
29%
14%
12%
11%
15%
8%
Height changes
Reaching
Sit – stand
Standing
Stepping
Substitution
Walking
Activity
FIGURE 12 Proportion of exercise activity logged per week by category. (a) Weeks 3–13; and (b) weeks 14–27.
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They seemed to feel quite confident with experimenting a little bit with their exercise without having
to refer back to the video, and with that came the fact that they weren’t logging in so much and
because they weren’t logging in so much they then weren’t logging how much exercise they were
doing. So even though they were telling me via e-mails that they were exercising, and when they
came back to the class they were exercising, actually I couldn’t witness that on the web-based logins.
T2
Participants were extremely positive about the opportunities for group exercise in the programme, with
some suggesting that more regular group exercise sessions would have been beneficial. Similarly,
participants valued the support from the programme therapist as a source of challenge and
encouragement to try exercises that they would otherwise have viewed as too difficult:
I certainly would have preferred more group exercise work, if it could have been a bit more, once a
week would have been great, once a fortnight maybe so that it would be possible to just share a little
bit also with the people, I know it is kind of easier to do it when someone’s you know giving you
ideas of what to do and keeping you at it.
P4
Yeah, yeah it pushes you into it more you know, I thought I’ll never be able to do it but having
somebody to sort of instruct you and say ‘right come on let’s do this and that’, it really, really pushes
you, you know, it sort of spurs you on sort of thing you know.
P6
TABLE 35 Summary statistics of the amount of time participants spent doing exercise
Exercise time per week Weeks attempted 12 weeks
Exercise time per week (minutes)
Mean (SD) 78.2 (70.8) 48.9 (44.7)
Median (IQR) 68.4 (21.3–119.3) 35.5 (8.4–96.3)
Minimum–maximum 0–357 0–126.6
Mean exercise per week (minutes), n (%)
≥ 120 6 (22.2) 3 (11.1)
100–119 4 (14.8) 3 (11.1)
80–99 N/A 2 (7.4)
60–79 4 (14.8) 1 (3.7)
40–59 3 (11.1) 3 (11.1)
< 40 10 (37) 15 (55.6)
Minimum exercise per week (minutes), n (%)
≥ 120 1 (3.7) N/A
100–119 N/A N/A
80–99 1 (3.7) N/A
60–79 1 (3.7) N/A
40–59 5 (18.5) N/A
< 40 19 (70.4) N/A
N/A, not applicable.
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Therapists also viewed the group exercise elements positively; however, one fidelity assessor queried
whether or not managing the group exercise with one therapist and a number of participants was difficult
in terms of managing risk while maintaining challenge.
Conversely, participants reported that they had successfully integrated their exercises into their daily life,
and recognised the value of being able to exercise at home:
Yes I think that being left alone in the home rather than having to go out and do the exercises is a
good thing but the group sessions make you to keep going.
P11
Discussion
Feedback from treating therapists and participants suggests that the validity of the exercise logs should
be viewed with caution. First, there were logistical challenges with recording exercises; for example, some
participants exercised in one room and then had to move to another room, where their computer was,
to record the exercises, or they had to remember to start and stop the exercise timer for each exercise.
Second, preferences about resources to support exercise engagement were variable, with some participants
preferring paper exercise sheets to the online system. According to participants and therapists, several
participants appeared not to be engaging with the programme at all, but were, in fact, exercising regularly.
This is a significant limitation to the feasibility of using this method of recording exercise engagement in
both a clinical and a trial situation, and one that is a priority to address before implementing a future trial.
It is likely that increasing the ease of use of the BRiMS online resources could go some way to addressing this,
but the findings of the qualitative elements of the process evaluation suggest that some people may still
prefer to use ‘offline’ resources.
Maintaining challenge in exercise practice
Therapists reported varied experiences with participants adapting their exercises as recommended, with
some participants using the resources once or twice and then feeling confident to ‘do their own thing’
and experiment, and others relying on the therapist to lead their exercise activities:
On the site, they reckon that once you get into a particular exercise then it becomes easier, they give
you hints as to how to work it harder because the whole point is making it harder so you get better.
P11
Mine tended to watch the videos once or twice but then they felt they had a handle on the exercise,
so they then as they understood their exercise and as they really understand the notion that they
needed to be challenging.
T2
In general it made me think about exercising little and often and every day if possible and I did
something which I don’t think is particularly in the programme, but I incorporated quite a few of the
exercises in daily life . . . I do it every day and every time I think of the BRiMS exercises and so I was
able to, you know, and standing by the kettle waiting for the kettle to boil, I am able to stand up on
my toes so I did find that very useful.
P10
BRiMS exercise programme reviews
Therapists were asked to review the participants’ progress with their online exercise programmes on six
occasions, making adjustments/progressions as appropriate. Table 36 details the number of reviews that
were reported by the therapists.
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The extent of feedback provided by participants on the website was variable, and this had an impact on
therapists’ ability to progress the exercises. Evaluation of the web-based exercise logs showed that only
2444 (35%) of the 7063 separate exercise entries recorded over the trial period included comments added
in the diary section. Of these, 1599 (23% of the total entries) had comments that could enable the
therapist reviewing the programme to assess the participant’s progress. The remaining 845 comments
were general in nature (e.g. ‘OK’). Unsurprisingly, the majority of the comments (98%, n = 2397) were
added during the intervention period, which was when programme therapists were reviewing the diary
entries.
In many instances, therapists had to rely on participant feedback by other means, including e-mail. The
scheduling and formatting of therapist reviews was also highlighted as a potential issue if participants
logged problems using the online diary in a week when no therapist review was scheduled:
Had I not had the e-mail correspondence alongside the comments in the diary I would have struggled
to progress their exercises, but because I had the e-mail where they seemed to be more willing to
chat about what they were doing, then that combination worked well and I felt that I was able to
progress them.
T2
It could have been just coincidence but there was the two weeks where you didn’t check their
programme, and one of those weeks unfortunately was one of the weeks when my ladies really
struggled and was really not well at all, so I didn’t pick that up until a week later, and I felt really
bad at that.
T4
Use of imagery techniques
Therapists reported varying experiences with using functional imagery training (FIT) to improve motivation
and maintain engagement, and there was a mix of feedback about participants’ experiences with using
the techniques. Some participants highlighted positive experiences, particularly those who were aware of
the approach or had previous experience of similar techniques:
One lady it was a very specific issue, it was getting in and out of the car to get around to the boot to
be able to lift the boot to be able to get a wheelchair out, and for her the imagery worked really
really well.
T4
TABLE 36 Number and percentages of each programme review completed by treating therapists
Programme review Completed (n) Randomised (%)
1 (week 3) 26 86.7
2 (week 5) 26 86.7
3 (week 7) 25 83.3
4 (week 9) 23 76.7
5 (week 11) 21 70.0
6 (week 13) 20 66.7
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Yes that was OK for me. That I think, because I have done the mindfulness course and I go to a
mindfulness group once a month so I’m kind of used to it but I think, I know at one of the group
meetings, the other participant it was new to her and she was embracing it and she was enjoying it.
I’m used to it, it wasn’t a new thing for me but it was a new thing for her and it made me think that
obviously it’s going to be a new concept for a lot of people and it’s not everybody’s thing either.
P13
Both therapists and participants described feeling more ‘comfortable’ with the other elements of the
programme (e.g. exercise training) and appeared to place more focus on these activities. Some participants
highlighted that the physical achievement of goals was a key motivator, rather than using imagery to
visualise any achievements beforehand:
In terms of them practising the imagery to enhance their adherence to exercise, that came less
naturally to them, but they seemed to manage that if I facilitated them quite a lot . . . but when I went
back to on home visit that’s not the one they chose to practice.
T2
OK, one of the things I wanted to do was to be able to get up more gracefully, which sounds very
pretentious but you know, more confidently, better all round and I do remember being in situations
where I was getting up and thinking that is better than it used to be. That positive association, but not
the sort of sitting down and visualising you are doing it and the benefit you are going to feel from
having done it. It was more seeing the benefit of it was happening, that I was doing something.
P8
The therapists consistently expressed concern that their lack of familiarity with the technique had an impact on
participant perception, and all the therapists said that more training and practice would have been valuable
prior to running the programme. Fidelity assessors identified examples of good practice in delivering the
imagery elements, including eliciting strong images to support goals (record 3) and encouraging participants
to continue with imagery by highlighting progress (record 93). However, it was suggested that greater
emphasis and reinforcement could have been used to support imagery practice in some instances (records 84,
103 and 104):
It was always something that I, perhaps didn’t fully to commit to because I perhaps underestimated its
worth or perhaps didn’t understand its worth . . . I partnered up with [T2] on the [training] day and I
really remember our conversation about it because I was thinking ‘this is new’ and ‘I’ve not done this
before’, so I think a little bit more practical time really to play around with the language in the words
and the concept.
T1
Despite the challenges, the therapists reported positive experiences of using the technique, particularly in
the early sessions, when participants were guided to apply imagery to their personal goals:
So I think I’ve owned up to the fact that I probably initially in that first session didn’t spend enough
time going through the nuts and bolts of practising the imagery, but what they did do was spend time
really getting the feel for imagining their goals, and for me that was a really nice opportunity to open
up a discussion about their expectations of what they might hope to be able to achieve really, how
they envisioned themselves at the end of the programme.
T2
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Some participants reported that, although they tried the imagery, they did not find it useful. One of the
participants with significant previous experience acknowledged that the approach may not suit everyone,
and that further support and time spent explaining and practising the technique could have been valuable:
So I wondered if it would be more useful to even have that separate because I felt it was just ‘straight
into it’ and I thought even if there was maybe a half hour class or just a wee introduction, ‘here’s
what it is and here’s what we hope you will get from it’, rather than just straight on in to it. It didn’t
put me off because I am used to it but I can see it putting off some people because it’s like ‘hang on a
minute, where did that come from?’, when there isn’t an introduction to it particularly useful . . . Just a
half hour or something attached onto you know a group or whatever.
P13
Discussion
The integration of functional imagery training into the BRiMS programme is a novel technique, and one
that was unfamiliar to therapists and most participants. The majority of participants in our qualitative
interviews and focus group agreed that the principle of imagery was consistent with the ethos of BRiMS,
and feedback from early one-to-one sessions was that the participants were able to engage with the
technique when guided to do so. However, it appears that more ongoing support and facilitation to use
the technique is needed, along with greater clarity on when and how to use it as part of BRiMS. The
fidelity assessors suggested that therapists were trying to support participants’ motivation by using the
goal-setting and imagery exercises specified in the manual, but that they sometimes struggled to do this
effectively, leading to lower fidelity scores on relevant ratings.
Not surprisingly, exercise prescription was the main focus of sessions, and motivating patients to undertake
the exercises sometimes seemed an optional extra, for participants as well as for therapists. This is
unfortunate, because participants needed to be motivated to do their exercises, to challenge themselves
appropriately, and to continue exercising after BRiMS ended. Effective motivational support could make a
substantial difference to the efficacy of the programme; this is a particular priority given the finding that
engagement in the BRiMS exercise programme appears to be significantly lower than that likely to be
required to maximise improvements in mobility and balance.
Therefore, increasing the time to support therapists in becoming familiar with FIT and being able to use
it confidently will be a priority when revising the BRiMS training session. Time is needed to develop
therapists’ understanding of the difference that effective motivational support can make, for example
by including some role play so that they can experience the techniques themselves, and helping them
look more proactively for opportunities to use imagery and other motivational techniques during BRiMS
sessions. Trainers need to recognise the considerable difference between the role of the therapist in
BRiMS as a collaborator who works in partnership with patients to elicit and strengthen their motivation,
and the more traditional view of the therapist as an expert providing advice and treatment.
It may also be helpful to include a specific session on motivation for participants, perhaps as a group
session or as a web-based FIT session where they would independently work through some imagery-based
motivational exercises. Either solution could help reduce pressure on therapists during the busy first home
visit, and provide higher-quality motivational support, allowing them to get greater benefit from the other
FIT exercises scheduled later in BRiMS.
Session-specific feedback
One-to-one sessions
Initial assessment
Fidelity scoring suggested that the main elements of this session were delivered appropriately, although
there was scope for greater depth in places (Table 37). Assessors highlighted opportunities for a more
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collaborative approach to be adopted, particularly in the identification of an immediate goal (records 27
and 47) and in the choice of an exercise to practice at home (records 26 and 46).
Therapists reported that both they and their participants found the initial assessment session
‘overwhelming’ as a result of both the amount of content and the number of elements that were
introduced. Therapists reported that explaining the session carefully, and breaking down the elements of
BRiMS during the session, enabled them to support their participants to get to grips with what was
expected. There were few specific comments about the one-to-one sessions from participants, possibly
because of the time between the sessions taking place and the participants being interviewed. However,
the general impression was that the sessions worked well and were valuable. There was no specific
feedback about the amount of content in these sessions:
The initial assessment, it’s hard to remember that long ago. It was OK, there was nothing too
untoward, too strenuous . . .
P9
T1: I think people reach their capacity of what they were open to take on board relatively early in the
session because we were doing lots of interviewing and starting homework early and then logins and
things and I think some of mine sort of looked a bit frazzled by the end as well as me actually!
T3: Yes, I’d agree with that, I think they got a bit saturated halfway through.
T1 and T3
I think once you spoke to them, encouraged them and broke it down then they were, quite a few of
them were, then there were a few lightbulb moments and they were like ‘OK, yes, no I understand this’.
T4
Home visit
Although the average fidelity scores in this section suggest that most areas were covered appropriately,
there was a greater range of scores than for the initial assessment (Table 38). Assessor comments indicate
that the main area for further consideration is how the exercise plan is presented to the participant,
including whether the exercise plan should be physically worked through in the session, or merely
discussed with the participant (records 137 and 147). It was highlighted that, on occasion, therapists
verbally suggested that they would progress the exercises, rather than handing control to participants
(records 108 and 127). The comments also highlighted that participants were experiencing challenges with
logging in and using the web-based resources, with varying degrees of success/engagement with the week 1
home package (records 99, 109, 129, 137 and 146).
TABLE 37 Fidelity scoring for session 1
Session-specific items: initial assessment (n= 8)
Median score
(IQR)
Provide an introduction to BRiMS, including the aims and structure of the programme 3 (2–3)
Evaluate balance and mobility to inform exercise prescription 2.5 (2–3)
Introduce the participant to initial exercise and imagery practice 2.5 (1–3)
Help the participant identify something they would like to accomplish that could be achieved soon, or to
practise imagining achieving a goal as vividly as possible
2 (1–2.25)
Issue the BRiMS workbook, signposting the participant to the log-in instructions and home package 1 3 (0)
Confirm arrangements for subsequent appointments 3 (2–3)
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The home visit was very well received by therapists, who valued the opportunity to work with participants
in their own homes. Therapists highlighted that being in the participant’s home appeared to encourage
the participant to talk ‘honestly’ about their engagement with the programme and presented them with
the opportunity to discuss specific issues and challenges in context. As with the initial assessment, there
was limited specific discussion of the home visit during participant interviews; however, the value of the
session for problem-solving and introducing the exercises was recognised:
In terms of a high, I think I’d really like, for me to put an emphasis on home visit, I thought as [T3] said
that it was really crucial to me to be able to see the setting up of the home exercises in the home
environment and things like where the computer was sited versus where they were actually going to
exercise and whether they can actually get to the computer in time, for example, to start and stop
the clock.
T2
Although the home visit was highlighted as taking longer than the time allocated, the activity was
perceived as vital to help therapists make a judgement about what was considered ‘safe and reasonable’,
which included re-evaluating the exercise plans in some situations. Given that one of the aims of BRiMS is
to support participants to undertake challenging balance exercise, this aspect is likely to be particularly
important to ensure that the balance between challenge and risk is optimised:
T2: It did mean that the session took longer than was allocated.
T3: I would agree with that because you have to move to different parts of the house – one guy had
to move from the garage to his front room to find the right place to do the exercises, so it was quite
time-consuming, but very worthwhile.
T4: Yes I agree, I think it was beneficial as well . . . I think some of them found it was quite tiring to do
all 12 [exercises] together, so we played that on an individual basis.
Discussion
The one-to-one sessions were viewed positively by therapists and participants and felt to be pivotal to
enabling therapists to tailor the elements of BRiMS to each participant. Our evaluation suggests that we
need to review the balance and timing of topics to aid clarity and reduce time pressures, particularly in the
assessment session and the home visit. Key questions include whether all of the elements of BRiMS should
be introduced at once or if they should be staged, and whether the feeling of sessions being ‘rushed’
relates to too much content or to therapists’ lack of familiarity with the materials. We also need to develop
TABLE 38 Fidelity scoring for home visits (n= 7)
Session-specific item
Median score
(IQR)
Deliver the exercise activity plan and ensure participant can carry out exercises safely and effectively 3 (1.5–3)
Review and refine personal goals, and encourage participant to achieve these 2 (1.5–3)
Explain personalised exercise prescription, including setting up online resource, and demonstrating/
supervising exercises to ensure that participant is able to carry out plan safely and effectively (adjusting
programme if necessary)
2 (1.5–3)
Instruct participant re principles of exercise prescription, including structure of exercise practice (based on
home package 1), balancing challenge and risk, and progressing the programme
2 (1–2.5)
Review and problem-solve BAASE analysis and action plan (based on home package 1 scenario) 2 (1.5–2)
Confirm arrangements for subsequent appointments 2.5 (2–3)
BAASE, Behaviours and Attitudes, Activities, MS Symptoms, Environment.
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consensus on best practice in the prescription and explanation of the exercise programme during the
home visit. Should exercises be run through during the session, or is an explanation/discussion adequate?
Group sessions
As fewer group sessions were held, the fidelity scoring and assessor feedback relating to all the group
sessions are combined (Table 39).
Fidelity assessors highlighted that, although good discussion developed, there was a lack of resolution in
several instances. For example, participants actively contributed to falls risk identification, but there was
limited action-planning to avoid future issues (records 159 and 167).
In contrast to the one-to-one sessions, participants contributed a lot of feedback about the group sessions;
most viewed these as a positive experience. The therapists also felt that the groups were positive, with
participants describing a ‘buzz’ in the first session in particular. The group participants were described as
bonding quickly, and group interaction and problem-solving were seen to be valuable and motivating.
TABLE 39 Fidelity scoring for sessions 3–5 (group sessions)
Session-specific item
Median score
(IQR)
Group 1 (one session assessed for fidelity scoring, four participants)
Introduce BRiMS group members to each other and begin to foster peer interaction 3 (0)
Review of exercise programme progress and problem-solving. Group practice of core exercises 3 (0)
Group activity: analysis of fall case trial and development of action plan using BAASE framework 3 (0)
Group activity: review of imagery and practise of imagery as a motivational tool 3 (0)
Summary and round-up 2 (0)
Confirm arrangements for subsequent sessions 1 (0)
Group 2 (two sessions assessed for fidelity scoring, five participants)
Welcome and review of progress with exercise activity plans. Explanation of exercise activity
substitution
2.5 (2.25–2.75)
BAASE – environmental factors – group work 2 (1.5–2.5)
Group photograph assessment activity 2.5 (2.25–2.75)
Practical falls management and action planning, including getting on and off the floor (practical) 2 (1.5–2.5)
Review goals: what have you achieved so far? Make new goals 1.5 (1.25–1.75)
Confirm arrangements for subsequent sessions 2.5 (2.25–2.75)
Group 3 (two sessions assessed for fidelity scoring, seven participants)
Welcome and review of BAASE environmental factors, activities and progress 3 (0)
Physical ability: review of progress and plan looking forward 2.5 (2.25–2.75)
BAASE: review of progress and plan looking forward 2 (1.5–2.5)
Goals: review of progress and plan looking forward 2.5 (2.25–2.75)
Round-up and summary, presentation of certificates 2 (1.5–2.5)
BAASE, Behaviours and Attitudes, Activities, MS Symptoms, Environment.
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Group discussions were highlighted as an opportunity for ideas to be generated by participants rather than
being therapy led, although there was recognition of the importance of therapist facilitation at times:
An independent high is the mutual support and really very powerful facilitation skills in fact that some
of the group members had in terms of really supporting each other and problem-solving for each
other as well.
T2
He has trouble going to the shops like I do and it was meeting him made me feel, I didn’t feel quite so
alone. I think you do because you are different all the time to other people who suffer from this. But
to meet somebody who has symptoms that is like your own, you know, he suffers with too many
people around him because as you said to me once, that is because your body is trying to work on
keeping you upright and it can’t cope with all the other things around it.
P11
When it came to falls analysis I think initially a bit of apprehension about ‘right, who’s going first
here?’ and ‘how we going to play this’? I think that then, once it got going it really generated a lot of
good discussion, and some of the other people rather than myself were kind of coming in with the
ideas of going ‘no you can’t do that’. And they had really good tips or ‘why have you not thought
about this?’ or ‘what about that?’ and that generated a lot of good discussion and I think they were
really positive sessions.
T4
Taking part in the groups also encouraged participants to try activities that they would have been reluctant
to do in other situations:
Yes definitely, definitely yeah. Definitely more confidence, I didn’t think I would have been able to do
it you know. When I’ve come away I’ve thought ‘gosh I didn’t think I’d be able to do that’.
P6
A number of session activities invited participants to contribute their own resources, which some did, while
other sessions required the use of stock resources. Regardless, discussions were described as positive and
involving all participants:
The two ladies in the group had prepared very well with their manuals, so they came with all their
things, and that stimulated the rest of the group into the discussion and they were all very good at
including everyone else, so I think I was lucky with a mix of the group there.
T3
It was really good coming together. I had a very nice first group of people. We were quite a small
group . . . but then maybe there are some people that don’t want to or wouldn’t feel as comfortable
in a larger crowd of people. So that could be an aspect that they are thinking of. But it was good
because you could come together and share your stories. I would say that the group sessions were
very good and I met some really nice people.
P8
As intimated by participant 8, not everyone felt comfortable in a group setting, and some found
contributing in a larger group challenging. Therapist support, and building familiarity with other
participants, was helpful and encouraged participation. There was also recognition among participants
and therapists that a group format may not suit everyone. Although for some non-attendance at the
group sessions was indicative of general non-engagement in the programme, examples were
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highlighted of participants who had engaged actively with the programme independently, suggesting that
non-attendance at the group sessions was not always an indication of non-adherence:
When it was just the other two woman that was fine, but the first time with the two women and the
bloke, [T3] had to ask me directly, because I was about to talk but one of the other ones would pipe
up and come in, so [T3] had to ask me what I was going to say. With that many people and if I have
not known them before, I am not really that forthright myself or talkative, so if someone wants to
know something they ask me directly, I don’t chip in.
P9
What really surprised me was how hard the previous [group] non-attender had worked at home
because she really thought she was going to be the one that was furthest behind and really she was
furthest ahead because she had committed so much to the online diary, compliance with the exercises
and the booklet.
T1
Discussion
The positive experiences of participants who attended the group sessions is encouraging, particularly the
utilisation of peer learning to support planning for future falls prevention. However, what needs to be
considered is whether or not, and how, these discussions and plans translated into action outside the
sessions. The aim of BRiMS was for the home packages and the techniques such as FIT to support the
translation of plans into action; however, given the relatively low engagement of participants with these
elements, it is likely that this support was suboptimal. This could be improved by changing the way in
which sessions and support are delivered. Perhaps changing the programme so that a group session takes
place early in the programme, and is followed by a therapist home visit, could facilitate the translation of
participants’ plans into action. Additionally, given the paucity of feedback that participants provided in
their exercise logs, perhaps ‘real-time’ interactive therapist reviews could provide more effective support for
both the exercise and the behaviour change elements of BRiMS. For example, Learmonth et al.165 have
utilised telephone coaching to support action-planning in physical activity programmes.
Mechanisms of impact
The focus here was on exploring participants’ and treating therapists’ perceptions about the effects of
engaging with the programme, and the programme-specific factors influencing engagement.
Participants and therapists reported that taking part in the programme had led to improvements in balance
and mobility and a reduction in falls:
I’m just really pleased that I was on the programme. The exercises have all helped . . . Unbelievably
because you know turning my head and not getting dizzy and going over, that, I mean it just amazed
me that such a simple thing and doing it regularly worked . . . I was very surprised in a really good way
over that.
P4
So I definitely think it has helped and the exercises that you do are tailored for you anyway, so I
thought it was becoming apparent, it was visual to me when I was filling in the diaries. That I was, I
was improving, my balance was improving and even a little improvement can have a huge impact you
know because you are a little bit more confident and even just the exercises that I was doing and just
slowing down and not [rushing] into the shower not that I [rush] that often, just taking your time and
doing the step ups and all that kind of thing. So yeah it was useful for me.
P13
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Participants and therapists reported a variety of other effects that they attributed to engagement with the
programme, including an increased awareness of falls risk and the introduction of falls prevention
strategies:
I would say that some of the falls that I had in retrospect were stupid. Right, so it was not thinking
about what I was doing, so the whole study helped me to have focus and think before being stupid
like leaning against the wall to put my shoes on. So now I sit down to put my shoes on . . . You look
down and you think ‘oh there’s a pair of shoes in the middle of the hall’, because that’s where they
got kicked off when we came in from so and so. It makes you more aware. So that’s another positive
aspect of it. It makes you more responsible about what’s going on around you. I can’t just rely on
[my husband] all the time. I have to look after myself as well.
P8
And I have learnt so much from it, about, towards deciding I’d do my housework on a one-day, one
room basis. I’ve split it up. I’ve learnt a lot of things that I wouldn’t have done – you know when I was
at work I had to do it at weekends because now I have split it up I only do what I can do.
P11
Therapists also reported positive effects associated with FIT for those participants who used it, although they
were unsure about whether or not the use of FIT influenced the extent to which those participants engaged:
Mine, the ones that engaged in the programme generally, they fed back that [FIT] did, it was a
positive part of it, and we kept visiting it, each time I saw them we would revisit that as well . . .
T2
The ones that found the visual imagery helpful, the ones that were able to use it, I’m not sure whether
they would have not stuck to the programme anyway, I’m not sure how much of a help it was to
them in sticking to the program but they certainly included it as part of the programme.
T3
However, not all participants found the programme helpful, and one participant highlighted that they
found it difficult to apply some of the learning, particularly from the group sessions, as they found it hard
to remember tips when they were back in the ‘real world’:
Interviewer: Having taken part and done the sort of the exercises and gone to the groups and so on,
do you think it’s made any or you have made any changes as a result of doing that? Has it made any
impact for you?
P7: No it hasn’t.
Discussion
Qualitative feedback supports the mechanisms of impact we expected in the programme design; participants
reported changes in both the physical and the behavioural aspects of falls prevention. Although the diary
data has significant limitations, and it is inappropriate to draw inferences from data in a feasibility trial, it is
certainly encouraging that the BRiMS participants appeared to experience fewer injurious falls. However,
the process evaluation has highlighted that engagement was lower than we would have hoped, and most
participants did not sustain their engagement throughout the intervention period and beyond. Given the
likely need for the long-term adoption of safe mobility strategies, it is a priority for the suggested changes
to the programme to be implemented before undertaking further evaluation work.
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Context
This section describes the feedback given about the impact that contextual factors were perceived to have
on engagement and the outcomes of the programme.
Personal circumstances
As expected, comorbidities, such as health issues that occurred alongside MS, and personal circumstances,
including childcare and family commitments, had an impact on people’s ability to engage with the
programme. However, the ‘portability’ of the programme was seen as useful. By contrast, some
participants highlighted MS-related difficulties, such as problems with writing because of impaired upper
limb dexterity, that made the paper-based elements of the programme impractical:
For me as well, at the time of year, it was holiday time. There was a couple of weeks, we were on
holiday, it was just down in the Lake District, but I managed to do some exercises because we were
renting a house and that was fine, so it was perfectly portable.
P13
No, no it’s me because it coincided with a really difficult time in my life anyway. I had a really rough
time with somebody. So it’s kind of, that’s the other side of course, everyone’s just really getting on
with their lives. We have other dramas. I think that’s probably what didn’t help as well.
P5
But the whole thing for me that put me off initially was the amount of paperwork that I was asked to
complete . . . the amount of work I just couldn’t do it – I can barely lift a pencil. It was very difficult
and there was an awful lot of it.
P12
Participant preference
The therapist focus groups noted variability in the patterns of engagement among participants. Although
this was influenced by personal circumstances and IT-related issues, it was notable that there were few
participants who engaged with all aspects of the programme. One therapist highlighted her perception
that personal preference was a factor influencing patterns of engagement. Personal preference was also
seen as influencing participants’ perceptions; for example, one participant suggested that they would have
preferred a purely online format:
I only had one person out of my group of five that did the online and the manual and attended the
groups. I found that the other candidates, they generally picked their most favourite way of interacting
and communicating and then stuck with it. So I had a lady that only came to the groups and didn’t do
anything online and didn’t do anything with the manual . . . the other one who didn’t come to the
group, she worked really hard with the manual because she was fearful that she was missing out in
the group aspect. So to get compliance across the board using the different modes of communication
and interaction was quite a bonus for me!
T1
See I would really like that because I am a computer-based person. Yes, that would be good. But you
wouldn’t have the advantage of taking it with you when you go to the group sessions unless you
could print it off. Maybe that could be an option.
P8
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Encouragement and support
The therapists highlighted the value of group interaction to encourage and support participants’
engagement. This applied to both exercise and educational activities:
One thing they absolutely loved was the exercises within the group session, so the exercises in the
session was a real motivator for them and they all really liked seeing what each other was up to, and
they got lots of good ideas about what each other was doing, so as a component within the group
I thought the exercises and the way it was set up worked really well for the group.
T2
However, although therapists described many positive experiences from the group sessions, they also
highlighted that the composition of the group could have an impact on participant experience:
In my group we had quite a frail lady who dropped out after the first group session because she broke
her hip, but quite a few of the group participants came to me afterwards and said they wouldn’t
come back to the group if she was there, because they were quite fearful of seeing future versions of
what might possibly happen . . .
T1
I would really support that because I similarly had a chap who was really very, wheelchair dependent,
pretty well, but in addition to that very very slow processing and had memory issues as well. I was
lucky in that the group were an incredibly empathic group of people and he was a lovely chap, so
actually that didn’t impact on my group’s experience.
T2
Alongside loss of input for the non-attenders, small group numbers were highlighted as a potential factor
affecting the experience of those who did attend. Although the majority of participants seemed to still get
the best from the sessions, the loss of opportunities for group interaction and shared learning when
numbers dropped was recognised as a limitation by therapists and participants:
. . . that might be by design but in some cases because of circumstances there were only two of us at the
meeting. So I wonder if there would have been more dialog if there had been a larger group of people.
P8
I had two guys that wouldn’t actually make it to any of the groups, and I think it does have a negative
affect then on some of the others, particularly some of the more really motivated, and I had one
group where there was only one lady turned up, so yeah you do miss a bit from the learning,
although she was really motivated and she got a lot from the programme, I just wonder how much
more she would have got from it.
T4
Technology
An important factor affecting engagement with the programme was the impact of technology-related
issues. Participants reported a number of problems with access to, setting up and using the web-based
elements of the programme, although these did reduce over time and with practice. For some participants,
however, this initial negative experience influenced their perceptions of, and engagement with, the whole
programme:
Well we couldn’t log onto it for one thing and by the time [my husband] spoke to somebody we did
get on and it went down again. So that was really stressful.
P7
Two main challenges were highlighted by therapists: participants’ skills, expertise and enthusiasm for using
technology, and issues relating to the BRiMS resources themselves.
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Participant skills and expertise
An unexpected issue encountered by the majority of therapists was the amount of support that participants
needed with basic IT tasks. Although there were issues with the programme infrastructure, the challenges
encountered extended to basic skills such as using a mouse and accessing the internet. In one instance,
the therapist needed to make an extra home visit just to address basic IT access issues. One of the trial
inclusion criteria was ‘access to a tablet/computer and the internet’, and the need to use a computer was
discussed with prospective participants. However, this issue will need careful consideration if progression
to a full trial is indicated:
I had one lady drop out immediately after the home visit because she was, she really couldn’t even,
she could switch on the computer but as far as actually moving the mouse and navigating she had
absolutely no idea about how to do that and she chose to drop out.
T2
We had a couple of issues in that the audio would only work on new internet browsers, so there was
one lady that didn’t like the internet and had an old browser and it wouldn’t work on it, and I think
that sealed the deal really . . .
T1
BRiMS resource issues
Alongside issues of computer literacy, significant issues were identified with the infrastructure of the IT
elements of BRiMS. The most notable problem was the need to access two separate websites (the main
BRiMS site and the online exercise resource) with separate log-ins, which presented challenges for access
as well as contributing to the lack of cohesion within the programme that was highlighted by participants
and therapists. In addition to this, the logistics of using the online exercise resource were problematic for
some participants, particularly those who relied on a desktop PC for their access. Therapists flagged that
using a mobile device (e.g. a tablet) was much more successful, although some participants continued to
prefer a paper resource:
T2: Mine struggled very much with the fact that it wasn’t an integrated package, that there was a
web pams [exercise] website and a BRiMS website so I think that would need to be integrated.
T4: Most of my people had tablets and were then using the programs on tablets and were just taking
it everywhere they needed to go and they were exercising with them as well . . .
T3: Most of mine didn’t have tablets and getting back to press the start/stop button was a bit of
a mission.
Facilitator 1: . . . they probably exercised as much doing the start and stop as they did . . .?
T3: [laughs] Yes I think they did!
Discussion
The findings of our process evaluation support the contextual factors we proposed in the BRiMS logic
model. However, additional factors warrant consideration. First, it appears that the way in which participants
engaged with BRiMS was highly personal. In terms of programme design, allowing flexibility to suit individual
needs and preferences is likely to be positive. However, in terms of gathering evidence as part of a clinical
trial, this presents a number of challenges. Second, our analyses highlight the importance of ensuring
that participants have a positive experience from the outset. For a number of participants, initial negative
experiences, from technical glitches to not achieving the perceived ‘minimum’ 120 minutes of exercise in
the first week, appear to have influenced their perceptions of the whole programme. In the words of
participant 5, ‘I never got back’. This narrow window of opportunity means that ensuring that participants’
initial sessions and interaction with the BRiMS materials are as trouble-free as possible is essential.
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Along with revising the timing and quantity of content in each session, addressing the technical issues
associated with our online materials (in particular the need to use two websites) is critical. Finally, although
there was comprehensive PPI during the development of BRiMS, we need to ensure that this continues
during any revisions, using as wide a variety of participants as possible to capture a range of views.
Health economics outcomes
Intervention costs (objective xiii)
Methods used in the feasibility trial have proven acceptable and appropriate for collection of resource-use
data on delivery of the BRiMS intervention.
Table 40 reports the estimated staff time input for the BRiMS intervention by contact type and type of
time input. Our original estimate of therapist time required was 7 hours and 15 minutes per participant
(see Appendix 6). However, based on therapist contact data, we estimated an actual mean time input for
each participant of 7 hours and 40 minutes. Using a unit cost of £52 per hour for staff time (scientific/
professional Agenda for Change band 7; salary per annum £38,786),125 we estimated a mean cost of
staff time of £400. When using a unit cost of £42 per hour for staff time (scientific/professional Agenda
for Change band 6; salary per annum £31,351),125 the estimated mean cost for staff time is £323.
The unit cost (£ per hour/time) applied here (see above)125 includes an estimate/allowance to cover
work-related travel costs (time input), so this is not included as a specific item in cost estimates. Trial data
indicate a mean travel time per participant home visit/contact of between 50 and 80 minutes.
Estimates are informed by per-participant contact data for 27 participants receiving the BRiMS programme,
and data reported for the time input to running of six BRiMS groups (each with three sessions). While
there was variation in estimated participant contact data by centre/site, there were no strong observations/
patterns across centre/site (see Appendix 7).
Data reported on the time input for group sessions were highly consistent, at 2 hours per session
(contact time), plus a requirement for administration time per session. Administration time varied by
session, with 16 out of the 18 sessions reporting between 30 minutes and 60 minutes (two sessions
reported administration times of 75 minutes and 150 minutes). Groups consisted of relatively small
numbers, with data reports showing between three and five participants for the first group session,
dropping to between one and four for the final/third group session.
TABLE 40 Resource use per participant for delivery of the BRiMS intervention
Contacts
Contact time,
mean (SD)
Administration
time, mean (SD)
Total time per
contact, mean (SD)
Contact
number
Total time,
mean (SD)
Clinic visit (minutes) 93 (13) 50 (18) 143 (20) 1 143
Home visit (minutes) 100 (18) 36 (19) 136 (20) 1 136
Online contacts (minutes) 15 (7) N/A 15 (7) 5.26 79
Group contactsa (minutes per person) 24 10 34 3 102
Total staff time input (minutes) 460
a Based on groups of five participants and three sessions of 2 hours, plus administration time of 52 minutes for
each session.
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Face-to-face and group sessions are expected to take place on NHS property (as was the case in this
feasibility trial) and are not expected to incur additional costs over and above the overhead allowances
included in the unit cost for staff time input.
Based on input/advice from the trial co-ordinator, the only additional expenses that would be incurred
would be the cost of printing manual copies of the BRiMS manual for participants, and the set-up cost
associated with training therapists to deliver the BRiMS intervention (although not considered in detail
here, we estimate this to be approximately £300 per trained person/therapist, to be distributed over an
expected caseload of participants/patients in years 1–2).
Effectiveness of the proposed health economics evaluation methods (objective xiv)
Resource-use questionnaire feasibility and item completion rates
The questionnaire used to collect resource use proved acceptable, with good rates of completion
(see Appendix 8). The questions themselves did not cause problems for the participants, and the ‘other’
open-text fields did not highlight any significant omissions from the resource-use questionnaire (i.e. no items
appearing with notable frequency). Missing data are generally associated with participant withdrawal
(loss to follow-up), as reported earlier in the main results.
Resource use and associated costs at baseline (objective xiii)
Appendix 9 summarises the resource use collected at baseline assessment (previous 6 months) and
estimated costs by treatment group. The resource use and estimated total costs at baseline assessment
were similar for both groups.
Resource use over the trial period (27-week follow-up)
Table 41 reports resource use over the 27-week follow-up period of the feasibility trial, for health and
social care, medications, and wider resource use associated with informal care/carers. Table 42 reports
the costs estimated for each of these areas associated with the resource use reported by participants.
Participants mainly reported relatively modest levels of resource use, mostly focused around items of
primary and secondary care (visits to general practitioner, MS nurse, occupational therapy, physiotherapy),
and what appears to be an annual outpatient visit to a neurologist (approximately 0.5 visits over 6 months).
Very little medication use was reported by participants, which is likely to be consistent with expectations
based on the participants having progressive MS, and aligned with our inclusion/exclusion criteria. We do
see consistent reporting of informal care provision across a range of activities/needs, with a similar reported
mean hours per week of informal care across groups, at approximately 24–25 hours per week. When
applying a unit cost to hours of informal care (a shadow cost, reflecting a scenario in which the state pays
for this care), we estimate a weekly cost of approximately £445 per participant, this being a relatively huge
cost component, currently provided via unpaid informal care inputs.
Table 42 provides a summary of the estimated costs for health and social care resource use, and the
estimated costs associated with the items reported for informal care/carers over the feasibility trial follow-up.
On health and social care we see estimated costs (27 weeks) of £640 and £1922 for those allocated to
the usual-care group and the intervention group, respectively. This large difference in mean costs is almost
entirely because in the usual-care group there are no (zero) reports of hospital stays (nights in hospital)
versus a total of 53 days (mean of 2.51 nights) in hospital in the intervention group (three participants
reported nights in hospital, with one of these reporting a stay of 44 nights/days). Furthermore, in the
intervention group one participant reported a stay of 44 days in a rehabilitation unit, the same participant
who reported 44 days/nights in hospital. All of these inpatient stays are unrelated to the BRiMS intervention.
In addition, in terms of balance, or lack of balance in these small groups – and/or potential outliers – on
reports for home-care visits (unit cost at £6.70 each), one participant in the usual-care group reported
210 home-care visits over the 27-week follow-up period.
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TABLE 41 Health and social care resource use per participant over the 27 weeks of the trial
Resource use
Group
Usual care Intervention
Mean (SD) Minimum Maximum n Mean (SD) Minimum Maximum n
Health and social care resource use
Primary care appointments/visits
Continence advisor: home 0.00 (0.00) 0 0 22 0.00 (0.00) 0 0 22
Community psychiatric nurse: home 0.00 (0.00) 0 0 22 0.00 (0.00) 0 0 22
Chiropodist: home 0.18 (0.66) 0 3 22 0.05 (0.21) 0 1 22
Chiropodist: surgery 0.09 (0.29) 0 1 22 0.23 (0.61) 0 2 22
Counsellor 0.00 (0.00) 0 0 22 0.18 (0.85) 0 4 22
GP: home 0.09 (0.43) 0 2 22 0.36 (0.73) 0 2 22
GP: surgery 2.41 (2.81) 0 12 22 1.77 (2.65) 0 11 22
GP: telephone 0.55 (0.86) 0 3 22 1.36 (1.94) 0 7 22
MS nurse: home 0.09 (0.43) 0 2 22 0.05 (0.21) 0 1 22
MS nurse: telephone 0.36 (0.90) 0 3 22 0.23 (0.53) 0 2 22
Occupational therapist: home 0.86 (1.78) 0 8 22 0.27 (0.70) 0 3 22
Community nurse: home 0.05 (0.21) 0 1 22 0.23 (1.07) 0 5 22
Practice nurse: surgery 1.09 (1.44) 0 5 22 1.09 (1.93) 0 8 22
Physiotherapist: home 0.50 (1.41) 0 6 22 0.59 (1.30) 0 5 22
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Resource use
Group
Usual care Intervention
Mean (SD) Minimum Maximum n Mean (SD) Minimum Maximum n
Secondary care outpatient appointments
Continence advisor 0.14 (0.35) 0 1 22 0.32 (0.84) 0 3 22
Chiropodist 0.14 (0.47) 0 2 22 0.09 (0.29) 0 1 22
MS nurse 0.59 (0.85) 0 3 22 0.32 (0.48) 0 1 22
Neurologist 0.50 (0.67) 0 2 22 0.41 (0.80) 0 3 22
Occupational therapist 0.05 (0.21) 0 1 22 0.14 (0.47) 0 2 22
Ophthalmologist 0.14 (0.35) 0 1 22 0.14 (0.35) 0 1 22
Orthotist 0.23 (0.61) 0 2 22 0.23 (0.69) 0 3 22
Pain clinic 0.14 (0.47) 0 2 22 0.41 (1.92) 0 9 22
Physiotherapist 2.45 (2.72) 0 8 22 1.09 (3.71) 0 17 22
Psychiatrist 0.00 (0.00) 0 0 22 0.00 (0.00) 0 0 22
Psychologist 0.05 (0.21) 0 1 22 0.09 (0.29) 0 1 22
Speech therapist 0.00 (0.00) 0 0 22 0.00 (0.00) 0 0 22
Secondary care attendances/admissions
Nights in hospital 0.00 (0.00) 0 0 22 2.41 (9.49) 0 44 22
A&E visits 0.23 (0.61) 0 2 22 0.09 (0.29) 0 1 22
Day admissions 0.00 (0.00) 0 0 22 0.14 (0.64) 0 3 22
Social and community care visits
Social worker: home visit 0.00 (0.00) 0 0 22 0.05 (0.21) 0 1 22
Home-care visit 9.55 (44.77) 0 210 22 0.14 (0.64) 0 3 22
Day-care centre days 0.00 (0.00) 0 0 22 0.00 (0.00) 0 0 22
Rehabilitation unit days 0.14 (0.47) 0 2 22 2.82 (9.88) 0 44 22
Respite care days 0.00 (0.00) 0 0 22 0.00 (0.00) 0 0 22
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TABLE 41 Health and social care resource use per participant over the 27 weeks of the trial (continued )
Resource use
Group
Usual care Intervention
Mean (SD) Minimum Maximum n Mean (SD) Minimum Maximum n
Medication usage
Disease-modifying medications 1.55 (5.58) 0 25 22 0.27 (1.28) 0 6 22
Botulinum toxin injections 0.05 (0.21) 0 1 22 0.00 (0.00) 0 0 22
Intrathecal baclofen 0.00 (0.00) 0 0 22 0.00 (0.00) 0 0 22
Phenol injections 0.00 (0.00) 0 0 22 0.00 (0.00) 0 0 22
Intravenous steroids 0.00 (0.00) 0 0 22 0.00 (0.00) 0 0 22
Steroid tablets 0.05 (0.21) 0 1 22 0.00 (0.00) 0 0 22
Informal care use
DIY 1.76 (2.06) 0 9 22 3.31 (4.42) 0 14 22
Gardening 1.40 (2.23) 0 7 22 0.89 (1.46) 0 5 22
Housework 6.18 (10.66) 0 44 22 5.48 (7.35) 0 28 22
Preparing meals 5.73 (6.77) 0 23 22 6.24 (8.08) 0 31 22
Personal care 1.12 (2.64) 0 9 22 0.77 (1.51) 0 6 22
Looking after pets 2.07 (4.79) 0 20 22 1.78 (2.88) 0 9 22
Shopping 2.33 (2.25) 0 7 22 2.30 (2.03) 0 6 22
Transport 4.09 (4.97) 0 13 22 3.98 (4.64) 0 17 22
Total informal care 24.67 (24.51) 0 87 22 24.74 (21.53) 0 80 22
Days off work over previous 6 months
Friend/relative’s days off work 0.59 (2.77) 0 13 22 0.00 (0.00) 0 0 22
A&E, accident and emergency; GP, general practitioner.
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Table 42 reports the time taken off work by friends or relatives to support the participant (as reported
by the participant), and here it can be seen that there are no (zero) reports in the intervention group
participants, and a mean of 0.59 days in the usual-care group participants (over 27-week follow-up). Of
note, in this latter report it can be seen that one participant reports 13 days off work for a friend/relative,
thereby skewing the data towards increased use in the usual-care group, when most participants reported
no requirements in this area of data collection.
Discussion
These data highlight the relatively modest ‘formal’ resource use by our participants and emphasise the
importance of ‘informal’ support. In addition, the data support our previous description of the likely format
of ‘usual care’ for our participants as focused around primary care and involving relatively infrequent
contact with rehabilitation providers.
Health state values (EuroQol-5 Dimensions, five-level version, and MSIS-8D) and
quality-adjusted life-years
Table 43 summarises the estimated mean health state values and QALY estimates derived from participant
reports for the EQ-5D-5L health states. We report data for the baseline assessment and the 15-week and
27-week assessments.
As with the other measures (see Data completion and accuracy), the completeness of the data to inform
calculation of health state values was high within the proportion followed up and as a percentage of those
randomised.
TABLE 42 Summary of health and social care/informal care costs (£) per week (27-week follow-up) and cost of days
off work over 27 weeks
Cost
Group
Usual care Intervention
Mean (SD) (£) n Mean (SD) (£) n
Summary: health and social care costs over 27 weeks
Total primary care 213 (224) 22 190 (162) 22
Total secondary care 349 (249) 22 1451 (4335) 22
Total social and community care 79 (309) 22 282 (986) 22
Total health and social care 640 (580) 22 1922 (5340) 22
Total medications 261 (921) 22 45 (209) 22
Total all health care 902 (1105) 22 1967 (5341) 22
Summary: informal care cost for days off work over 27 weeks
Total reported informal care (hours/week) 24.67 (24.5) 22 24.74 (21.5) 22
Total cost of weekly informal care 444.14 (441.27) 22 445.30 (387.59) 22
(Total cost × 27 weeks) (11,992) (12,023)
Friend/relative’s days off work (number of days) 0.59 (2.77) 22 0.00 (0.00) 22
Friend/relative’s days off work 72.28 (339.02) 22 0.00 (0.00) 22
In this table we use a unit cost (shadow price) for informal care of £18 per hour (reported costs for home-care worker from
Curtis and Burns, 2016, p. 160125).
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Table 44 presents the health state values and QALYs estimated using the MS-specific preference-based
measure, the MSIS-8D, with estimates derived from participant reports for the MSIS-29vs2. Health state
values and QALY estimates are lower when using the MSIS-8D, and further research is recommended to
consider possible reasons for this (e.g. that it is linked to specific domains of health-related QoL that may
not be covered fully by the EQ-5D-5L).
Summary
The feasibility research on the economic aspects of the BRiMS programme and the considerations for
methods in a future full economic evaluation indicate that the methods used are acceptable, practical
and feasible for use in a future full trial and economic evaluation. The methods used to collect data on
resource use for intervention delivery, broader self-reported health, social care, other resource use and
health outcomes are considered appropriate for a future full economic evaluation alongside a RCT of the
BRiMS programme (plus usual care) versus usual care alone.
TABLE 43 Health state values and QALYs
Period
Group
Usual care Intervention
Mean (SD) Minimum Maximum n Mean (SD) Minimum Maximum n
Baseline data
EQ-5D-3L 0.58 (0.16) 0.04 0.77 26 0.54 (0.17) –0.04 0.88 29
EQ-5D-5L 0.66 (0.20) 0.07 0.89 26 0.63 (0.17) 0.22 0.95 29
Week 15 data
EQ-5D-3L 0.60 (0.18) 0.20 0.91 24 0.59 (0.17) –0.00 0.88 25
EQ-5D-5L 0.69 (0.18) 0.19 0.95 24 0.67 (0.17) 0.26 0.95 25
Week 27 data
EQ-5D-3L 0.59 (0.25) –0.13 0.91 22 0.57 (0.11) 0.30 0.77 22
EQ-5D-5L 0.67 (0.25) 0.05 0.95 22 0.65 (0.15) 0.38 0.89 22
Estimated 27-week QALYs
EQ-5D-3L 0.30 (0.08) 0.13 0.43 22 0.30 (0.05) 0.20 0.42 22
EQ-5D-5L 0.34 (0.09) 0.11 0.46 22 0.34 (0.07) 0.22 0.47 22
TABLE 44 Health state values and QALYs, estimated/derived using MSIS-29 data and the MSIS-8D MS-specific QALY
measure
Period
Group
Usual care Intervention
Mean (SD) Minimum Maximum n Mean (SD) Minimum Maximum n
MSIS-8D
Baseline 0.51 (0.21) 0.08 0.80 26 0.49 (0.15) 0.21 0.76 30
Week 15 0.54 (0.20) 0.13 0.82 24 0.56 (0.16) 0.22 0.83 25
Week 27 0.56 (0.19) 0.08 0.88 22 0.54 (0.17) 0.18 0.77 22
Estimated 27-week QALYs
MSIS-8D 0.28 (0.10) 0.09 0.42 22 0.29 (0.06) 0.20 0.40 22
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We provide good-quality data on resource use associated with delivery of the intervention, focused on
therapist time input across the intervention form, and across the four research (intervention) centres. Our
original estimate of the therapist time required was slightly under that reported by our treating therapists;
however, we estimate that the intervention may cost in the region of £400 per participant, a relatively low
cost intervention for this type of therapist-/facilitator-led self-management intervention.
We suggest that, in any future economic evaluation, the collection of data across health and social care
services could be streamlined, because a number of items included in the feasibility data collection (but
with very few, and often no, data reported) could be removed from a future data collection process. We
suggest also that for large (high cost) items of resource use, such as hospital stay(s), a cross-check against
participant records (or via SAE reporting) may be helpful.
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Chapter 4 Discussion, conclusions and
recommendations
This feasibility trial aimed to obtain the necessary data and operational experience to finalise the planningof an intended future definitive multicentre RCT to compare a manualised 13-week education and
exercise programme (BRiMS) plus usual care with usual care alone in improving mobility, QoL and reducing
falls in people with SPMS. The intention was to learn lessons to enable a definitive trial to be successfully
delivered with confidence. The specific learning points related to the objectives we set are detailed below.
However, there are also a number of overarching strengths and limitations associated with this trial.
First, stakeholders (including people with MS, carers, therapists and commissioners) were integral to the
process of developing the BRiMS programme and trial protocol; we believe that this has contributed to the
high levels of engagement with the trial and the positive feedback from treating therapists and participants.
However, there were logistical issues that particularly affected those in the intervention group, and could
have adversely affected retention. It is imperative that these issues are addressed before a definitive trial
is undertaken.
Second, the trial was undertaken using robust methodology, with comprehensive documentation and
evaluation of our processes, decisions and outcomes at each step. Despite this, there were issues with some
aspects of the trial methodology. Most notably, the low return rate of the paper falls diaries means that our
falls data must be viewed and interpreted with caution. In particular, this issue highlights the need to find a
valid and reliable method of collecting these data before considering falls as a potential primary outcome.
This feasibility trial recruited people with SPMS. It is possible that people with other types of MS had issues
that were not highlighted in this trial (e.g. relapses). In addition, the participants were followed up for only
3 months, and hence the impact of a longer follow-up period on operational issues (e.g. trial retention)
and clinical outcomes is unknown. However, our experience with this and other related studies, and our
ongoing strong links with service users, means that we are well placed to identify and address issues as we
move forward.
Specific learning points and recommendations
The objectives were grouped into four clusters:
l trial feasibility
l trial outcomes
l process evaluation
l health economics analysis.
Many lessons have been learnt from undertaking this trial. For ease of reading and for future reference,
these have been summarised in Tables 44–49, in line with the set objectives.
Trial feasibility
Trial feasibility outcomes investigated the feasibility, utility and acceptability of the trial procedures;
suitability and feasibility of eligibility criteria; participant recruitment, retention and completion rates; and
measures of trial safety and AEs. Overall, relatively few problems were encountered in relation to the
operationalisation of the trial, and our pre-defined criteria for progressing to a definitive trial were met.
Nevertheless, challenges were experienced in a number of areas, and lessons were learnt. These are
described in Table 45. The recommendations we have made to improve the operationalisation of a future
definitive trial should be relatively straightforward to implement.
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Trial outcomes
Data on participant demographics, clinical characteristics and a range of potential primary and secondary
outcomes were collected to inform a future definitive trial. The completion and performance rates of
the measures were excellent, clearly meeting our pre-defined progression criteria for a definitive trial.
As can be seen in Table 46, our experience suggests that few changes would be needed in relation to
the primary outcomes in a future trial. A number of lessons were learnt in relation to the implementation,
analysis and interpretation of some of the secondary outcomes; solutions have been identified to these
and recommendations made should these outcomes be chosen for inclusion in a future trial.
One of the key purposes of a feasibility trial is to obtain data to inform the sample size calculation for a
full-scale trial. Our shortlist of potential primary outcomes was based on two key principles: the need to
identify a measure with robust psychometric properties and maximum completion rates, and the need for
the measure to be relevant and meaningful to the aims of the BRiMS programme and to people with MS,
clinicians and service commissioners. All three of the potential primary outcome measures had excellent
rates of completion at all time points, were acceptable to participants and produced outcomes that were
comparable with those of other similar samples. From the outset, the MSWS-12vs2 was highlighted as the
key potential primary outcome, given its direct applicability to the problem that the BRiMS programme was
TABLE 45 Lessons learnt, challenges faced and recommendations for a definitive RCT: trial feasibility
Activity Lessons learnt/challenges faced
Recommendation for an anticipated
definitive trial
1a. Trial set-up
Governance approvals Attempting to complete the governance
approval process during a 6-month pre-
funded period proved challenging as this
was dependent on spare workforce
capacity, which was difficult to predict
A full trial should incorporate a longer run-in
period (minimum of 9 months) to ensure
sufficient time to secure the appropriate
approvals
Gaining ETC approvals Gaining ETC approvals was time-consuming
and required considerable facilitation by the
CRN deputy chief operations manager
Feedback from clinical teams highlighted
that there was no spare capacity to deliver
the BRiMS intervention for the purposes of a
research project, in addition to their usual
workload
Close communication with the local CRN is
key to facilitating the ETC approval process
The availability of funding for ETCs is
essential to be able to deliver rehabilitation
research trials
Embedding the BRiMS
research trial within an
existing NHS service
Co-ordinating the BRiMS programme was
time-consuming and required pre-scheduling
to enable research assessments to be
undertaken within a limited time frame
Close communication with managers of
local therapy services is important to ensure
that the additional requirements of the
project fit with existing service commitments
1b. Trial procedures
Recruitment methods Conversion rates varied according to
recruitment method used; and were highest
when a personal approach with clinicians
and potential participants was used
Recruitment methods should prioritise
the personal approach by clinicians or
research staff to optimise conversion rate
for recruitment. This should be further
augmented by undertaking study awareness-
raising activities with clinicians and people
with MS prior to trial commencement and
during the recruitment period
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TABLE 45 Lessons learnt, challenges faced and recommendations for a definitive RCT: trial feasibility (continued )
Activity Lessons learnt/challenges faced
Recommendation for an anticipated
definitive trial
Inclusion criteria The exclusion criterion of ‘any patient
who had previously had treatment with
alemtuzumab’ was the most frequent
reason for a patient failing the screening
process. This was an issue for the recruiting
sites across Devon, but not in Scotland,
highlighting geographical variations in
practice
Exclusion criteria included being within
3 months of switching disease-modifying
therapies or within 6 months of ceasing
Tysabri
Some participants allocated to the BRiMS
group withdrew from the trial because of
their lack of confidence in using a computer
to access the programme resources
On the basis of discussion with expert
neurologists in the field, we would
recommend that this exclusion criterion be
amended to ‘people within 12 months of
the second alemtuzumab cycle’. As many
participants had received it in the south-
west, another alternative would be to
stratify for previous treatment with
alemtuzumab
The disease-modifying therapy exclusion
criterion is appropriate; however, the move
towards more frequent switching of disease-
modifying therapies,132 and the potential
new drugs for people in the progressive
phase of MS to be licensed, should be taken
into careful consideration when predicting
the recruitment rate for a future trial
Inclusion criteria for a definitive trial should
clearly state that participants should be
confident and competent in using a
computer/tablet, rather than ‘have access to
a computer/tablet’
Recruitment blocks Participants had to be recruited in blocks
of 8–12, as group sessions (four or five
per group) were integral to the BRiMS
programme. Although pre-scheduling of
group session dates was an advantage in
that it enabled potential participants and
treating therapists to diarise these sessions
(should they be allocated to the intervention
group), it was challenging to recruit these
prespecified numbers within the available
4-week recruitment window
A future study is likely to need approximately
8 weeks to recruit each block of participants,
should block randomisation be utilised
Elapsed time between key
trial points
Within the protocol, the time from
randomisation to each follow-up was given
a ± 1 week window. This time frame proved
too short, as the block randomisation design
required assessments for the whole block to
be undertaken on the same date. This was
logistically challenging, particularly in one
site where the research therapist was
employed for only 1 day per week
In a future trial, we would recommend that
a ± 2-week window be incorporated for
undertaking assessments at each time point,
on the basis that there is evidence to
indicate that significant change in key
outcomes over this time is unlikely in people
with progressive disease50
Methods to maintain
blinding
The assessors correctly identified the
allocation group for between 75% and
77% of participants at the week 15 and
27 assessments
In line with updated CONSORT guidance,135
research assessors should not be asked
to guess which group the participant
was allocated to at each assessment,
as this method has proven unreliable.
We recommend, however, that all instances
of known compromises in blinding are
reported
Recruitment and trial
information provided to
participants
Some of the participants interviewed felt
that the initial patient information packs
were too long and detailed, particularly for
those with cognitive impairment
The participant information packs provided
should be comprehensive, but with an
appropriate level of detail to ensure that
people with symptoms such as cognitive
impairment and fatigue do not feel
overwhelmed by the volume of information
received
continued
DOI: 10.3310/hta23270 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 27
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Gunn et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
105
TABLE 45 Lessons learnt, challenges faced and recommendations for a definitive RCT: trial feasibility (continued )
Activity Lessons learnt/challenges faced
Recommendation for an anticipated
definitive trial
Retention Retention rates were lower than anticipated Given the dropout rates seen in this
feasibility trial, we would recommend that a
6-month trial end point be chosen instead
of the 12-month follow-up period proposed
in our original plan for a future definitive
trial
Assessment procedures Some of the participants interviewed felt
that the assessment sessions, particularly
the cognitive demands of the self-report
questionnaires, were very tiring. However,
overall, the sessions were considered well
structured, and participants appreciated that
the cognitive tasks were interspersed with
physical tasks to minimise fatigue
The most common method of completing
the self- report questionnaires was for the
research therapist to read the questionnaire
to the participant and then record the
participant’s response. This method
increases the likelihood of assessor
influence/unblinding
The scheduling of assessments at local
community health centres to reduce
participant travel time is an important
consideration to minimise participant burden
and fatigue
Assessment procedures should continue to
be structured such that cognitive tasks are
interspersed with physical tasks to minimise
fatigue
Wherever possible, to avoid any potential
influence from the research assessor, the
self-report questionnaires should be read
and completed by the participants, and
there should be consistency in the
completion methods at each time point.
When this is not achievable, the procedure
should unambiguously state how this should
be operationalised to ensure standardisation
of approach across assessors
A future trial should review the format of
any change in assessment procedures to
ensure that people can achieve this without
adding significant extra burden
AEs reporting by
pre-formatted daily diaries
(in 2-week batches)
AE data were gathered by patient
self-reported daily diary data. Other trials
have found that there can be ambiguity in
both the definition and the interpretation
of a new symptom/relapse,134 and this was
reflected in our own experience in this
feasibility trial on analysing the free-text
diary data
The injurious falls data were collected by
self-report, with some participants returning
their diaries at variable times (sometimes
several diaries at a time). This, coupled with
the timeline of normal data entry processes,
occasionally caused a time lag with SAE/AE
data
A further challenge was optimising the
return rate of the diaries
Careful consideration should be given to
the most effective and reliable system for
collecting AE data in a future trial. A review
of the literature should be undertaken to
inform this
If pre-formatted daily diaries are used to
report AEs, then one option could be to
allocate one line per AE, with a tick box
to indicate the severity and duration of
each event
If pre-formatted daily diaries are used, then
each diary should be clearly dated by the
research team before being given to the
participant
DMC meetings Because of the low-risk nature of this trial,
the DMC meetings were not scheduled in
line with the TSC meetings. Instead, a
predetermined trigger, related to injurious
falls, was set
In a definitive trial, regular DMC meetings
should be scheduled in line with TSC
meetings
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TABLE 46 Lessons learnt, challenges faced and recommendations for a definitive RCT: trial outcomes – 2a
Activity Lessons learnt/challenges faced
Recommendation for an anticipated
definitive trial
2a. Data completion and accuracy
Baseline data collected The baseline data collected were useful and
none were redundant. However, there was
no option in the CRF for a participant to
declare that they had fallen once
There was an imbalance in the groups at
baseline for some characteristics (e.g. EDSS
score, anxiety/depression and cognition),
which could potentially affect intervention
outcomes
An option for declaring one-off falls should
be included in the data collected at baseline
A future definitive trial may require
stratification according to key variables that
may influence outcome
Completeness and
performance of potential
primary outcome measures
All three of the potential primary outcome
measures had excellent rates of completion
at all time points, were acceptable to
participants and produced outcomes that
were comparable with those of other similar
samples. Criterion for progression to
definitive trial was clearly met
We recommend that the primary outcome
for a definitive trial, on which a sample size
is calculated, is the MSWS-12vs261
Completeness and
performance of potential
secondary outcome
measures:
l CPI
l 2MWT
l Accelerometry data
l Falls diary data reported
by pre-formatted daily
diaries (in 2-week
batches)
All of the potential secondary outcome
measures had excellent rates of completion
at all time points and produced outcomes
that were broadly comparable with those
of other similar MS samples. Criterion for
progression to definitive trial was clearly met
The self-report measure of participations,
the CPI, proved to be complicated to
interpret and burdensome to complete.
Our analysis of item CPI (part 1) highlighted
ambiguity in the scoring instructions
There were some minor problems with
recording the 2MWT data, resulting in data
discrepancies
The use and return rate of accelerometers
demonstrated that these were a feasible
method of collecting activity data for a
future trial, and the minimum recommended
5 days of data were available for the
majority of participants and time points.
However, a significant amount of time was
required for data cleaning to ensure that
5 consecutive days of data were available
for analysis
Accelerometry data were unreliable for three
participants who had very low levels of
activity/speed of walking
Evaluation of the quality and completeness
of the daily recording of falls in the diaries
highlighted other issues, including
duplication of data (e.g. when participants
sent back two diaries with the same dates,
or when there was an overlap in the dates
recorded in two sequential diaries)
A measure of participation is important and,
ideally, should be included in a future
definitive trial
The inclusion of a measure of participation is
important; however, further exploration of
an alternative measure is required for use
in the definitive trial. Before the inclusion
of the CPI as a measure in a future trial,
ambiguities in its scoring would need to
be addressed with the developer of this
measure
If the 2MWT is included as a secondary
outcome measure in a future trial, then the
CRF needs to be formatted in a manner that
provides a restriction on the time format,
tick-box categories for assistive walking
device (using the same categories as at
baseline) and a requirement to record the
time walked in all cases to avoid ambiguity.
These amendments to the CRF could help to
limit future data discrepancies
Accelerometry data provided useful
complementary data to the other measures,
and should be considered in a future trial.
However, it is recommended that the timed
start/stop function on the monitor is utilised
to reduce the amount of data cleaning
required
Further consideration of the validity of data
for those with significant mobility limitations
is also required if trials are to include people
from across the disability spectrum
Although the diary format for recording
falls was that recommended by the
International MS Falls Prevention Network,
continued
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developed to address, namely the impact of poor balance and falls on the mobility of people with MS.
The findings of the process evaluation support our hypothesis that the mechanism of impact of the BRiMS
programme is likely to be through changes in walking and balance. Together, these findings inform our
recommendation that the MSWS-12vs2 be used as the primary outcome for a future definitive trial, as
summarised in Table 47. A potential alternative is the rate of injurious falls, which is clinically important
and has been used as a primary outcome in older peoples fall prevention trials alongside falls rate.166–168
Our hesitancy in recommending this because of the problem we experienced in terms of the self-reported
falls diary data completeness and accuracy. However, if these issues can be resolved, then injurious falls
should be carefully reconsidered as a primary outcome of a definitive trial.
TABLE 46 Lessons learnt, challenges faced and recommendations for a definitive RCT: trial outcomes – 2a
(continued )
Activity Lessons learnt/challenges faced
Recommendation for an anticipated
definitive trial
Some of the participants who were
interviewed reported that the diaries were
‘a little complicated’ to fill in, which may
have had an impact on user engagement
and data quality
Input of diary data was sometimes delayed
because of reduced staff capacity
A further challenge was optimising the
return rate of the diaries
our recommendation would be that the diary
needs further refinement and simplification
to optimise clarity for participants before it is
used in a definitive trial
Each diary should be clearly dated by the
research team before it is given to the
participant to avoid participant error in diary
dating
Refinement of mechanisms for checking and
following up on diary returns is recommended
to optimise diary data completeness and
accuracy. Data input within a 2-week time
frame of receiving the returned diary would
enhance this
TABLE 47 Lessons learnt, challenges faced and recommendations for a definitive RCT: trial outcomes – 2b
Activity Results
Recommendation for an anticipated
definitive trial
2b. Sample size calculation and estimated number of recruiting sites
Associations between
baseline characteristics and
potential primary outcome
measures
Associations appear to be significant
between the potential primary outcomes
and disease severity (EDSS), depression and
use of mobility aid
These data suggest that a future trial should
consider stratification for mood and/or
disease severity (EDSS)
The sample size and
number of recruiting sites
required for a fully
powered trial
Sample size has been calculated to detect a
between-group difference for the primary
outcome of MSWS-12vs2 of 5.2 units156 at
the primary end point of 6 months post
randomisation. Full details regarding the
assumptions used in this calculation are
in Calculation of sample size required
for a fully powered RCT to evaluate the
effectiveness of the BRiMS intervention
The recruitment rate for this trial was
14 participants per month over four sites
(i.e. 3.5 participants per month per site)
We recommend that the primary outcome
for a definitive trial, on which a sample size
is calculated, is the MSWS-12vs2. Based
on the data from this feasibility trial, the
estimated sample sizes for a definitive trial
range from 575 to 900 participants
We estimate that, for a definitive trial, at
least 7 out of 12 sites would be required,
based on the two estimates of sample size
described above. This calculation assumes
that each site recruits 3.5 participants per
month over a 24-month recruitment period,
and would be informed by ongoing
evaluation and developmental activities
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Process evaluation
A process evaluation was undertaken to gain a more in-depth understanding of some of the trial procedures,
which included the fidelity assessments. Table 48 highlights that only easily remediable minor changes would
be needed in relation to these procedures in a future trial.
The other key purpose of the process evaluation was to gain a more in-depth understanding of the
acceptability and utilisation of the BRiMS programme. The intention, outlined in the trial objectives, was to
determine the optimum way of delivering the BRiMS programme and to gain a detailed understanding of
its acceptability to therapists and participants, and the level of participant adherence to and engagement
with the programme. This involved undertaking participant and therapist interviews, reviewing records of
attendance at face-to-face sessions, and calculating online exercise diary completion and web-based
programme log-in data. Together, these data provided us with a fuller understanding, from the perception
of both service providers and users, of the complexities of implementing a programme of this nature in the
NHS environment. Table 49 focuses on the many lessons we learnt in relation to the operationalisation of,
and engagement with, this programme.
TABLE 48 Lessons learnt, challenges faced and recommendations for a definitive RCT: process evaluation – 3a
Activity Lessons learnt/challenges faced
Suggestions and recommendation for
an anticipated definitive trial
3a. Process evaluation: assessment procedures
Fidelity assessment of
sessions
The fidelity assessment was appropriate in
its coverage and was feasible to implement,
albeit time-consuming
Assessment using audio recordings of
the BRiMS face-to-face sessions was
time-consuming and sometimes challenging
because of difficulties hearing details
during group interactions, and not being
able to observe non-verbal elements of
communication
The qualitative feedback (in the form of
annotated comments) provided by the
fidelity assessors to support their scoring
judgments on the Fidelity Checklist Rating
Scales was undertaken ad hoc, rather than
according to a prespecified method
Fidelity assessment is essential in a definitive
trial, which will invariably be multisite in
nature, to ensure that all therapists deliver
the intervention in line with the
programme’s ethos. We recommend that
this should be conducted in two stages:
1. Early on to ensure fidelity from the trial
inception. This will enable feedback to be
given to individual therapists to ensure
the programme is delivered in the way
that it was intended throughout the trial
2. In the latter stages to provide an
understanding of how well therapists can
deliver BRiMS when they are experienced
at doing so
In a future trial, a structured system for
providing qualitative feedback to
complement the scores on the Fidelity
Checklist Rating Scales should be
implemented to enable a comprehensive
qualitative overview of delivery fidelity
Qualitative interviews with
participants and treating
therapists
Qualitative interviews were undertaken after
completion of the final trial assessment
(week 27 ± 1 week), relying on participant
recall of sessions undertaken up to
25 weeks previously. This may compromise
the accuracy of the information collected,
particularly for participants who may have
memory problems
We recommend that, when logistically
possible (e.g. taking into account issues such
as unblinding), participant and therapist
interviews should be undertaken as soon as
possible after the programme is completed
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TABLE 49 Lessons learnt, challenges faced and recommendations for a definitive RCT: process evaluation – 3b
Activity Lessons learnt/challenges faced
Suggestions and recommendation for
an anticipated definitive trial
3b. Process evaluation: implementation of the BRiMS programme
Attendance rates of
face-to-face sessions
Attendance rates were variable. They were
considerably higher for one-to-one sessions
than for group sessions, and attendance at
group sessions reduced over time. At times
this meant that group sessions had to be
cancelled, or had a limited number of
participants, which had an impact on peer
interaction
Considering alternative formats (e.g. a single
longer workshop, rather than several
sessions) is warranted to ensure effective
use of therapist time, and maximise the
benefits reported from peer interaction
Fidelity in delivering the
programme
As anticipated, therapists needed to utilise
high-level skills to establish an effective
relationship with participants and to deliver
the key elements of the programme
Therapists experienced challenges with some
aspects of the programme with which they
were less familiar (e.g. the functional
imagery component)
The online BRiMS discussion forum was
perceived as very helpful by the treating
therapists, who used it throughout the trial
to gain peer support and solve problems
We recommend that band 7 level therapists
be required to deliver the BRiMS programme
A longer initial training session is needed for
therapists, with a focus on elements such as
motivational support and functional imagery
training. This will need to be factored into
revised estimates of costs associated with
delivery of the BRiMS programme prior to a
definitive RCT
Identification of a therapist who can take
the lead on supporting others in relation to
motivational support would be helpful in a
future multicentre trial wherein multiple
therapists are likely to be involved in
delivering the intervention
An online discussion forum should remain
integral as a support mechanism for
therapists, but could be expanded to include
peer supervision sessions and debriefs
Participant engagement
with the programme
Engagement with the programme was
suboptimal in terms of both attendance
at the group sessions and online log-in
of exercises and educational activities
Refinement of the BRiMS programme is
necessary prior to implementation of a
definitive trial. Consideration of alternative
formats to increase user engagement is
warranted. People with MS should be
closely involved with this developmental
process
The content and timeframe
for delivering the BRiMS
programme
The time taken to deliver the BRiMS
programme content was underestimated.
This related to all aspects of the programme,
both face-to-face sessions and online activity
Logistical issues, such as problems with
initial log-in to the programme and internet
issues, were encountered, which proved
time-consuming at the home visit
The treating therapist time allocated for
delivery of the programme (in its current
format) should be increased to 8 hours,
and costed accordingly
There should be one website for the BRiMS
programme which houses both the
education and the exercise components
A mobile version of this website should be
considered, as it has the potential to simplify
the logistics of some of the home visits
BRiMS educational
activities
Participant engagement with the
educational elements of BRiMS was variable
and dropped off over time
Preferences for online/paper information
format varied between participants
Rationalisation and simplification of the
educational component is required, in line
with suggestions made during this process
evaluation. For example, the balance and
timing of topics need to be revisited to
aid clarity and reduce time pressures,
particularly in the assessment session and
DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
TABLE 49 Lessons learnt, challenges faced and recommendations for a definitive RCT: process evaluation – 3b
(continued )
Activity Lessons learnt/challenges faced
Suggestions and recommendation for
an anticipated definitive trial
Both participants and therapists reported
that, overall, the content of the educational
resources was too long and detailed, which
may have been a contributing factor to
levels of engagement. Some content was
considered repetitive
home visit. People with MS should be
closely involved with this developmental
process
BRiMS exercise activities The combination of one-to-one, online and
group support was reported to be helpful to
maintain engagement
Group sessions were reported to be helpful
for progressing the challenge of exercise
regimes
People with MS liked the fact that the video
exercises were filmed with people with MS,
and reported that this helped them to
engage with the programme
Some participants reported that they found
the accumulative online diary a useful way
of logging their exercise, whereas others
reported challenges with the logistics of
using the diary to log exercise practice
Participants were asked to undertake
120 minutes of exercise per week, which was
considered by some to be too demanding,
particularly early in the programme
Many participants appeared to rely on the
therapists to guide the progression of their
exercise programme, rather than initiate
this themselves, despite the scheduling of
regular online reviews. This may have meant
missed opportunities to maximise the extent
of ‘highly challenging’ exercise undertaken
Refinement of the exercise component is
required, particularly with regard to the
advice and support provided to help
participants self-manage the progression of
their exercise activities over time. People
with MS should be closely involved with this
developmental process
Participants should be advised that they can
‘build up’ to achieving 120 minutes of
exercise per week, rather than being
expected to undertake this from the outset.
This should be built into the timeline/analysis
approach in a future definitive trial
Supporting participants to take the lead in
how, when and in what way they engage
with the BRiMS programme needs to be
further developed. Further PPI work, and an
updated review of the literature, would help
to inform this complex issue
Online logging of exercise
activity
Use of the online exercise resource varied
among participants. A range of factors
accounted for this variability, including
participant preference for a paper-based
exercise sheet; logistical difficulties, such as
difficulty logging in; and participants’
confidence in using IT
Online log-in data showed that the pattern
of logging exercise was variable, but
typically reduced over time. Logistical issues
played some part in the (lack of) accuracy
and completeness of these data
There was a mismatch between the amount
of exercise that some participants told the
therapist they had undertaken, and the
amount the reported online. This casts
doubt on the accuracy and validity of the
exercise data recorded
An alternative method of recording exercise
activity is essential for valid conclusions to
be drawn about adherence to unsupervised
home-based exercise when the focus is on
challenging balance. Wearable sensors may
offer a solution, providing that they can
record more subtle changes in posture and
position (i.e. that they do not require any
change in the axes of movement) that are a
key focus of many of the exercise/balance
activities utilised in the BRiMS programme.
This is a priority to address before
implementing a future trial
Portable systems, such as response to
text-based phone messages or mobile
applications, may also offer a potential
solution to increasing the reliability of the
exercise log-in data
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Our experience in this feasibility trial highlighted that some elements of the BRiMS programme require
further developmental work prior to a definitive trial. Other issues identified have proven more
straightforward and, for these, we have been able to identify solutions and make clear recommendations.
It is notable that many of the issues we faced are common to MS rehabilitation trials of this nature. For
example, sustaining patient engagement with unsupervised physical activities over the long term113 and
monitoring patient adherence to home-based exercise programmes169 are both issues that, thus far, remain
unresolved in the MS clinical and research community. Our experience of undertaking this feasibility
study has provided us with invaluable learning, which moves us one step closer to addressing these very
complex issues.
Health economics
The focus of the health economics evaluation was on determining the feasibility of the proposed methods
for assessing health, social care and other resource use in a future definitive trial was undertaken, plus
evaluation of the intervention delivery costs for the BRiMS programme. This feasibility study demonstrated
that, overall, this element of the trial was feasible and few challenges were faced in relation to this. Those
identified, described in Table 50, have straightforward solutions that will be easily implementable within a
definitive trial.
Conclusions
This trial aimed to assess the feasibility of undertaking a definitive trial to compare BRiMS plus usual care
with usual care alone in a sample of people with SPMS. We achieved this. Our results suggest that our trial
procedures are feasible and acceptable, and retention, programme engagement and outcome completion
rates were sufficient to satisfy our a priori trial progression criteria. Challenges were experienced in some
areas of data collection, such as the recording of adherence to exercise activity and the completion of daily
diaries; the lessons learnt in this feasibility trial will enable these processes to be refined for a future trial.
TABLE 49 Lessons learnt, challenges faced and recommendations for a definitive RCT: process evaluation – 3b
(continued )
Activity Lessons learnt/challenges faced
Suggestions and recommendation for
an anticipated definitive trial
The limited exercise data entered by most
participants (including free-text comments to
enable review of exercises by the therapists)
restricted therapists’ ability to provide advice
about progression of exercise regimes
Use of imagery techniques Functional imagery training is a novel
technique that was unfamiliar both to
therapists and to most participants, who felt
that more ongoing support and facilitation
in its use was needed, along with greater
clarity on when and how to use it as part of
BRiMS
When revising the BRiMS training session,
more time should be allocated to educating
and supporting therapists so that they can
confidently include functional imagery
training techniques as part of the
motivational support they offer participants
BRiMS infrastructure Significant issues were encountered with
technological infrastructure, the most
notable being the need to access two
separate websites with separate log-ins
(the main BRiMS site and the online exercise
resource). This presented challenges for
access, as well as having an impact on the
cohesion of the programme
Development of an integrated online BRiMS
resource, which incorporates all elements
of the programme on one site, is a high
priority. This should be piloted with people
with MS prior to implementation of a
definitive trial
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The comprehensive and robust process evaluation and input from PPI team members have proven invaluable
in finding potential solutions and indicating remedial actions, which have been discussed in detail throughout
this report and summarised in this chapter. Our experience has highlighted that further development of the
BRiMS programme is required to address logistical issues and enhance user satisfaction and adherence,
which will benefit from ongoing input from both therapists and people with MS. Following this, a definitive
trial to assess the clinical effectiveness and cost-effectiveness of the BRiMS intervention is warranted.
TABLE 50 Lessons learnt, challenges faced and recommendations for a definitive RCT: health economics
Activity Lessons learnt/challenges faced
Suggestions and recommendation for
an anticipated definitive trial
4. Health economics: evaluation procedures
Health economics methods The methods used were acceptable,
practical and feasible for use in a future full
trial and economic evaluation
A future definitive trial should use similar
methods to those described in this feasibility
trial
Data quality Good-quality data were collected on
resource use associated with delivery of the
intervention
A number of items included in the resource
form collection had very few, and often no,
data reported suggesting redundancy of
these items
We recommend that the collection of data
across health and social care services could
be streamlined
Items in the resource-use form that were
rarely populated could be removed from a
future data collection process
We suggest that for large (high-cost) items
of resource use, such as hospital stay(s),
a cross-check against participant records
(or via SAE reporting) may be helpful
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Appendix 1 Daily diary example
 
 
 
BRiMS Study daily diary – to be returned in the FREEPOST envelope provided.  
 
Please send us one of these diaries every two weeks 
 
Participant Number: 1001 
    
Instructions: 
1. Enter the date of the first day of this diary and which day of the week you start 
in the spaces provided. 
2. For each day, please write down the number of falls you have (if any) and the 
number of falls that cause any injury.  
3. If you don’t have a fall that day please enter ‘0’ rather than leaving the box blank. 
 
 
Start Day of Diary:               _________day (Monday, Tuesday etc) 
 
Start Date of Diary:  
 
Please consider a fall as “an unexpected event in which you come to rest on 
the ground, floor, or lower level”. 
Week 1 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Day of week  
(inial only: M, T, W, Th, F, Sa, Su) 
       
Number of falls        
Number of falls that 
caused you injury 
       
Week 2 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Day of week  
(inial only: M, T, W, Th, F, Sa, Su) 
       
Number of falls        
Number of falls that 
caused you injury 
       
 
At the end of the two weeks please answer the questions on the following pages: 
D D M M M Y Y Y Y 
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Participant Number: «Participant_Number» 
 
If you have not had any falls, please go directly to question 5 
1. Please write down the number of each type of injury as a result of any fall: 
 
No injuries in this two week period (tick) 
 
 
 Head Body Arms Legs 
Bruises     
Cuts/scrapes     
Sprain/Strain     
Dislocation     
Broken Bone     
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Participant Number: «Participant_Number» 
 
2. Did you use any of the following medical or other services because of any falls?   
 
No                  Yes                             Not applicable 
 
If YES, please complete this chart: 
Medical Service or Other Care Number of times  
Nurse visit  
GP practice visit   
Specialist doctor visit (hospital or privately)  
What type of specialist? 
 
Emergency Department  
Admission to hospital  
How many days were you hospitalized?  
 
Other (please state)  
 
 
3. Did you lay on the ground or floor for more than 10 minutes because of any falls?   
 
 
No      Yes        Not applicable 
 
If YES, please complete this chart: 
Time on the ground or floor Number of times  
Between 10 and 30 minutes  
Between 30 and 60 minutes  
For more than 60 minutes  
 
 
Please Turn over and continue …. 
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Participant Number: «Participant_Number» 
 
4. Did you need help to get up after any falls? 
 
No       Yes        Not applicable 
 
If YES, please complete this chart: 
Help provided by: Number of times  
Family member  
Friend or neighbour  
Healthcare Professional (e.g. paramedic)  
 
 
5. Have you experienced any new or worsening problems (e.g. pain, fatigue, 
anxiety) related to activities or exercise that you have undertaken in this two-week 
period?  
 
No      Yes     
 
If YES, please complete this chart: 
Problem Please tell us if you felt it 
was Mild, Moderate or 
Severe 
Duration (how long 
did it last for? 
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Participant Number: «Participant_Number» 
 
6. Have you had any MS relapses in the last two weeks? 
 
 
No     Yes     
 
A relapse is defined as: "the appearance of new symptoms, or the return of old 
symptoms, for a period of 24 hours or more – in the absence of a change in 
core body temperature or infection" 
 
If YES, please complete the following: 
When did the relapse 
start?  
 
How long did it 
continue? 
 
What symptoms did 
you notice? 
 
 
Did you consult a 
healthcare 
professional? 
 
No                                                                                          Yes
 
If Yes, which 
healthcare 
professional did you 
see? 
 
What treatment did 
you have? 
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Appendix 2 Fidelity assessment generic scoring
This scale was used to score session-specific items. The four core items were assessed using indivualisedcriteria, which are included in the main body of the report:
0: absence (or very limited/highly inappropriate coverage) of the item and lack of discussion.
1: some coverage of the item. Some key elements are omitted or only superficially discussed.
2: appropriate coverage of the item. Discussion lacks depth and/or clarity in some areas.
3: appropriate coverage of the item. Appropriate depth of discussion.
DOI: 10.3310/hta23270 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 27
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Gunn et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
137

Appendix 3 Unit costs of BRiMS resource items
TABLE 51 Unit costs of BRiMS resource items
Resource item
Unit cost
(£, 2016) Source of cost estimate Basis of cost estimate
Primary care
GP contacts (surgery) 27.00 PSSRU 2016, p. 145125 Surgery consultation, 9.22 minutes
GP contacts (home) 34.20 PSSRU 2016, p. 145;125 PSSRU
2015, p. 176126
Per minute of patient contact = £3
(allows for average of 12 minutes
travel time per visit)
Home visit, 11.4 minutes
GP telephone calls 21.30 PSSRU 2016, p. 145;125 PSSRU
2015, p. 176126
Per minute of patient contact = £3
Telephone call, 7.1 minutes
MS specialist nurse contacts
(home)
68.00 NHS Reference Costs 2016/2017124 Community health services, other
specialist nursing, adult, face to face
MS specialist nurse telephone
calls
33.00 NHS Reference Costs 2016/2017124 Community health services, other
specialist nursing, adult, not face to
face
Physiotherapist contacts
(home)
53.00 NHS Reference Costs 2016/2017124 Community health services,
physiotherapist, adult, one to one
Occupational therapist
contacts (home)
77.00 NHS Reference Costs 2016/2017124 Community health services,
occupational therapist, adult, one to
one
Practice nurse contacts
(surgery)
9.30 PSSRU 2016, p. 143;125 PSSRU
2015, p. 174126
£36 per hour, 15.5-minute
consultation
Community nurse contacts
(home)
37.00 NHS Reference Costs 2016/2017124 Community health services, district
nurse, adult, face to face
Chiropodist/podiatrist contacts
(surgery)
41.00 NHS Reference Costs 2016/2017124 Community health services, podiatrist,
tier 1, general podiatry
Continence advisor contacts 83.00 NHS Reference Costs 2016/2017124 Community health services, specialist
nursing, adult, face to face
Community psychiatric nurse
contacts (home)
36.00 PSSRU 2016, p. 142125 £36 per hour, 1-hour visit
Counsellor contacts 44.00 PSSRU 2016, p. 137125 Band 6 scientific and professional staff;
£44 per hour, 1-hour consultation
Secondary care
Hospital stays (nights) 455.17 NHS Reference Costs 2016/2017124 Medical care of patients with MS,
non-elective stays (mean across
complication and comorbidities scores
by mean length of stay, £3420/7.51
days)
Visits to A&E 147.80 NHS Reference Costs 2016/2017124 Outpatient attendance data, A&E
Days in hospital 369.00 NHS Reference Costs 2016/2017124 Medical care of patients with MS, day
cases (mean across complication and
comorbidities scores)
continued
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TABLE 51 Unit costs of BRiMS resource items (continued )
Resource item
Unit cost
(£, 2016) Source of cost estimate Basis of cost estimate
Neurologist 167.50 NHS Reference Costs 2016/2017124 Outpatient attendance data, neurology
MS specialist nurse 44.00 PSSRU 2016, p. 188125 Hospital-based nurses. Band 6
scientific and professional staff,
£44 per hour
Occupational therapist 64.99 NHS Reference Costs 2016/2017124 Outpatient attendance data,
occupational therapy
Physiotherapist 48.81 NHS Reference Costs 2016/2017124 Outpatient attendance data,
physiotherapy
Ophthalmologist 55.99 NHS Reference Costs 2016/2017124 Outpatient attendance data, medical
ophthalmology
Orthotist 119.07 NHS Reference Costs 2016/2017124 Outpatient attendance data, orthotics
Chiropodist 46.64 NHS Reference Costs 2016/2017124 Outpatient attendance data, podiatry
Speech therapist 96.52 NHS Reference Costs 2016/2017124 Outpatient attendance data, speech
and language therapy
Psychologist 168.65 NHS Reference Costs 2016/2017124 Outpatient attendance data, clinical
psychology
Psychiatrist 142.00 NHS Reference Costs 2016/2017124 Mental health, other psychiatric liaison
services, adult and elderly
Pain clinic 139.23 NHS Reference Costs 2016/2017124 Outpatient attendance data, pain
management
Continence advisor 109.40 NHS Reference Costs 2016/2017124 Outpatient attendance data, urology
New wheelchair 191.00 PSSRU 2016, p. 96125 Per active user chair per year
New cushion 31.99 www.uk-wheelchairs.co.uk This is the source used by PSSRU
for wheelchair costs, based on a
mid-price-range cushion
Medication use (per week of use)
Disease-modifying medicine 163.50 British National Formulary 70,
p. 730170
Multiple sclerosis, interferon beta;
once-weekly injection; 12 pre-filled
injections = £1962.00
Botulinum toxin injections 46.07 British National Formulary 70,
p. 324170
Total dose of 400 units in 3-month
period. Botox Allergan 200-unit
powder for solution for injection vials:
£276.40
Phenol injections 4.90 British National Formulary 70,
p. 81;170 Jarrett paper171
5% phenol in glycerol, between 1.5
and 2.5 ml. 10 × 5-ml ampoules
= £47.91–50.00. Doses at least
6 weeks apart (mean of three doses)
Intravenous steroids 58.00 British National Formulary 70,
p. 584170
Intravenous methylprednisolone:
500 mg to 1 g daily, for 3–5 days
500-mg vial of methylprednisolone
powder with solvent, £9.60; 1 g
vial = £17.30
Requires 3 × 500-mg vials to 5 × 1 g
vials, £28.80 to £86.50
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
140
TABLE 51 Unit costs of BRiMS resource items (continued )
Resource item
Unit cost
(£, 2016) Source of cost estimate Basis of cost estimate
Steroid tablets 145.00 British National Formulary 70,
p. 584170
Oral methylprednisolone: 500 mg to
2 g daily, for 3–5 days
20 × 100-mg tablet pack, £48.32
15–100 tablets (1–5 packs),
£48.32–241.60
Social care
Home-care worker contacts 6.90 PSSRU 2016, p. 160125 Mean hourly cost of all home care.
£18 per hour, 23-minute visit
Social worker/care manager
contacts
55.00 PSSRU 2016, p. 156125 Per hour of client-related work
Rehabilitation unit stays (days) 98.73 PSSRU 2016, p. 197;125 PSSRU
2015–6, p. 40125,126
Community rehabilitation unit,
£691.13 per person, per week. 2014
cost of £671 uprated by 3% based on
PSSRU’s annual percentage increases
for adult service (all sectors – pay and
prices including capital)
Respite unit/facility stays (day) 141.00 PSSRU 2016, p. 65125 Local authority own-provision care
homes for adults requiring physical
support
Day-care centre (days) 87.00 PSSRU 2016, p. 67125 Day care for adults requiring physical
support
Informal care 18.00 Same as home-care cost Based on replacement cost approach
A&E, accident and emergency; GP, general practitioner; PSSRU, Personal Social Services Research Unit.
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Appendix 4 Gantt chart
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Appendix 5 Correlations between outcome
measures at each assessment time-point
TABLE 52 Pearson’s correlation coefficient between baseline and weeks 15 and 27 with exact two-sided 95%,
one-sided lower 90% and one-sided lower 80% confidence bounds for the potential primary and secondary outcomes
Variable Time point
Correlation with baseline
Coefficient 95% CI
Lower 90%
one-sided CI bound
Lower 80%
one-sided CI bound
Potential primary outcomes
MSWS-12vs2 (imputed) Week 15 0.54 0.31 to 0.71 0.40 0.45
Week 27 0.59 0.36 to 0.76 0.45 0.50
EQ-5D-3L (crosswalk) Week 15 0.46 0.21 to 0.66 0.30 0.36
Week 27 0.50 0.24 to 0.69 0.33 0.39
EQ-5D-5L (VAS) Week 15 0.66 0.46 to 0.79 0.54 0.58
Week 27 0.60 0.37 to 0.76 0.46 0.51
MSIS-29vs2 (physical) Week 15 0.75 0.59 to 0.85 0.65 0.68
Week 27 0.77 0.61 to 0.87 0.67 0.71
MSIS-29vs2 (psychological) Week 15 0.73 0.56 to 0.84 0.63 0.67
Week 27 0.82 0.69 to 0.9 0.75 0.77
Potential secondary outcomes
2MWT Week 15 0.83 0.72 to 0.9 0.76 0.79
Week 27 0.83 0.72 to 0.9 0.69 0.72
Mini-BEST Week 15 0.63 0.42 to 0.77 0.50 0.55
Week 27 0.75 0.58 to 0.86 0.65 0.69
Forward FRT Week 15 0.75 0.59 to 0.85 0.65 0.69
Week 27 0.67 0.46 to 0.81 0.55 0.59
Lateral FRT Week 15 0.62 0.41 to 0.77 0.49 0.54
Week 27 0.67 0.46 to 0.81 0.54 0.59
FES-I Week 15 0.57 0.34 to 0.73 0.43 0.48
Week 27 0.63 0.41 to 0.78 0.49 0.54
CPI 1 Week 15 0.44 0.17 to 0.65 0.27 0.33
Week 27 0.49 0.22 to 0.69 0.32 0.38
CPI 2 Week 15 0.69 0.51 to 0.82 0.58 0.62
Week 27 0.73 0.55 to 0.84 0.62 0.66
CPI 3 Week 15 0.78 0.64 to 0.87 0.70 0.73
Week 27 0.82 0.68 to 0.9 0.74 0.77
FRT, Functional Reach Test.
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Appendix 6 Original estimate of therapist
resource requirement for delivery of BRiMS
Week BRiMS activities (participant and therapist) Therapist administrative and technical activities
1 Session 1: individual assessment and introduction to the
programme
Takes place at local health-care establishment
Expected time commitment (participant): 1 hour
Expected time commitment (therapist): 1 hour per participant
Write-up of session and development of exercise
prescription (including setting up web-based
exercise programme)
Expected time commitment (therapist): 30 minutes
per participant
2 Session 2: home visit by BRiMS therapist to explain and
set up exercise programme
Expected time commitment (participant): 1.25 hours
Expected time commitment (therapist): 2 hours per visit
(inclusive of travel)
Write-up of session and fidelity checklist
Expected time commitment (therapist): 30 minutes
per participant
2–4 Home-based individual practice of exercise programme,
plus education activities, with online support from the
BRiMS therapist
Expected time commitment (participant): 3 hours per week
Online review and adjustment of web-based
exercise prescription 15 minutes per review × 6 over
the programme
Expected time commitment (therapist): 1.5 hours
over 12 weeks per participant
4 Group session 1: group exercise and education activities
Takes place at local health-care establishment
Expected time commitment (participant): 2 hours
Expected time commitment (therapist): 2 hours
Group set-up and clearing away
Write-up of session and fidelity checklist
Expected time commitment (therapist): 45 minutes
per group
5–8 Home-based practice of exercise programme, plus
education activities
Expected time commitment (participant): 3 hours per week
8 Group session 2: group exercise and education activities
Takes place at local health-care establishment
Expected time commitment (participant): 2 hours
Group set-up and clearing away
Write-up of session and fidelity checklist
Expected time commitment (therapist): 45 minutes
per group
9–13 Home-based practice of exercise programme, plus
education activities
Expected time commitment (participant): 3 hours per week
13 BRiMS group session 3: group exercise and education
activities
Takes place at local health-care establishment
Expected time commitment (participant): 2 hours
Expected time commitment (therapist): 2 hours
Group set-up and clearing away
Write-up of session and fidelity checklist
Expected time commitment (therapist): 45 minutes
per group
Estimated therapist time: 35.75 hours (per programme for five participants) plus one half-day training session. Participant
time: 44.25 hours.
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Appendix 7 Detailed breakdown of actual
contact/administration time for delivery of BRiMS
one-to-one sessions
Site
Session (participants)
1 (n= 5) 2 (n= 9) 3 (n= 4) 4 (n= 9) All
Clinic visit (minutes), mean (SD)
Contact time 90 (0) 101 (18) 82 (16) 92 (5) 93 (13)
Administration time 47 (13) 43 (10) 60 (40) 55 (11) 50 (18)
Total clinic visit time 137 (13) 144 (13) 142 (47) 147 (13) 144 (20)
Home visit (minutes), mean (SD)
Contact time 93 (7) 108 (9) 116 (28) 89 (15) 100 (18)
Administration time 51 (13) 14 (4) 39 (8) 28 (15) 36 (19)
Total home visit time 144 (17) 123 (16) 155 (33) 137 (14) 136 (20)
Online contacts, n (%) 23 (11) 10 (2) 16 (3) 15 (0) 15 (7)
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Appendix 8 Resource-use costs over the
27 weeks of the trial
TABLE 53 Health and social care costs per person over the 27 weeks of the trial
Service
Group
Usual care Intervention
Mean (SD) (£) n Mean (SD) (£) n
Primary care appointments/visits
Continence advisor: home 0.00 (0.00) 22 0.00 (0.00) 22
Community psychiatric nurse: home 0.00 (0.00) 22 0.00 (0.00) 22
Chiropodist: home 6.00 (21.93) 22 1.50 (7.04) 22
Chiropodist: surgery 3.73 (12.06) 22 9.32 (25.09) 22
Counsellor 0.00 (0.00) 22 8.00 (37.52) 22
GP: home 3.11 (14.58) 22 12.44 (24.85) 22
GP: surgery 65.05 (75.76) 22 47.86 (71.64) 22
GP: telephone 11.62 (18.27) 22 29.05 (41.34) 22
MS nurse: home 6.18 (29.00) 22 3.09 (14.50) 22
MS nurse: telephone 12.00 (29.77) 22 7.50 (17.44) 22
Occupational therapist: home 66.50 (137.12) 22 21.00 (54.09) 22
Community nurse: home 1.68 (7.89) 22 8.41 (39.44) 22
Practice nurse: surgery 10.15 (13.43) 22 10.15 (17.90) 22
Physiotherapist: home 26.50 (74.51) 22 31.32 (68.73) 22
Total primary care 212.51 (223.50) 22 189.63 (162.10) 22
Secondary care outpatient appointments
Continence advisor 14.92 (38.43) 22 34.81 (91.76) 22
Chiropodist 6.36 (21.81) 22 4.24 (13.72) 22
MS nurse 26.00 (37.58) 22 14.00 (20.98) 22
Neurologist 83.75 (112.66) 22 68.52 (133.39) 22
Occupational therapist 2.95 (13.86) 22 8.86 (30.39) 22
Ophthalmologist 7.64 (19.67) 22 7.64 (19.67) 22
Orthotist 27.06 (72.86) 22 27.06 (81.60) 22
Pain clinic 18.99 (65.10) 22 56.96 (267.16) 22
Physiotherapist 119.81 (132.80) 22 53.25 (181.33) 22
Psychiatrist 0.00 (0.00) 22 0.00 (0.00) 22
Psychologist 7.67 (35.96) 22 15.33 (49.62) 22
Speech therapist 0.00 (0.00) 22 0.00 (0.00) 22
continued
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TABLE 53 Health and social care costs per person over the 27 weeks of the trial (continued )
Service
Group
Usual care Intervention
Mean (SD) (£) n Mean (SD) (£) n
Secondary care attendances/admissions
Nights in hospital 0.00 (0.00) 22 1096.55 (4317.34) 22
A&E visits 33.41 (89.95) 22 13.36 (43.25) 22
Day admissions 0.00 (0.00) 22 50.32 (236.01) 22
Total secondary care 348.55 (249.24) 22 1450.89 (4334.60) 22
Social and community care visits
Social worker: home visit 0.00 (0.00) 22 2.50 (11.73) 22
Home-care visit 65.86 (308.93) 22 0.94 (4.41) 22
Day-care centre days 0.00 (0.00) 22 0.00 (0.00) 22
Rehabilitation unit days 13.46 (46.16) 22 278.24 (975.78) 22
Respite care days 0.00 (0.00) 22 0.00 (0.00) 22
Total social and community care 79.33 (309.37) 22 281.68 (986.43) 22
Total health and social care 640.38 (580.26) 22 1922.20 (5340.09) 22
A&E, accident and emergency; GP, general practitioner.
TABLE 54 Medication costs per person over the 27 weeks’ follow-up of the trial
Medication
Group
Usual care Intervention
Mean (SD) (£) n Mean (SD) (£) n
Disease-modifying medications 252.68 (912.04) 22 44.59 (209.15) 22
Botulinum toxin injections 2.09 (9.82) 22 0.00 (0.00) 22
Intrathecal baclofen 0.00 (0.00) 22 0.00 (0.00) 22
Phenol injections 0.00 (0.00) 22 0.00 (0.00) 22
Intravenous steroids 0.00 (0.00) 22 0.00 (0.00) 22
Steroid tablets 6.59 (30.91) 22 0.00 (0.00) 22
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TABLE 55 Informal care cost per week over the 27 weeks’ follow-up of the trial by type of task and days off work
Task
Group
Usual care Intervention
Mean (SD) (£) n Mean (SD) (£) n
DIY 31.70 (37.07) 22 59.52 (79.63) 22
Gardening 25.16 (40.22) 22 15.95 (26.19) 22
Housework 111.27 (191.80) 22 98.59 (132.26) 22
Preparing meals 103.09 (121.79) 22 112.30 (145.42) 22
Personal care 20.11 (47.52) 22 13.91 (27.14) 22
Looking after pets 37.23 (86.25) 22 32.11 (51.78) 22
Shopping 41.93 (40.43) 22 41.32 (36.50) 22
Transport 73.64 (89.47) 22 71.59 (83.48) 22
Total cost of weekly informal care 444.14 (441.27) 22 445.30 (387.59) 22
Days off work over previous 6 months
Friend/relative’s days off work 72.28 (339.02) 22 0.00 (0.00) 22
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Appendix 9 Baseline (previous 6 months)
resource use and costs data
Health and social care use and cost at baseline
TABLE 56 Health and social care resource use per person at baseline (6 months prior to trial)
Resource
Group
Usual care Intervention
Mean (SD) Minimum Maximum n Mean (SD) Minimum Maximum n
Primary care appointments/visits
Continence advisor:
home
0.08 (0.39) 0 2 26 0.00 (0.00) 0 0 29
Community psychiatric
nurse: home
0.00 (0.00) 0 0 26 0.00 (0.00) 0 0 29
Chiropodist: home 0.08 (0.27) 0 1 26 0.07 (0.37) 0 2 29
Chiropodist: surgery 0.08 (0.27) 0 1 26 0.17 (0.47) 0 2 29
Counsellor 0.00 (0.00) 0 0 26 0.00 (0.00) 0 0 29
GP: home 0.04 (0.20) 0 1 26 0.21 (0.49) 0 2 29
GP: surgery 1.35 (2.40) 0 12 26 1.03 (1.09) 0 3 29
GP: telephone 0.69 (0.84) 0 3 26 0.83 (1.07) 0 3 29
MS nurse: home 0.08 (0.27) 0 1 26 0.00 (0.00) 0 0 29
MS nurse: telephone 0.35 (0.56) 0 2 26 0.14 (0.35) 0 1 29
Occupational therapist:
home
0.23 (0.71) 0 3 26 0.07 (0.26) 0 1 29
Community nurse:
home
0.58 (2.74) 0 14 26 0.07 (0.26) 0 1 29
Practice nurse: surgery 0.35 (0.80) 0 3 26 0.31 (0.71) 0 3 29
Physiotherapist: home 0.00 (0.00) 0 0 26 0.10 (0.56) 0 3 29
Secondary care outpatient appointments
Continence advisor 0.04 (0.20) 0 1 26 0.17 (0.38) 0 1 29
Chiropodist 0.12 (0.33) 0 1 26 0.07 (0.26) 0 1 29
MS nurse 0.50 (0.65) 0 2 26 0.34 (0.48) 0 1 29
Neurologist 0.35 (0.49) 0 1 26 0.17 (0.38) 0 1 29
Occupational therapist 0.04 (0.20) 0 1 26 0.10 (0.31) 0 1 29
Ophthalmologist 0.08 (0.27) 0 1 26 0.10 (0.41) 0 2 29
Orthotist 0.15 (0.46) 0 2 26 0.00 (0.00) 0 0 29
Pain clinic 0.00 (0.00) 0 0 26 0.00 (0.00) 0 0 29
Physiotherapist 1.58 (3.40) 0 11 26 0.31 (0.85) 0 4 29
continued
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TABLE 56 Health and social care resource use per person at baseline (6 months prior to trial) (continued )
Resource
Group
Usual care Intervention
Mean (SD) Minimum Maximum n Mean (SD) Minimum Maximum n
Psychiatrist 0.00 (0.00) 0 0 26 0.00 (0.00) 0 0 29
Psychologist 0.04 (0.20) 0 1 26 0.03 (0.19) 0 1 29
Speech therapist 0.04 (0.20) 0 1 26 0.00 (0.00) 0 0 29
Secondary care attendances/admissions
Nights in hospital 1.54 (6.50) 0 33 26 0.52 (1.94) 0 10 29
A&E visits 0.12 (0.43) 0 2 26 0.10 (0.31) 0 1 29
Day admissions 0.00 (0.00) 0 0 26 0.14 (0.58) 0 3 29
Social and community care visits
Social worker: home
visit
0.00 (0.00) 0 0 26 0.03 (0.19) 0 1 29
Home-care visit 7.38 (35.29) 0 180 26 0.14 (0.74) 0 4 29
Day-care centre days 0.00 (0.00) 0 0 26 0.00 (0.00) 0 0 29
Rehabilitation unit days 0.69 (2.09) 0 10 26 0.28 (0.92) 0 4 29
Respite care days 0.00 (0.00) 0 0 26 0.00 (0.00) 0 0 29
A&E, accident and emergency; GP, general practitioner.
TABLE 57 Baseline (previous 6 months) health and social care cost data
Costs
Group
Usual care Intervention
Mean (SD) (£) n Mean (SD) (£) n
Primary care appointments/visits
Continence advisor: home 6.38 (32.56) 26 0.00 (0.00) 29
Community psychiatric nurse: home 0.00 (0.00) 26 0.00 (0.00) 29
Chiropodist: home 2.54 (8.97) 26 2.28 (12.26) 29
Chiropodist: surgery 3.15 (11.14) 26 7.07 (19.20) 29
Counsellor 0.00 (0.00) 26 0.00 (0.00) 29
GP: home 1.32 (6.71) 26 7.08 (16.80) 29
GP: surgery 36.35 (64.77) 26 27.93 (29.30) 29
GP: telephone 14.75 (17.84) 26 17.63 (22.82) 29
MS nurse: home 5.23 (18.48) 26 0.00 (0.00) 29
MS nurse: telephone 11.42 (18.53) 26 4.55 (11.58) 29
Occupational therapist: home 17.77 (54.70) 26 5.31 (19.86) 29
Community nurse: home 21.35 (101.56) 26 2.55 (9.54) 29
Practice nurse: surgery 3.22 (7.41) 26 2.89 (6.62) 29
Physiotherapist: home 0.00 (0.00) 26 5.48 (29.53) 29
Total primary care 123.47 (157.86) 26 82.76 (74.99) 29
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TABLE 57 Baseline (previous 6 months) health and social care cost data (continued )
Costs
Group
Usual care Intervention
Mean (SD) (£) n Mean (SD) (£) n
Secondary care outpatient appointments
Continence advisor 4.21 (21.46) 26 18.86 (42.06) 29
Chiropodist 5.38 (15.20) 26 3.22 (12.03) 29
MS nurse 22.00 (28.52) 26 15.17 (21.28) 29
Neurologist 57.98 (81.27) 26 28.88 (64.39) 29
Occupational therapist 2.50 (12.75) 26 6.72 (20.14) 29
Ophthalmologist 4.31 (15.22) 26 5.79 (22.91) 29
Orthotist 18.32 (55.26) 26 0.00 (0.00) 29
Pain clinic 0.00 (0.00) 26 0.00 (0.00) 29
Physiotherapist 76.97 (165.77) 26 15.15 (41.46) 29
Psychiatrist 0.00 (0.00) 26 0.00 (0.00) 29
Psychologist 6.49 (33.07) 26 5.82 (31.32) 29
Speech therapist 3.71 (18.93) 26 0.00 (0.00) 29
Secondary care attendances/admissions
Nights in hospital 700.26 (2958.90) 26 235.43 (882.45) 29
A&E visits 16.96 (63.42) 26 15.21 (45.56) 29
Day admissions 0.00 (0.00) 26 50.90 (214.35) 29
Total secondary care 919.09 (3007.45) 26 401.15 (917.84) 29
Social and community care visits
Social worker: home visit 0.00 (0.00) 26 1.90 (10.21) 29
Home-care visit 50.95 (243.47) 26 0.95 (5.13) 29
Day-care centre days 0.00 (0.00) 26 0.00 (0.00) 29
Rehabilitation unit days 68.35 (206.66) 26 27.24 (91.01) 29
Respite care days 0.00 (0.00) 26 0.00 (0.00) 29
Total social and community care 119.31 (309.92) 26 30.08 (90.83) 29
Total health and social care 1161.87 (3113.23) 26 513.99 (984.65) 29
A&E, accident and emergency; GP, general practitioner.
DOI: 10.3310/hta23270 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 27
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Gunn et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
157
Medication use and cost per person at baseline
TABLE 58 Medication use in weeks used per participant at baseline (6 months prior to trial)
Medication
Group
Usual care Intervention
Mean (SD) Minimum Maximum n Mean (SD) Minimum Maximum n
Disease-modifying
medications
0.92 (3.26) 0 12 26 0.41 (2.23) 0 12 29
Botulinum toxin
injections
0.04 (0.20) 0 1 26 0.00 (0.00) 0 0 29
Intrathecal baclofen 0.00 (0.00) 0 0 26 0.00 (0.00) 0 0 29
Phenol injections 0.00 (0.00) 0 0 26 0.00 (0.00) 0 0 29
Intravenous steroids 0.00 (0.00) 0 0 26 0.00 (0.00) 0 0 29
Steroid tablets 0.04 (0.20) 0 1 26 0.00 (0.00) 0 0 29
TABLE 59 Medication costs per participant at baseline (6 months prior to trial)
Medication
Group
Usual care Intervention
Mean (SD) (£) n Mean (SD) (£) n
Disease-modifying medications 150.92 (533.17) 26 67.66 (364.33) 29
Botulinum toxin injections 1.77 (9.04) 26 0.00 (0.00) 29
Intrathecal baclofen 0.00 (0.00) 26 0.00 (0.00) 29
Phenol injections 0.00 (0.00) 26 0.00 (0.00) 29
Intravenous steroids 0.00 (0.00) 26 0.00 (0.00) 29
Steroid tablets 5.58 (28.44) 26 0.00 (0.00) 29
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Informal care use and cost per person at baseline by type of task and
days off work
TABLE 60 Informal care use, hours per week per participant at baseline by type of task and days off work
Care provided
Group
Usual care Intervention
Mean (SD) Minimum Maximum n Mean (SD) Minimum Maximum n
DIY 1.08 (1.79) 0 6 26 2.55 (8.84) 0 48 29
Gardening 1.69 (4.01) 0 20 26 1.13 (3.78) 0 20 29
Housework 2.63 (3.68) 0 14 26 3.76 (5.24) 0 15 29
Preparing meals 1.94 (2.78) 0 10 26 3.72 (5.93) 0 25 29
Personal care 1.05 (2.42) 0 9 26 1.06 (2.06) 0 7 29
Looking after pets 0.92 (2.17) 0 7 26 1.11 (2.62) 0 10 29
Shopping 1.31 (1.64) 0 6 26 1.62 (2.66) 0 12 29
Transport 2.54 (4.09) 0 15 26 2.84 (4.71) 0 20 29
Total informal care 13.17 (14.56) 0 63 26 17.80 (20.69) 0 78 29
Days off work over previous 6 months
Friend/relative’s
days off work
1.42 (6.27) 0 32 26 0.05 (0.28) 0 2 29
TABLE 61 Informal care cost per week per participant at baseline by type of task and days off work
Care provided
Group
Usual care Intervention
Mean (SD) (£) n Mean (SD) (£) n
DIY 19.38 (32.17) 26 45.93 (159.09) 29
Gardening 30.46 (72.09) 26 20.33 (67.98) 29
Housework 47.42 (66.31) 26 67.66 (94.35) 29
Preparing meals 34.96 (50.03) 26 67.03 (106.80) 29
Personal care 18.92 (43.53) 26 19.14 (37.04) 29
Looking after pets 16.62 (39.08) 26 20.02 (47.16) 29
Shopping 23.54 (29.59) 26 29.17 (47.91) 29
Transport 45.69 (73.64) 26 51.21 (84.81) 29
Total cost of weekly informal care 237.00 (262.16) 26 320.48 (372.45) 29
Days off work over previous 6 months
Friend/relative’s days off work 174.07 (767.54) 26 6.33 (34.07) 29
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Appendix 10 Potential associations between
potential primary outcomes and baseline
characteristics at week 27
Note that the 95% CIs are not available for categories if there was only one observation. The results ofany category with a small number of participants should be viewed with caution as the small sample
size provides weak data.
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TABLE 62 Number of participants in each category with follow-up data, mean and 95% CI of the potential primary outcomes at week 27 by demographic and clinical
characteristics at baseline
Characteristic n
Potential primary outcome, mean (95% CI)
MSWS-12vs2 EQ-5D-3L (crosswalk) EQ-5D-5L (VAS) MSIS-29vs2 (physical) MSIS-29vs2 (psychological)
Agea 44 0.0 (–0.3 to 0.3) 0.1 (0.3 to 0.1) 0.1 (0.1 to –0.2) –0.1 (–0.2 to 0.4) –0.2 (0.4 to 0.1)
Sex
Male 13 75.5 (62.7 to 88.3) 0.6 (0.5 to 0.7) 55.0 (42.7 to 67.3) 55.8 (40.7 to 70.8) 45.3 (28.2 to 62.4)
Female 31 78.2 (71.3 to 85.2) 0.6 (0.5 to 0.6) 57.3 (49.6 to 64.9) 59.6 (52.8 to 66.4) 40.1 (31.6 to 48.6)
Living arrangements
Alone 10 75.0 (57.7 to 92.3) 0.6 (0.5 to 0.8) 58.1 (44.3 to 71.9) 51.1 (33.7 to 68.5) 37.5 (15.3 to 59.7)
With spouse/partner 29 79.7 (72.9 to 86.4) 0.6 (0.5 to 0.6) 56.1 (48.2 to 63.9) 61.5 (54.5 to 68.5) 43.9 (35.9 to 52)
With parent(s) 3 61.0 (13.7 to 108.3) 0.6 (0 to 1.1) 56.7 (–31.5 to 144.8) 58.7 (–16.2 to 133.5) 43.3 (–67.3 to 153.9)
With children 7 82.6 (72.3 to 92.8) 0.6 (0.4 to 0.8) 52.0 (40.6 to 63.4) 61.7 (46.2 to 77.2) 42.9 (27.5 to 58.2)
Place of residence
Flat/apartment 5 58.0 (24.7 to 91.3) 0.7 (0.5 to 0.8) 64.2 (50.5 to 77.9) 44.0 (11 to 77) 37.0 (4.3 to 69.7)
House/bungalow 39 79.9 (74.4 to 85.5) 0.6 (0.5 to 0.6) 55.6 (48.7 to 62.5) 60.3 (54.1 to 66.5) 42.2 (34.2 to 50.2)
Occupation status
Unemployed 2 86.5 (42 to 131) 0.3 (0 to 0.7) 27.5 (–4.3 to 59.3) 87.5 (81.1 to 93.9) 78.0 (–112.6 to 268.6)
Part-time work 5 84.8 (71.8 to 97.8) 0.5 (0 to 0.9) 48.6 (28.9 to 68.3) 66.4 (54.3 to 78.5) 60.2 (42.6 to 77.8)
Full-time work 3 61.7 (10.4 to 113) 0.7 (0.2 to 1.2) 63.3 (–17.5 to 144.1) 41.7 (–15.9 to 99.3) 33.3 (17.6 to 49.1)
Age retired 9 70.9 (56.6 to 85.2) 0.7 (0.5 to 0.8) 68.6 (56.9 to 80.2) 46.9 (31.5 to 62.3) 33.8 (11.2 to 56.3)
Medically retired 24 80.7 (72.1 to 89.3) 0.6 (0.5 to 0.6) 53.8 (45.9 to 61.6) 62.1 (54.3 to 69.9) 40.1 (30.7 to 49.5)
Other 1 50.0 0.7 95.0 27.0 7.0
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Characteristic n
Potential primary outcome, mean (95% CI)
MSWS-12vs2 EQ-5D-3L (crosswalk) EQ-5D-5L (VAS) MSIS-29vs2 (physical) MSIS-29vs2 (psychological)
Age at diagnosisa (years) 44 0.1 (–0.2 to 0.4) –0.1 (0.4 to –0.1) 0.1 (–0.1 to –0.4) 0.0 (–0.4 to 0.2) 0.1 (0.2 to 0.1)
Time since last relapse
At least a year 34 78.2 (72 to 84.5) 0.6 (0.5 to 0.6) 56.1 (48.6 to 63.5) 60.0 (53.5 to 66.5) 44.0 (35.7 to 52.3)
3–12 months 8 78.3 (64.3 to 92.2) 0.5 (0.3 to 0.8) 59.3 (42.4 to 76.1) 55.5 (41.9 to 69.1) 36.6 (13.9 to 59.3)
With 3 months 1 100.0 0.7 60.0 88.0 41.0
SDMTa 44 0.3 (0.1 to 0.6) –0.2 (0.6 to –0.2) –0.2 (–0.2 to –0.5) 0.3 (–0.5 to 0.1) –0.1 (0.1 to –0.2)
EDSS score (points)
4 1 40.0 0.9 90.0 25.0 4.0
4.5 1 38.0 0.9 95.0 15.0 26.0
5 1 83.0 0.6 90.0 53.0 0.0
5.5 0
6 21 74.0 (65.6 to 82.5) 0.6 (0.5 to 0.6) 50.3 (42.7 to 58) 57.5 (49 to 66) 45.0 (34.3 to 55.6)
6.5 18 82.9 (74.8 to 91.1) 0.6 (0.5 to 0.7) 57.4 (46.9 to 68) 61.2 (51.6 to 70.7) 42.3 (29.6 to 55)
7 2 99.0 (86.3 to 111.7) 0.4 (–2.3 to 3.1) 62.5 (30.7 to 94.3) 85.0 (–3.9 to 173.9) 48.0 (–91.8 to 187.8)
Previous 4-week continence
Not at all 22 71.8 (62.1 to 81.5) 0.6 (0.5 to 0.7) 60.0 (50.9 to 69.2) 51.5 (43 to 60.1) 35.5 (23.6 to 47.3)
Once 2 78.5 (46.7 to 110.3) 0.6 (–0.4 to 1.6) 50.0 (–204.1 to 304.1) 51.5 (32.4 to 70.6) 40.5 (–4 to 85)
2–4 times 6 84.8 (68.6 to 101) 0.5 (0.3 to 0.7) 51.7 (37.3 to 66) 75.8 (61.7 to 90) 59.8 (41.6 to 78.1)
More than weekly 8 83.6 (67 to 100.2) 0.6 (0.4 to 0.8) 58.1 (36 to 80.2) 61.0 (39 to 83) 40.3 (18.6 to 61.9)
Daily 6 82.0 (69.6 to 94.4) 0.6 (0.4 to 0.7) 49.2 (30.3 to 68.1) 65.3 (50 to 80.7) 48.2 (28.6 to 67.7)
Continence device
No 39 77.9 (71.7 to 84.1) 0.6 (0.5 to 0.7) 56.2 (49.6 to 62.8) 57.8 (51.4 to 64.1) 39.2 (31.8 to 46.5)
Yes 5 73.6 (44.9 to 102.3) 0.5 (0.2 to 0.9) 60.0 (30.6 to 89.4) 63.8 (29.6 to 98) 60.8 (18.6 to 103)
continued
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TABLE 62 Number of participants in each category with follow-up data, mean and 95% CI of the potential primary outcomes at week 27 by demographic and clinical
characteristics at baseline (continued )
Characteristic n
Potential primary outcome, mean (95% CI)
MSWS-12vs2 EQ-5D-3L (crosswalk) EQ-5D-5L (VAS) MSIS-29vs2 (physical) MSIS-29vs2 (psychological)
Depressed
No 26 72.6 (64 to 81.3) 0.6 (0.5 to 0.7) 60.6 (51.8 to 69.4) 51.1 (42.8 to 59.5) 32.5 (22.9 to 42.1)
Yes 18 84.4 (77.5 to 91.3) 0.5 (0.5 to 0.6) 50.8 (42.1 to 59.5) 69.1 (61.7 to 76.4) 54.8 (44.9 to 64.6)
Lack of pleasure
No 32 75.0 (67.6 to 82.3) 0.6 (0.5 to 0.7) 58.5 (50.9 to 66.2) 54.8 (46.9 to 62.6) 36.3 (27.5 to 45)
Yes 12 84.0 (74.3 to 93.7) 0.6 (0.5 to 0.7) 51.5 (39.9 to 63.1) 68.3 (60.6 to 75.9) 55.9 (43 to 68.8)
Fear of falling
Not at all 8 73.0 (50 to 96) 0.7 (0.6 to 0.8) 64.4 (50 to 78.8) 52.4 (26.4 to 78.4) 31.5 (5.3 to 57.7)
Somewhat 13 70.3 (59 to 81.6) 0.6 (0.5 to 0.7) 59.8 (45.9 to 73.8) 55.1 (44.6 to 65.5) 41.8 (26 to 57.6)
Fairly 9 81.7 (74.9 to 88.4) 0.5 (0.3 to 0.7) 46.3 (32.3 to 60.4) 60.7 (49.1 to 72.2) 51.4 (35.1 to 67.8)
Very 13 83.2 (71.5 to 94.8) 0.6 (0.4 to 0.7) 56.6 (44 to 69.2) 63.7 (51.5 to 75.9) 41.7 (28.8 to 54.6)
Do not know 1 93.0 0.7 45.0 63.0 30.0
3-month fall history
Not fallen 1 40.0 0.7 80.0 50.0 22.0
Twice 10 74.5 (61 to 88) 0.6 (0.5 to 0.8) 66.2 (52.1 to 80.3) 51.2 (37.1 to 65.3) 38.6 (18 to 59.2)
3–5 times 19 79.6 (69 to 90.2) 0.6 (0.5 to 0.7) 52.5 (43.5 to 61.5) 59.7 (48.1 to 71.3) 43.6 (31.8 to 55.4)
More often 14 79.3 (71.1 to 87.5) 0.5 (0.4 to 0.7) 53.6 (40.9 to 66.4) 62.6 (53.7 to 71.4) 42.5 (28.9 to 56.1)
Indoor walking aids
One stick/crutch 19 76.4 (65.5 to 87.3) 0.5 (0.4 to 0.6) 53.9 (44.8 to 63) 58.5 (48.4 to 68.5) 42.3 (30.1 to 54.5)
Two sticks/crutches 6 79.5 (61.4 to 97.6) 0.6 (0.5 to 0.7) 50.5 (31.3 to 69.7) 63.8 (43.1 to 84.5) 48.2 (26.3 to 70)
Walker/frame 16 86.3 (80.1 to 92.4) 0.5 (0.4 to 0.6) 55.9 (46.1 to 65.8) 65.2 (56.1 to 74.3) 43.1 (30.2 to 55.9)
Wheelchair 4 95.8 (87.7 to 103.8) 0.3 (–0.3 to 0.9) 51.3 (17.3 to 85.2) 75.0 (54.7 to 95.3) 40.8 (12.8 to 68.7)
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Characteristic n
Potential primary outcome, mean (95% CI)
MSWS-12vs2 EQ-5D-3L (crosswalk) EQ-5D-5L (VAS) MSIS-29vs2 (physical) MSIS-29vs2 (psychological)
Outdoor walking aids
One stick/crutch 30 74.3 (66.8 to 81.9) 0.6 (0.5 to 0.7) 55.1 (47 to 63.2) 57.1 (49.1 to 65.1) 41.6 (31.9 to 51.3)
Two sticks/crutches 12 83.9 (75.2 to 92.6) 0.6 (0.5 to 0.7) 57.0 (46.7 to 67.3) 65.2 (53.7 to 76.6) 50.7 (36.6 to 64.8)
Walker/frame 18 75.8 (64.9 to 86.8) 0.6 (0.5 to 0.7) 57.5 (47.4 to 67.6) 55.8 (43.9 to 67.8) 37.7 (26.2 to 49.1)
Wheelchair 21 78.8 (69.3 to 88.2) 0.6 (0.5 to 0.7) 50.4 (41.3 to 59.4) 61.3 (51.2 to 71.4) 42.5 (32.7 to 52.4)
Assistive devices
AFO 13 78.6 (67.6 to 89.6) 0.7 (0.6 to 0.7) 61.5 (47.4 to 75.5) 58.7 (45.4 to 72) 38.2 (22.6 to 53.7)
Functional electrical stimulation 12 77.1 (64.3 to 89.9) 0.6 (0.6 to 0.7) 60.5 (52.2 to 68.8) 56.2 (43 to 69.3) 44.2 (29 to 59.4)
Other 3 88.7 (75.9 to 101.4) 0.6 (0.4 to 0.8) 53.3 (–29.4 to 136) 70.0 (26.3 to 113.7) 59.0 (–21.1 to 139.1)
AFO, ankle–foot orthosis; SDMT, Symbol Digit Modalities Test.
a Pearson’s correlation coefficient and 95% CI.
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